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FOREWORD 
 
This dissertation describes the work performed under the 
supervision of Dr. Cláudio Gomes, at the Protein Biochemistry Folding 
and Stability Laboratory, at the Instituto de Tecnologia Química e 
Biológica, from January 2006 to August 2009. 
The studies presented here aim to contribute to a better 
understanding of frataxin conformational and functional properties and, 
at the same time, also intend to shed some light into the pathological 
process  associated to Friedreich's ataxia (FRDA). Initially, the impact 
of FRDA-related mutations in human frataxin (FXN) was studied and 
their potential rescue by chemical chaperones addressed. Still focusing 
on the mechanisms underlying FRDA pathogenesis the susceptibility 
and possible role of oxidative stress relations on human frataxin were 
investigated. Further, the yeast frataxin orthologue (Yfh1) was used to 
explore the conformational and functional properties of frataxin. 
This thesis is organised in three parts. The first is an introduction 
comprising two chapters: the first one presenting an overview on the 
protein folding problem and on how protein misfolding is associated to 
disease; the second chapter focuses on the state of the art on frataxin, 
its function and association with Friedreich's ataxia (FRDA). The 
second part of the thesis is organised in six chapters describing the 
experimental results obtained. The third and last part consists of a 
single chapter where a general discussion integrating the results is 
presented. 
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DISSERTATION ABSTRACT 
This dissertation focuses on the study of frataxin, a small 
mitochondrial protein whose deficiency is associated with the 
neurodegenerative disease Friedreich's ataxia (FRDA).  Aiming at a 
better understanding of frataxin conformational  and  functional 
properties, two lines of research were followed: first, the effect of 
FRDA-related mutations in human frataxin (FXN) were studied and the 
role of oxidative stress related modification addressed; second, yeast 
frataxin (Yfh1) orthologue was used to explore the conformational and 
functional properties of the protein.  
FRDA is the most common recessive ataxia among the Caucasian 
population with an estimate prevalence of 1-2 cases per 40,000 
individuals in Europe.  Most patients are homozygous for a GAA triplet 
expansion in a non-coding region that reduces the transcription of the 
gene encoding for frataxin, leading to reduced protein levels (5-30% of 
the normal levels). However, some patients (~4%) are compound 
heterozygous patients, meaning that they have the expansion in one 
allele and a deleterious point mutation on the other. The currently 
known mutations include missense, non-sense and splice mutations. 
Here we focused on the study and characterisation of four of the 
indentified missense mutations. Deletion of frataxin gene in eukaryotes 
is lethal, hence, even if in residual levels, all FRDA patients must 
express the protein. 
The first part of the work was focused on the study of the following 
FRDA-related mutations: D122Y, G130V, I154F and W155R. While the 
first two mutations are associated to mild presentations of the disease 
the other two are associated to a severe phenotype identical to the 
xii 
 
observed for homozygous patients. None of the studied mutations 
compromised the protein fold; nevertheless, they decreased the 
protein's intrinsic stability (Tm varying between approximately -5ºC 
and -23ºC).  Opposite to what might have been expected, the mutants 
associated to milder phenotypes were more destabilised ((G)=2.11-
2.86 kcal.mol-1) than the mutants associated to severe phenotypes 
((G)=1.35-1.66 kcal.mol-1), suggesting that the pathological process 
in heterozygous patients is not exclusively related to the decreased 
stability of the mutants. The foldability and conformational flexibility of 
the clinical variants were also shown to be altered. Variants associated 
with severe phenotypes presented a higher tendency towards 
aggregation and exhibited increased conformational flexibility, as shown 
by NMR and limited proteolysis experiments. Iron binding, essential for 
frataxin cellular functional, was shown to be differently affected by the 
clinical mutations. Under controlled pH conditions and at 25ºC, we have 
observed that the FXN-D122Y and FXN-G130V appear to have their 
iron binding capacity partially compromised, binding only 4 irons per 
frataxin instead of the 6/7 observed for the wild type. The other two 
mutants, FXN-W155R and FXN-I154F, precipitated above the threshold 
of 2 irons per frataxin. Thus, mutations seem to compromise frataxin 
ability to bind iron but do not abolish it. Altogether, the data here 
presented suggests that the clinical effects in heterozygous FRDA 
patients are likely to result from a combination of effects, such as a 
reduced efficiency of protein folding, an accelerated degradation in vivo 
and misfolding and conformational destabilisation, which altogether 
contribute to a decrease in the levels of functional frataxin. In this 
scenario, FRDA in heterozygous patients carrying frataxin single point 
mutations could be considered a type of protein misfolding disorder.   
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Small compounds, such as sugars and polyols, are often called 
chemical chaperones due to their ability to stabilise proteins and to 
correct their misfolding or folding defects. Thus, the presence of these 
compounds is particularly relevant in the context of a genetic 
modification, such as a clinical point mutation, or in adverse 
environment conditions. The therapeutic potential of these compounds 
has been explored for many misfolding diseases like Gaucher's or 
cystic fibrosis and here we have evaluated the potential chaperone-like 
behaviour of four small compounds on two frataxin FRDA-related 
variants: FXN-D122Y and FXN-I154F. The wild type was used as a 
control and 4-phenyl butyrate (small fatty acid), trehalose (sugar), 
trimethylamine-N-oxide (methylamine) and glycerol (polyol) were tested 
for their potential chaperone-like effect on frataxin clinical variants. 
First, the effect of small compounds on early folding events was 
tested. Using the E. coli expression system, the mutants were 
expressed in the presence of different concentrations of the small 
compounds and the ratio between expressed soluble and insoluble 
protein allowed to assess the impact of the compounds on the proteins’ 
folding efficiency. Intriguingly, the effect of the different compounds was 
mutant dependent. While the FXN-D122Y folding efficiency was only 
modestly improved, the FXN-I154F folding efficiency improved 
significantly with the amount of expressed soluble protein increasing up 
to ~3fold in the presence of glycerol.  
Furthermore, we have also evaluated the impact of the small 
compounds on the folded native-like variants, namely the compounds’ 
effect on the proteins conformation and stability was addressed. FXN-
D122Y is more positively affected. The presence of trehalose and 
trimethylamine-N-oxide (TMAO) improved FXN-D122Y thermal stability 
to values close to the determined for the wild type in the absence of the 
compounds, as shown by the melting temperatures obtained by 
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differential scanning fluorimetry (Tm of up to ~7.8ºC). Three of the 
compounds, 4PBA, trehalose and glycerol, showed a positive impact on 
the FXN-D122Y conformational defects, as evaluated through the 
GroEL sink assay (GroEL specifically binds exposed hydrophobic 
regions, thus when conformational defects are present the proteins 
patition onto GroEL). The effects on the folded FXN-I154F were 
moderate; stability was only increased up to a Tm of ~2.5ºC. However, 
the addition of TMAO (500mM) positively affected this mutant’s 
conformation, preventing its partitioning onto the molecular chaperone 
GroEL. 
Our results show that the effects induced during the early folding 
events are distinct from those observed on the folded protein and also, 
different point mutations are modulated by the same chemical 
chaperone in a different manner. These differences are likely to result 
from the conformational variations introduced by each mutation. The 
results presented here suggest that FXN-D122Y conformational 
variation might be overcome by the presence of chemical chaperones 
and in vivo increased concentrations of different chemical chaperones 
may rescue the pathological phenotype associated to this mutant.  On 
the other hand, the FXN-I154F mutant should only be partially rescued, 
but the presence of small compounds may attenuate the phenotype 
observed. 
 
One other aspect that was investigated concerns the impact of 
oxidative stress related modification on frataxin. A priori, frataxin is a 
potential target for oxidative stress modifications, not only due to its 
location in the mitochondria, where oxygen and nitric oxide are 
available in a reducing environment, but also as a result of its iron-
binding properties. Thus, wild type frataxin was subjected to conditions 
mimicking increased oxidative stress inside the mitochondria (H2O2 + 
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Fe(II) and ONOO-) and then analysed by mass spectrometry for the 
presence of oxidative stress related modifications. The protein is 
susceptible to carbonylation and nitration modifications in residues from 
the -sheet surface (Tyr143, Tyr174, Tyr205 and Trp155). Frataxin 
functions are not significantly affected: frataxin-mediated protection 
against ROS is still observed, as well as iron-binding necessary for the 
metallochaperone activity. However, the protein is up to 1.0 kcal.mol-1 
destabilised, with conformational opening, as shown by the thermal 
unfolding reactions and the limited proteolysis experiments. 
Interestingly, the strictly conserved Trp155, whose mutation leads to 
FRDA, is both susceptible to carbonylation and nitration modifications, 
suggesting that this residue may be a functional hotspot in frataxin. 
The human and yeast frataxin orthologues have a high degree of 
amino acid and structural identity. In addition, the phenotype caused by 
frataxin depletion is very similar in human and yeast cells, thus the 
yeast model system has been proven to be a very useful model to study 
frataxin function. Here, when addressing frataxin functional and 
conformational properties we have used the yeast frataxin orthologue 
(Yfh1). Aiming at a better functional understanding of frataxin structure, 
we have characterised eight variants involving mutations on two 
putative functional regions – the  acidic ridge and the conserved 
-sheet surface.  Frataxin's iron binding capacity was shown to be quite 
robust: even when five of the most conserved residues from the 
putative iron binding region are mutated, the protein still binds iron (~2 
iron atoms per monomer), although with decreased affinity. 
Furthermore, it is observed that the negative charges comprising the 
iron binding region also have structural and conformational implications. 
Removing five of those charges results in a thermal stabilisation of 
~24ºC and reduces the inherent conformational plasticity. This 
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illustrates a rather interesting tradeoff between activity and stability in 
this region.  In addition, our study suggests that residues Asp101 and 
Glu103 are involved in the iron-mediated interaction between Isu and 
Yfh1, but their alteration does not abrogate the interaction, as 
evidenced by the rescue of the yfh1 phenotype.  
Mutations on the conserved -sheet residues had been shown to 
severely compromise frataxin function; here we show that these 
mutations only have a modest impact on the protein stability (Tm ~0-
4ºC), which highlights the functional importance of residues 122-124.  
 
Frataxin has been shown to be stabilised by different metal ions and, 
in addition, nickel has been shown to be able to rescue, at least 
partially, FRDA-mutants cellular deficiencies. Therefore, we have 
explored the frataxin's ability to bind other metals ions besides iron.  
Among the tested metals - calcium, copper, sodium, magnesium, 
nickel, manganese and zinc - only copper was shown to cause Yfh1 Trp 
fluorescence  emission quenching, suggesting that the protein only 
binds this metal ion. Frataxin was shown  to be able to bind Cu(I) 
(3Cu(I):Yfh1) and Cu(II) (4Cu(II):Yfh1), but its affinity for Cu(I) is higher. 
The binding of Cu(II) to the protein was further confirmed by EPR, these 
experiments confirmed the copper binding behaviour and also 
suggested the existence of different binding sites. Considering Yfh1 
mitochondrial localisation and the high levels of copper in the matrix it 
may be suggested that frataxin contributes to the balance of the 
mitochondrial copper homeostasis by preventing copper Fenton 
reactions. Iron binding induces frataxin oligomerisation, maximising its 
protective role against free iron. However, DLS experiments have 
shown that Yfh1 oligomerisation is not induced by copper and, as a 
result, if Yfh1 has a protective role against copper toxicity it does not 
involve its oligomerisation. Frataxin affinities to copper and to iron are 
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identical which may suggest another hypothesis as to the role of Yfh1 
copper binding ability. Copper may regulate frataxin iron-chaperone 
function, and, as shown by copper/iron competition assays, this might 
be occurring at least to some extent. The presence of copper was 
shown to be able to reduce Yfh1 affinity to Isu however, even the 
excess of copper does not abrogate this interaction. Alternatively, it 
may be suggested that, in addition to its already described iron-
chaperone function, frataxin may also act as a copper-chaperone, 
directing the copper present in the matrix to the appropriate copper-
chaperones within the IMM. Thus, we have evaluated frataxin copper-
chaperone ability and we have found that frataxin improves SOD1 
reconstitution, meaning that this protein may act as a copper 
chaperone. Frataxin copper binding ability must be further explored: 
first it has to be assessed whether this feature is also occurring in vivo 
and if does what is its biological meaning; in addition, a more chemical 
approach must be followed in order to characterise in detail the binding 
of copper to this protein. 
 
The results here presented aim to contribute to a better 
understanding of FRDA pathological process. The studies on frataxin's 
yeast orthologue contributed to the characterisation of frataxin's 
functional regions and also revealed a new functional feature of the 
protein.  
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RESUMO DA DISSERTAÇÃO 
 
A presente tese foca-se no estudo da frataxina, uma proteína 
mitocondrial cuja deficiência está associada à doença 
neurodegenerativa atáxia de Friedreich (FRDA). Com o objectivo de 
contribuir para uma melhor compreensão das propriedades 
conformacionais e funcionais da frataxina, foram seguidas duas linhas 
de investigação: a primeira envolveu o estudo de mutantes clínicos da 
frataxina  humana e também a avaliação do efeito das modificações 
associadas a condições de stress oxidativo; a segunda focou-se na 
investigação das propriedades funcionais e conformacionais da 
proteína, tendo os estudos sido realizados com a frataxina de levedura 
(Yfh1). 
A atáxia de Friedreich é a atáxia recessiva mais comum na 
população caucasiana, sendo a  sua prevalência na Europa de cerca 
de 1-2 casos por cada 40,000 indivíduos. A maioria dos pacientes são 
homozigóticos para uma expansão do tripleto GAA numa região não 
codificante, a qual causa uma redução da transcrição do gene que 
codifica a frataxina e que resulta em reduzidos níveis celulares de 
frataxina (5-30% dos níveis normais). No entanto, alguns pacientes são 
heterozigóticos (~4%), o que significa que apresentam a expansão 
num dos alelos e uma mutação nociva no outro. As mutações 
conhecidas até a data incluem mutações missense, non-sense e 
mutações que alteram o splicing. O estudo focou-se na caracterização 
de quatro mutações missense identificadas em pacientes com FRDA. 
Nos organismos Eucariotas, a supressão do gene que codifica a 
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frataxina é letal, pelo que, ainda que com níveis reduzidos, todos os 
pacientes expressam frataxina. 
A primeira parte do trabalho aqui apresentado centrou-se no estudo 
do impacto das seguintes mutações clínicas: D122Y, G130V, I154F e 
W155R. Enquanto as duas primeiras mutações estão associadas a um 
fenótipo moderado da doença, as duas outras estão associadas a um 
fenótipo severo e idêntico ao observado em pacientes homozigóticos. 
Nenhuma das mutações aqui estudadas impede o enrolamento da 
proteína, no entanto, causam uma diminuição da sua estabilidade 
intrínseca (o Tm varia aproximadamente entre -5ºC e -23ºC). 
Contrariamente ao que seria esperado, os mutantes associados a 
fenótipos moderados são aqueles que causam uma maior 
destabilização da proteína ((G)=2.11-2.86 kcal.mol-1), o que sugere 
que o processo patológico associado aos pacientes heterozigóticos 
não resulta exclusivamente de uma menor estabilidade apresentada 
pelos mutantes. A capacidade de enrolamento e a flexibilidade 
conformacionais também são alteradas pela inserção das mutações. 
Mutantes associados a fenótipos severos apresentam uma maior 
susceptibilidade para agregarem e simultaneamente apresentam uma 
maior flexibilidade conformacional, como é observado através das 
experiências de NMR e proteólise limitada. A capacidade de ligar ferro, 
essencial para a função celular da frataxina, também é alterada pelas 
mutações. Em condições controladas de pH e temperatura, verifica-se 
que a capacidade dos mutantes FXN-D122Y e  FXN-G130V ligarem 
ferro é afectada pelas mutações e que estes passam a ligar apenas 4 
ferros em vez de 6/7 como é observado para a proteína selvagem.  Os 
outros dois mutantes, FXN-W155R e FXN-I154F, precipitam quando a 
estequiometria ferro:proteína é maior que 2. Assim, os resultados 
demonstram que embora as mutações estudadas afectem a 
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capacidade de a proteína ligar ferro não a comprometem por completo. 
Em suma, os resultados aqui apresentados sugerem que os efeitos 
clínicos observados para os pacientes heterozigóticos resultam 
provavelmente da combinação de várias factores, tais como a redução 
da capacidade de enrolamento, o aumento da degradação in vivo, o 
mau enrolamento e a destabilização conformacional, que, em conjunto, 
contribuem para uma redução dos níveis funcionais de frataxina. 
Considerando este cenário, a atáxia de Friedreich em pacientes 
heterozigóticos pode ser considerada uma doença conformacional 
(misfolding disorder). 
Compostos pequenos, como os açúcares e os polióis, são 
frequentemente designados chaperões químicos uma vez que 
estabilizam e corrigem alguns defeitos de enrolamento das proteínas. 
Assim, estes compostos são particularmente relevantes num contexto 
biológico, quando ocorre uma modificação genética ou em condições 
adversas como um aumento da temperatura. O potencial terapêutico 
destes compostos tem sido explorado para muitas patologias 
conformacionais, como sendo a doença de Gaucher ou a fibrose 
quística. Assim, avaliámos aqui a potencial utilização de quatro 
compostos como chaperões químicos de dois mutantes clínicos da 
frataxina: FXN-D122Y e FXN-I154F. A proteína selvagem foi utilizada 
como controlo e o 4-phenilbutirato (ácido gordo), a trealose (açúcar), a 
trimetilamina-N-oxide (metilamina) e o glicerol (poliol) foram testados 
no sentido de avaliar as suas capacidades como chaperões químicos 
dos mutantes estudados.  
Primeiro, o efeito dos compostos na capacidade de enrolamento foi 
testado. Recorrendo ao sistema de expressão em E. coli, os mutantes 
foram expressos na presença de diferentes concentrações dos 
compostos e a razão entre proteína solúvel e insolúvel determinada de 
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forma a permitir uma quantificação do efeito dos compostos na 
eficiência do processo de enrolamento proteico. Curiosamente, o efeito 
dos compostos depende do mutante considerado. Enquanto a 
eficiência de enrolamento do mutante FXN-D122Y foi apenas 
marginalmente alterada, a do mutante FXN-I154F aumentou 
significativamente com a presença dos vários compostos, 
nomeadamente a adição de glicerol triplicou a quantidade de FXN-
I154F solúvel. Posteriormente, o efeito dos compostos na proteína 
enrolada, mais especificamente o efeito na conformação e estabilidade, 
foi também avaliado. Considerando a proteína já enrolada, os efeitos 
no mutante FXN-D122Y são mais significativos. A presença de TMAO 
resulta num aumento da estabilidade térmica do mutante FXN-D122Y 
para valores idênticos aos determinados para a proteína selvagem na 
ausência dos compostos (o aumento máximo do Tm de ~7.8ºC). Os 
estudos com a GroEL (GroEL sink  assay) permitiram ainda avaliar os 
defeitos conformacionais dos mutantes e a potencial correcção desses 
defeitos em consequência da presença dos chaperões químicos.  Três 
dos compostos testados (4PBA, trealose e glicerol) permitiram corrigir 
pelo menos parte dos defeitos conformacionais associados a mutação 
D122Y, resultando num atenuamento da ligação da proteína mutante à 
GroEL. Os efeitos destes compostos no mutante FXN-I154F enrolado 
são, no entanto, mais modestos: em termos de estabilização da 
proteína os compostos conseguem apenas induzir pequenas variações 
(máx. Tm de ~2.5ºC); considerando a conformação deste mutante, o 
ensaio com a GroEL revelou que apenas o TMAO (500mM) consegue 
reverter os defeitos conformacionais associados a este mutante, 
retardando a sua interacção com o GroEL. 
Este estudo revelou que os efeitos induzidos pelos potencias 
chaperões químicos durante o enrolamento são distintos dos 
observados na proteína enrolada. Verificou-se ainda que diferentes 
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mutantes são modulados de forma distinta pelo mesmo composto. 
Provavelmente estas diferenças resultam das variações 
conformacionais causadas por cada mutação. Os resultados aqui 
apresentados sugerem que provavelmente a variação conformacional 
inerente ao mutante FXN-D122Y pode ser ultrapassada, ou 
parcialmente revertida, pela presença de chaperões químicos, e, in 
vivo, a presença de chaperões químicos deverá presumivelmente 
evitar o fenótipo patológico associado à expressão deste mutante. Por 
outro lado, a presença de chaperões químicos in vivo deve apenas 
atenuar o fenótipo patológico associado à mutação I154F.   
O estudo aqui apresentado abordou ainda o impacto de 
modificações associadas ao stress oxidativo na frataxina humana. A 
priori, a frataxina é um potencial alvo de modificações associadas a 
este tipo de stress, não só devido a sua localização na mitocôndria, em 
que oxigénio e óxido nítrico estão disponíveis num ambiente redutor, 
mas também devido a sua função de chaperão de ferro. Assim, a 
frataxina humana selvagem foi submetida a condições que simulam o 
aumento de stress oxidativo dentro da mitocondria (H2O2 + Fe(II) ou 
alternativamente ONOO-), e posteriormente a proteína foi analisada por 
espectrometria de massa de forma a identificar possíveis modificações. 
Verificou-se que os resíduos na superfície da folha  são susceptíveis 
a carbonilações e nitrações (Tyr143, Tyr174, Tyr205 e Trp155). No 
entanto, estas modificações não alteram significativamente as 
propriedades funcionais da frataxina: a proteína modificada retém a 
sua capacidade de evitar a formação de espécies reactivas de oxigénio   
bem como a sua capacidade de ligar ferros essencial às suas funções 
como chaperão de ferro. Contudo, as modificações destabilizam a 
proteína (1.0 kcal.mol-1) e induzem uma abertura da conformação, 
como é evidenciado pelas desnaturações térmicas e pelas reacções de 
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proteólise limitada. Curiosamente, o Trp155, que é estritamente 
conservado e cuja mutação resulta em FRDA, é susceptível aos dois 
tipos de modificação identificadas, o que sugere que este resíduo 
talvez seja um hotspot funcional.  
 
A frataxina humana e de levedura têm um elevado grau de 
identidade estrutural também em termos da sua sequência de amino 
ácidos. Adicionalmente, o fenótipo inerente à ausência de frataxina é 
idêntico em células humanas e de levedura. Assim, o sistema modelo 
de levedura tem-se revelado extremamente útil no estudo da função da 
frataxina. Os estudos de seguida apresentados, em que as 
propriedades conformacionais e funcionais da frataxina são avaliadas, 
realizaram-se com o ortólogo de levedura (Yfh1). Com vista a uma 
melhor compreensão das propriedades funcionais e estruturais da 
frataxina, caracterizámos oito variantes envolvendo mutações nas duas 
regiões funcionais da proteína: a região entre a hélice 1 e a fita 1 e a 
superfície conservada da folha A capacidade da frataxina ligar ferros 
revelou-se bastante robusta, alterando cinco dos resíduos mais 
conservados da região envolvida na ligação do ferro. Não foi, contudo, 
suficiente para inibir a ligação de ferros. Assim, embora com uma 
menor afinidade, este mutante quíntuplo retém a capacidade de ligar 
ferro (2 Fe(II) por monómero). Os resultados aqui apresentados 
revelam ainda que estas cargas negativas, que estão associadas à 
capacidade da frataxina ligar ferro, têm também um papel estrutural e 
conformacional. A neutralização de cinco dessas cargas induz uma 
estabilização térmica de cerca de 24ºC e, simultaneamente, reduz a 
plasticidade conformacional da proteína. Estas observações, ilustram 
um interessante compromisso entre actividade e estabilidade 
associado a esta região da proteína. Adicionalmente, os resultados 
sugerem que os resíduos Asp101 e Glu103 estão também envolvidos 
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na  interacção entre a Yfh1 e a Isu, mas que no entanto a sua alteração 
não é suficiente para abolir a referida interacção, como é evidenciado 
pela recuperação do fenótipo causado pela yfh1. 
É também aqui demonstrado que os resíduos 122-124, cuja 
mutação compromete de forma drástica a função da frataxina, têm 
apenas um impacto modesto em termos da estabilidade da proteína 
(Tm ~0-4ºC) o que evidencia a importância destes resíduos na 
interacção com a Isu.    
A frataxina é estabilizada por diferentes iões metálicos; 
posteriormente foi também descrito que o níquel pode recuperar, pelo 
menos parcialmente, as deficiências celulares associadas aos 
mutantes clínicos. Assim, pretendeu-se explorar a hipótese de a 
frataxina ligar outros metais, além do ferro. De entre os metais 
estudados - cálcio, cobre, sódio, magnésio, níquel, manganês e zinco - 
apenas o cobre causa o quenching da fluorescência emitida pelos Trp 
da Yfh1, sugerindo que este metal se liga à frataxina.  A frataxina liga 
Cu (I) (3Cu(I):Yfh1)  e Cu(II) (4Cu(II):Yfh1), sendo a sua afinidade para 
Cu (I) maior. A ligação do Cu(II) à proteína foi posteriormente avaliada 
por EPR. Estas experiências permitiram confirmar que o cobre se liga 
especificamente à frataxina e também sugeriram a existência de 
diferentes locais de ligação. Uma vez que a frataxina se localiza na 
matriz mitocondrial e este compartimento apresenta uma elevada 
concentração de Cu(I), é talvez possível que a frataxina contribua para 
o equilíbrio da homeostase mitocondrial de cobre: ao ligar-se ao cobre, 
a frataxina poderá evitar a formação de espécies reactivas de oxigénio 
em consequência da oxidação do cobre. O ferro, ao ligar-se à frataxina, 
induz a sua oligomerização, maximizando a função protectora da 
frataxina. Contudo, as medições por DLS revelaram que a ligação de 
cobre à frataxina não induz a sua oligomerização. Assim, se de facto a 
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frataxina está envolvida na protecção contra a toxicidade do cobre, 
esta hipotética função não está associada à oligomerização da 
proteína. A afinidade para o cobre e para o ferro são idênticas, o que 
pode sugerir uma função alternativa para a capacidade desta proteína 
ligar cobre. Este metal pode potencialmente regular a função da 
frataxina como chaperão de ferro e, de acordo com os ensaios de 
competição cobre/ferro, isto pode ocorrer parcialmente. A presença de 
cobre em solução reduz a afinidade da Yfh1 para a Isu, no entanto, 
mesmo em excesso, a presença de cobre não impede esta interacção. 
Alternativamente, além de uma função com chaperão de ferro, a 
frataxina poderá também funcionar como um chaperão de cobre, 
direccionando o cobre presente na matriz para os chaperões de cobre 
presentes na membrana interna da mitocôndria. Assim, a potencial 
capacidade de a frataxina funcionar como um chaperão de cobre foi 
avaliada através da reconstituição da Apo-SOD1 in vitro. Os resultados 
aqui apresentados revelam que a presença de frataxina facilita a 
reconstituição da apo-SOD1, o que sugere que esta proteína poderá 
efectivamente funcionar como um chaperão de cobre.  
A capacidade de a frataxina ligar cobre tem que ser mais explorada: 
primeiro é necessário estabelecer se, in vivo, a frataxina é também 
capaz de ligar cobre e, caso isto se verifique, mais estudos serão 
necessários no sentido de clarificar o significado biológico de a 
frataxina ligar cobre. Adicionalmente, um estudo mais químico visando 
a caracterização da ligação do cobre à frataxina terá que ser realizado. 
 
Os resultados aqui apresentados pretendem contribuir para uma 
melhor compreensão do processo patológico da ataxia de Friedreich. 
Os estudos realizados com o ortológo de levedura permitiram contribuir 
para a caracterização das regiões funcionais da frataxina e revelaram 
ainda uma nova propriedade destas proteínas.  
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1.1. The Importance of Folding 
Proteins are remarkable and mysterious molecules. Not only they 
are the most abundant molecules in biology (besides water) but they 
are also responsible for every chemical process that makes the 
existence of living systems possible. Proteins are synthesised as 
polymeric sequences of amino acid residues but, in order to be 
functional, most proteins need to acquire a specific three-dimensional 
structure. The folding process is usually extremely efficient, leading to 
the formation of highly specific structures that grant proteins selective 
and diverse functions. However, the folding process is not fail proof 
and indeed a percentage of all proteins produced in the cell fail to fold 
correctly. Misfolded proteins are not only a product of inefficient folding 
but can also be formed as a consequence of stress conditions. 
Changes in the cellular environment due to ageing or temperature 
fluctuations, as well as genetic mutations, are known to cause protein 
misfolding or unfolding.  To cope with misfolding and unfolding of 
proteins, cells have developed a protein quality control system, which 
comprises both chaperones and proteases and is responsible for 
limiting this burden. Unfortunately, the capacity of the protein quality 
control is limited and protein aggregation and misfolding are now 
recognised as the cause of a large and diverse group of diseases 
called protein conformational diseases or misfolding diseases. 
This chapter describes the mechanisms proposed to explain the 
protein folding problem to then focus on the complexities inherent to 
protein folding in the crowded cellular environment and further the 
consequences of overloading the protein quality control system are 
addressed.  
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1.1.1. The Protein Folding Mystery 
How a protein folds to its functional native state is a fundamental 
process that has occupied the mind of scientists for almost 50 years. 
The protein folding process can be divided in two major problems. The 
first was introduced through the pioneering work of Anfinsen and his 
co-workers on the folding/refolding of ribonuclease A [1-2].  They have 
shown that a polypeptide chain can spontaneously fold downhill to its 
lowest free-energy conformation (predetermined functional native 
state) without the help of any other biological machinery. This 
observation encompasses one of the key concepts in protein science, 
which is that all the information necessary for a protein to fold is 
encoded in its own amino acid sequence.  
The second problem focuses on the kinetics and dynamics of 
folding, and it was introduced by Levinthal in 1968 [3-4]. He has 
demonstrated that the folding process could not consist of a systematic 
search of all the conformational space otherwise it would take an 
enormous amount of time for a protein to acquire the native state, 
approx. 1052 sec for a protein with ~100 amino acid residues - 
Levinthal Paradox. 
The solution to the second problem would automatically solve the 
first one, however, in spite of the numerous folding studies, both 
theoretical and experimental, that have focused on the folding kinetics 
and dynamics, this is still an open field and many questions and 
uncertainties remain. Methods such as threading [5] and homology 
modelling [6-7] will probably allow for the prediction of the native 
structure, thus solving the first problem without going over a complete 
description of how a polypeptide acquires its structure in a short 
amount of time.  
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1.1.2. The Search for a Protein Folding Mechanism 
During the folding process, amino acid residues are not 
independent pieces: they interact with each other and these 
interactions are not limited to consecutive residues. Long-range 
interactions are also involved in the folding process and if on one hand 
these interactions allow the folding process to be cooperative, they 
also increase the complexity of describing the folding process of any 
given protein [8-9]. In addition, folding kinetics are also puzzling, as 
folding is generally accomplished in a timescale in the order of 
milliseconds to seconds.  Levinthal postulated the first protein folding 
model, proposing that the folding pathway occurs through a well 
defined and sequential path (sequential model) [10]. Since then other 
models have been postulated aiming at describing the folding process. 
Here, an overview of those models is presented.  
In 1973, Wetlaufer has proposed the classical nucleation model 
[11].  This model suggests that the folding process is initiated by the 
formation of native secondary structure through the interaction of 
consecutive/neighbouring residues. The first elements of secondary 
structure will then act as seeds for the folding process, which occurs in 
a stepwise way without the formation of intermediates. During the 
1970s and the 1980s, scientists have focused on the study of folding 
intermediates [12] and the classical nucleation model was discredited.  
In 1976, and based on Afinsen experiments  [2] and on the Ptitsyn 
and Rashin model [13-14], Karplus and Weaver postulated the 
diffusion-collision model (Fig. 1.1) [15-16]. This model relies on the 
existence of small elements of secondary structure, microdomains, 
which can assemble and disassemble transiently. Microdomains 
diffuse and their collision and coalescence lead to the formation of 
long-range interaction - tertiary structure. The model contemplated the 
existence of multiple folding pathways as coalescence can proceed 
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through a unique path or by parallel paths. Folding process dynamics 
are reduced as they rely on the global properties of each microdomain 
and its interactions. A few years later, in 1982, and based on 
experimental evidence, Kim and Baldwin proposed the framework 
model [12] whose description did not differ significantly from the 
diffusion-collision.  
Figure 1.1: Simplified energy diagrams for folding of small single-domain proteins 
describing the differences between diffusion-collision and nucleation-condensation 
models.  (A) Pure diffusion-collision: first secondary structure is formed leading to the 
formation of a low energy intermediate and then through diffusion and collision of 
secondary structure elements the tertiary structure is formed; (B) pure diffusion-
collision as in (A) but a high energy intermediate is formed; (C) mixed diffusion-
collision/nucleation-condensation: the formation of a high energy intermediate 
containing secondary and tertiary structure; (D) pure nucleation-diffusion: no 
intermediate is formed and at the transition state both secondary and tertiary 
structures are formed concurrently. As the propensity to form secondary structure 
increases, the folding mechanism shifts from the nucleation-condensation to the 
diffusion-collision.  Adapted from [17]. 
 
The jigsaw-puzzle model was proposed by Harrison and Durbin in 
1985 and suggests that folding occurs through different, parallel 
pathways rather than through a single path [18]. The existence of 
multiple paths makes folding more robust (kinetically) to mutations that 
do not disrupt the native structure.  According to this model, the 
selection of the pathways follows the search for structures with 
increasing stability. Several unfolded states can be considered and the 
paths are enumerable, meaning that if intermediates do exist they 
G
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should comprise a random assortment of substructures of the native 
protein.  Pulsed hydrogen exchange studies have demonstrated that 
the folding intermediates formed along the folding pathway are 
specific. These observations contradict what was proposed by the 
jigsaw-puzzle model and thus the model was abandoned. 
The hydrophobic collapse model [19-21], suggests the existence of 
an initial hydrophobic collapse that restricts and consequently guides 
the subsequence folding steps, since folding/conformations are only 
allowed within the confined volume defined by the initial collapse.  
Later, folding studies on CI2 [22-23] have demonstrated that folding 
does not rely on the accumulation of intermediates and that, in fact, 
folding can occur via a simple two state kinetics. These results, 
together with the CI2 -value analysis, lead to the formulation of a new 
folding model: the nucleation-condensation model [24-25]. -value 
analysis is the only experimental method allowing the evaluation and 
characterisation of the transition state (Fig. 1.2) [26-29]. It consists on 
the systematic study of the energetic consequences of introducing 
mutations throughout the protein. The effect of mutations is measured 
in both kinetic and equilibrium studies yielding information on the 
transition states of the folding-unfolding reaction. Mutations can be 
regarded as structural probes of each residue and the -value is 
defined by the following equation: 
 
∆∆Φ
∆ ∆
∆ ∆
 
∆∆
∆∆
   (equation 1) 
GTS-D and GN-D are the free energies of the transition 
state/intermediate and the native state, respectively, relative to the 
denatured state for the wild type protein.  
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Figure 1.2: Information redrawn from the -value analysis. After introducing a 
mutation, if the transition state energetics is the same as in the native state, the 
protein is immune to that mutation until after the transition state is reached, meaning 
that both the transition and the native states are equally affected by the mutation 
(GTS-D = GN-D), 1 (residue a). On the contrary, 0 means that the structure of 
the transition state at the site of the mutation is the same as in the denatured stated 
(residue b). 0 < <1, correspond to structures that are partially folded at the transition 
state. From [30].  
 
The nucleation-condensation model conciliates the concepts from 
the framework and the hydrophobic-collapse models. It postulates the 
existence of a nucleus that constitutes the transition state; if a mutation 
occurs within the residues of the nucleus, this will not abolish the 
folding process but it will slow it down. The folding process is guided 
by an initial collapse around the protein hydrophobic side chains 
(generating the nucleus), after which the structure rearranges from the 
restricted conformational space occupied by the intermediate until it 
acquires the native like structure. According to this model the 
secondary structure formation is guided by the native-like tertiary 
interactions formed during the initial collapse (Fig. 1.1).  
a b
Native
State
Denatured
StateTransition
State
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1.1.3. Energy Landscapes  
With the exception of the diffusion-collision model, that correlates 
the folding time with some of the system parameters, the models 
presented above describe the phenomenological aspects of the folding 
process without addressing the kinetic problem. In 1994, Sali, 
Shakhnovich and Karplus postulated a model that solves Levinthal’s 
paradox [31-32]. They have used a lattice Monte Carlo model to 
simulate the folding reaction. In this model, the allowed interactions 
within the polypeptide chain are expressed by a potential function. The 
protein is described as a string/chain of self-avoiding beads positioned 
at determined sites on a cubic lattice: Due to steric constraints for a 
given conformation, each site can at most be occupied by one bead. 
The beads interact with each other by pair wise contact potentials that 
represent the residue-residue interactions [33-34]. Changes in the 
chain conformation are made repeatedly and accepted or rejected 
according to the energy change they induce. The algorithm is designed 
to favour conformational changes that lead to a decrease in energy, 
which is in agreement with the folding search of a real protein where 
native-like interactions are on average more stabilised (have lower 
energy) than non-native ones.  The successive conformational 
changes are described by a potential energy function and constitute 
the folding trajectory. This new model allows for the exact 
determination of the native state, for the calculation of the 
thermodynamic properties of the system as a function of the folding 
coordinate (amount of native contacts formed) and for the calculation 
of the free-energy surface for the folding reaction. The free-energy 
surface is a schematic three-dimensional representation of the folding 
progress coordinates where the free energy of each conformation is 
represented as a function of the total number of contacts, native and 
non-native, between non-consecutive residues and the number of 
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native contacts. The Monte Carlo simulations performed by Karplus 
and his co-workers on a simplified protein model, a 27-bead self 
avoiding chain on a cubic lattice, lead to the establishment of a three-
stage folding model (Fig. 1.3).  
 
 
Figure 1.3: Three-stage mechanism of folding proposed by Karplus 
and co-workers (Lattice model). The number of states was calculated 
considering a 27-mer.Adapted from [31].  
 
The first step involves a rapid collapse to a semi-compact random 
globule (with ~60% of the total number of possible contacts), this step 
reduces the amount of possible conformation from ~1016 to ~1010 [32]. 
The second step is the rate limiting step and involves the search for 
the transition states that will successfully and rapidly lead to the native 
state.  The transition states are similar to the native state and comprise 
80-95% of the native contacts. In the last step, the native state is 
rapidly obtained from any of the transition states. As folding proceeds 
along the three stages, the number of available conformations 
decreases and this loss of entropy between stages is determinant for 
the shape of the free-energy surface. If the contribution to the free-
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energy of the conformational entropy decreases faster than the 
average energies, a barrier is formed on the free-energy surface, 
corresponding to the transition states [35]. Also, this decrease in the 
available conformations as the sequence approaches the native fold 
leads to the introduction of an important concept in protein folding – 
the folding funnel [36].  
Although all the phenomenological models previously described 
already contain energetic concepts, the lattice simulation imposed a 
need to describe the energetic factor biasing the folding process. Also, 
the Monte Carlo simulations highlighted the fact that a sequence can 
undergo several folding trajectories at the same time, leading to an 
ensemble of high energy intermediate states close in structure to the 
native state that corresponds to the unique transition state described 
by experimentalists. The pathway view is replaced by the energy 
landscape description, and the folding process is viewed as an 
ensemble of conformations sliding down through a unique energy 
funnel leading to the most energetically stable conformation - the 
native state. As proteins increase in size, the folding process becomes 
more complex and barriers to the organisation on the collapse-state 
are likely to be larger, leading to rougher landscapes and multiple 
"pathways" [37]. Experiments on lysozyme (129 aa) showed that the 
folding kinetics of this protein are quite complex and heterogeneous 
[38-40]. Nonetheless, they can be explained, qualitatively, through a 
free-energy surface (Fig. 1.4). At least two folding 
trajectories/scenarios can be put forward, a fast trajectory involving a  
rate constant of less than 100 ms (yellow) [41] and a slower one that 
although significantly more populated (~70%) has a rate constant of 
~400 ms (red) [40].  
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Figure 1.4: Schematic free-energy (F) surface representing features of 
the folding of hen lysozyme (a protein comprising an  and a  domain 
with 129 amino acid residues). Through the yellow trajectory (fast track) 
the  and the  domains are formed concurrently populating the 
intermediate only briefly. Through the red trajectory (slow track) the 
polypeptide chain is trapped in a long-lived intermediate with persistent 
structure involving only the -domain. Further folding from this 
intermediate involves either a transition over a higher barrier or partially 
unfolding.  Adapted from [35]. 
 
When the unfolded state proceeds through the yellow trajectory, 
both  and  lysozyme domains are simultaneously formed and the 
transition state is very close to the native state. However, when folding 
follows the red trajectory, the formation of the two domains is not 
simultaneous. First, the  domain is formed, leading to an intermediate 
that traps the folding process, a free-energy minimum. For the -
domain to be formed, it is not clear whether the  domain has to be 
partially unfolded or go over a higher barrier.  The last step of the two 
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trajectories seems to be identical and comprises the docking of the two 
domains [40]. The similarity between the folding landscape obtained 
experimentally for lysozyme and the one obtained when simulating the 
folding of a 125-mer with a 5x5x5 cubic native state is remarkable. 
Therefore, energy landscapes constitute a conceptual framework for 
understanding both two-state and multi-state folding kinetics [35, 42]. 
Since the folding time will increase exponentially with the chain length, 
due to the fact that the number of semi-compact states increases 
faster than the number of transition states, the three-stage model will 
not be able to give reasonable folding times for long chains. 
The traditional models can, in particular cases, be better 
phenomenological descriptions of the folding process, but this ‘new 
view’ of folding provides a unifying mechanistic description for the 
different proteins regardless of their folding complexity. More 
importantly, it provides a framework for the interpretation of 
experimental observations.  
 
1.1.4. Protein Folding in the Cell 
Partially folded proteins expose regions that in the native state are 
buried and this promotes inappropriate intramolecular interactions that 
may lead to aggregation. To overcome this problem, biological 
systems have developed the molecular chaperone machinery that 
prevent and guarantee efficient folding within the cellular environment.  
Molecular chaperones stabilise and guide folding without altering the 
predetermined native fold. It has been shown that a large portion of the 
proteins that are synthesised require further assistance in order to fold 
correctly in a biologically relevant amount of time. The physical 
principles guiding folding in vitro and in vivo are the same but in vivo 
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additional factors will affect the success of folding. The first obvious 
difference between the test tube and cellular environment is the 
concentrations of macromolecules. While polypeptide chains in vitro 
refold in very diluted solutions (<1 mg/ml), the cellular environment is 
extremely crowded (300-400 mg/ml of proteins and other 
macromolecules [43]) which significantly increases the affinity between 
the different species present such as folding intermediates and could 
lead to aggregation [44]. The crowding effect can indeed increase the 
association constants between macromolecules, favouring 
aggregation, but this effect is more significant for small proteins, as 
larger ones will have a reduced diffusion which limits the encounter 
rate with other macromolecules. Nevertheless, crowding may also 
have a positive impact on the folding propensity [45-46]. It promotes 
the exclusion volume, stabilising the native and compact states. In 
addition, it may increase molecular chaperones function by promoting 
their encounter with partially unfolded proteins, facilitating chaperones 
successive reaction cycles with non-native proteins [44, 47].  
In the cell folding can be co-translational and, while on a first 
approach this could be regarded as a mechanism to avoid the harmful 
interaction between polypeptide chains and to guide proper folding, it 
can also have a negative impact. As chains elongate, the polypeptide 
chains move along the ribosome tunnel until they are released to the 
cytosol. However, this tunnel is quite long and not very wide [48] (only 
after the addition of 20-40 amino acids the chain starts to emerge from  
the ribosome [49]), which represents constraints to the conformational 
space available to the nascent chain [50-51]. This conformational 
constraint can guide the folding process and avoid harmful interactions 
but, at the same time, also avoid native–like interactions or promote 
non-native ones leading to folding traps.  The conformational 
constraints imposed by the ribosome tunnel can be particularly harmful 
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for the assembly of parallel -sheets and complex antiparallel -sheet 
topologies since these structure elements involve interactions between 
residues that are distant in sequence. In addition, translation is 
relatively slow (~15-75s for a 300 amino-acid protein [52]) leading to 
the exposure of partially folded nascent chains to cellular environment 
for a long period of time which represents another challenge for the de 
novo folding.  Individual ribosomes are grouped in polysomes during 
active protein synthesis.  
The 3D organisation of 
the polysomes revealed 
that ribosomes are 
organised along the mRNA 
through a pseudohelical 
orientation. The transcript 
is sequestered inside, 
while the tRNA entrance 
sites as well as the 
polypeptide exit sites face 
the cytosol (Fig. 1.5). This 
orientation allows for the 
maximisation of the 
distance between nascent chains on adjacent ribosomes, thus also 
contributing for decreasing the probability of intermolecular interactions 
that would lead to aggregation. 
Considering the complexity inherent to the folding process within 
the cell, a new schematic energy landscape had to be re-drawn to 
describe protein folding and the aggregation process under 
physiological conditions [54].  
 
Figure 1.5: Model of nascent chain 
configurations in a representative polysome.  
From [53]. 
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Figure 1.6: Folding funnels designed to describe the competition between 
productive/efficient folding and aggregation. Left.  A higher-dimensional energy 
landscape contour plot that includes stabilising interactions between two polypeptide 
chains. In this simplified example, the stable aggregate is formed via intermolecular 
stabilising interactions that develop between two partially folded conformations with 
about 50% of the contacts present in the native state. Darker colours represent lower 
energy conformations. Right. A double funnel depicting the competition between 
folding and aggregation. The surface shows the ensemble of unfolded conformations 
funnelling towards the native state via intramolecular contacts formation or towards 
the formation of aggregated states via intermolecular contacts. The relative population 
of the different states depend on the kinetics and thermodynamics of the various 
equilibrium states. The lowest energy state for the aggregate might or might not 
represent the true global energy minimum regardless of this it is sufficiently kinetically 
trapped from the native conformation and in living systems, the fate of a given protein 
molecule is closely related by the protein quality control. Adapted from [54-56]. 
 
This new energy landscape formulation was extended to 
contemplate different scenarios like aggregation, fibril formation and 
co-translational folding, as well as the action of molecular chaperones 
and other cellular factors (Fig. 1.6) [57-59]. The surface shows the 
diversity of the unfolded state as previous descriptions. On the left side 
of the funnel, intermolecular contacts lead to the formation of non-
native structures such as aggregates and amyloid fibrils that are likely 
to occur due to misfolding and exposure of hydrophobic regions. 
Intermolecular contacts lead to the deepest minima (more stable), thus 
the native state is not necessarily the most stable structure. On the 
Disordered 
aggregate
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funnel right hand side, intramolecular interactions are dominant, and 
the native state is formed, however, intermediates that might need 
some refolding to evolve towards the native state are also present.  
1.1.5. Protein Evolution 
The concept of a funnelled energy landscape has its biological 
consequences, the first immediate one being that proteins are 
structurally robust [60]. A mutation may not disrupt the balance 
between the entropy of the unfolded state and the free energy of the 
folded state; if this occurs, the funnel landscape model allows for the 
new native state to be identical in terms of structure and stability to the 
primordial protein and likely function is also retained [61-62].  
Structural studies on proteins have shown that different unrelated 
sequences (no homology) can assume the same fold, which means 
that the space of possible sequences exceeds by far the space of 
allowed structures. Also, proteins with the same fold may not have the 
same ancestor, which constitutes evidence of a convergent evolution 
[63]. Proteins that are structurally homologous usually show an 
identical folding funnel since their folding mechanism is expected to be 
conserved. Transition state conformations among homologous 
proteins are likely to be identical and thus the differences in terms of 
folding rate are a direct consequence of different native state stabilities 
[61]. The enzymes’ ability to process chemicals that have only recently 
appeared on this planet and the emergence of drug resistance 
highlights the proteins’ tremendous capacity to acquire new functions 
and structures. Evolution of function within the same fold is largely 
accepted [64], however, the mechanisms underlining structural 
evolution are still controversial. Tawfik and co-workers suggested that 
protein evolution relies on protein functional promiscuity and 
Chapter 1 
18 
 
conformational diversity [65-66]. Natively unfolded proteins constitute 
the most extreme, yet remarkable, example of protein conformational 
diversity.  These proteins can have two distinct structures: unfolded 
and folded once they bind to their ligands or proteins partners [67]. The 
analysis of several proteomes has shown that natively unfolded 
proteins are not rare events, and in fact eukaryotes have a percentage 
of natively unfolded proteins between 31-51% [68]. Eukaryote 
organisms have the higher percentage of natively unfolded proteins 
which may result from the fact that these organisms have a greater 
need for protein mediated signalling, regulation and control, functions 
that are common among natively unfolded proteins. The identification 
of intrinsically unfolded/disorder proteins has imposed a review of the 
structure-function paradigm, a defined structure is no longer a 
prerequisite for function or at least not for all proteins.   
Fold is likely to have co-evolved with function and accordingly, 
structural plasticity (the ability to adapt to mutations) enables a parallel 
and smooth evolutionary transformation of structure and function via 
intermediates containing a structural ensemble [65, 69]. Two different 
folds may not be totally separated in sequence space and the marginal 
stability of native folds ensures that novel folds are evolvable upon a 
few mutations via intermediate bridge sequences called evolutionary 
bridges (Fig. 1.7, [70]). The existence of these bridges allows proteins 
to explore new structures and new functions but at the same time 
retain the original ones. The sequence of these bridges impairs the 
exclusive selection of one of the possible folds and crossing this state 
will depend on the functionality of both folds. However, these bridges 
can also result in evolutionary discontinuity. They can be regarded as 
evolutionary dead ends when leading to constrains to allosteric 
systems or protein misfolding.  
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Figure 1.7: Transition folds through an evolutionary bridge. Two different topologies 
(mediated by three different disulfide bridges) are found in two naturally occurring 
cysteine-rich domains (NW1 and Mcol1C) that show almost no sequence identity 
beyond the conserved cysteines. Conversion between these topologies was 
demonstrated via one mutation Lys21 → Pro21 (K21P). This mutation leads to an 
intermediate that equilibrates between the two topologies (evolutionary bridge). A 
second mutation Gly11→Val11 (G11V) completes the transition [71]. Adapted from 
[70] .  
 
Protein folds are robust not only as a result of sequence selection, 
but also due to the presence of chaperones and to the stability 
thresholds associated to each fold that may lead to the accumulation 
of damaging mutations [72-74]. By stabilising proteins against 
misfolding chaperones, they act like buffers preventing the formation of 
non-native structures extending the neutral networks (no effect results 
from the introduction of mutations). Due to the chaperones sensitivity 
and response to environmental stress, they are likely to act like 
evolutionary aiders. 
 Considering this scenario of co-evolution of fold and function, and 
the existence of proteins with structural plasticity, it may be suggested 
Lys21Pro Gly11Val
~78% ~22%
<95% 95%
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that the early folds evolved from functional but yet intrinsically unfolded 
proteins [75]. 
1.2. When the Folding Process Goes Wrong:  
Misfolding and Aggregation 
Life depends enormously on the ability of proteins to be functional, 
which for most relies on their ability to fold into their correct native-like 
three dimensional structures. However, the folding process is not 
perfect and proteins may not fold correctly. In fact, ~20% of newly 
synthesised proteins are unable to attain the correct fold, even with the 
help of molecular chaperones, and are degraded by proteases [76]. In 
a concerted way, molecular chaperones and proteases supervise and 
regulate the folding process (protein quality control). Only when these 
fail or become overloaded pathological behaviours associated with 
protein misfolding start to be observed. Changes in the cellular 
environment, such as temperature fluctuations, increased oxidative 
stress and ageing, as well as changes at the protein level, such as the 
insertion of mutations, culminate in an increase of the burden of 
misfolded proteins, leading to the failure of the protein quality control. 
Protein misfolding and aggregation can result in a large and diverse 
group of diseases described as 'protein misfolding' or 'protein 
conformational' diseases [77]. These pathologies may result either 
from a 'loss-of-function' or a 'gain-of-function'. Typically, pathologies 
associated to 'loss-of-function', such as Cystic Fibrosis, result from a 
high proteolytic degradation of a given protein. If a protein misfolds to a 
greater extent and is unable to refold, it is degraded by the protelytic 
system which results in reduced functional levels of that protein. 
Alternatively, misfolding can lead to a 'gain-of-function' if it confers 
cytotoxicity to the 'diseases protein', promoting inappropriate 
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interactions that lead to protein aggregation. Amyloid diseases and 
Huntington's are examples of diseases associated to a 'gain-of-
function' [78].  Mutations increasing the protein's hydrophobicity or 
decreasing its charge favour intramolecular interactions and hence 
aggregation. Also, alterations to proteins that lead to a deficient 
processing may result in the accumulation of protein fragments that 
can act as seeds of the aggregation process [55, 79-80]. 
1.2.1. Molecular Chaperones 
Molecular chaperones are involved in a wide range of cellular 
processes including de novo folding, refolding of stress-denatured 
proteins, oligomeric assembly, intracellular protein transport and 
assistance in proteolytic degradation (Table 1.1) [52]. Chaperones 
interact, stabilise and guide non-native proteins to fold into the native-
state, but do not determine the native fold nor are present in the final 
functional structure.  
Chaperones are expressed in multiple cellular compartments. 
Although not much is known about their cellular concentration or 
whether they are freely available in the cell to cope with sudden folding 
requirements, they should constitute a considerable fraction of the 
cellular machinery [81-83].  These folding 'helpers' are growth-
regulated and stress-responsive bridging stress signalling processes 
with protein homeostasis. The key regulator of molecular chaperones 
in eukaryotes is the heat-shock factor-1 (HSF1) which is highly 
conserved and ubiquitously expressed. Its DNA-binding and 
transcriptional activities are inhibited and regulated by the molecular 
chaperones themselves that remain weakly bound to HSF1 in the 
absence of stress [83]. 
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Table 1.1: Major chaperone and proteases families.
 
Family 
 
E.Coli 
Interacting 
partner 
(co-chaperone) 
Eukaryotic 
Homolog 
(localization)a 
 
Activityb 
 
Phenotype 
(null 
mutants) 
Ref.d 
AAA+ 
(Hsp100/
Clp) 
Clp A Clp P Clp P (m) AP 
No 
Phenotype 
[76, 84] 
Clp B  
Hsp104 (c), 
Hsp 78 (m) 
AD of 
aggregates 
Impaired 
Thermo-
tolerance 
[85-89] 
Clp X Clp P 
Clp X 
(Humans - m; 
plants - ch) 
AP 
No 
phenotype 
[90-94] 
Clp Y 
(HsIU) 
Clp Q (HsIV)  AP 
No 
phenotype 
[95-97] 
FtSH  
Agf3, Rcalp 
(m) 
AP Lethal [98-101] 
Lon  PIM1 (m) AP 
Mucoid 
Growth 
[102-107] 
Hsp 90 Htp G  Hsp 82 AC 
Reduced 
growth rate at 
44ºC 
[108] 
Hsp 70 DnaK DnaJ, CbpA, 
DjlA 
Hsp70, 
Hsp72, Bip, 
etc 
AC 
Temperature 
sensitive 
growth 
(39ºC) 
[108] 
 Hsc A Hsc B Ssq1p ACc Slow Growth [109] 
 Hsc 62 (YbeS, YbeY)  AC No 
phenotype 
[110-111] 
Hsp 60 GroEL GroES CCT, TriC AC Lethal [109] 
sHSP IbpA, 
IbpB 
 Hsp 25, etc AC 
No 
phenotype 
[109] 
Hsp 33 Hsp33   
Redox-
regulated 
AiC 
Slightly 
sensitive 
towards High   
temperature 
and H2O2 
[109] 
TF Trigger 
factor 
  
PPIase, 
AiC 
No 
phenotype 
[109] 
a (m) – mitochondria, (c) – cytosol and (ch) – chloroplasts; 
b AP – ATP-dependent proteolysis; AD – ATP-dependent disaggregation; AC – ATP-dependent 
chaperone; ATP-independent chaperone; 
c ATP-dependent chaperone involved in Fe-S cluster formation and protein maturation 
d References are not all-inclusive. Emphasis on review articles and papers demonstrating the 
chaperon/protease activity.  
 
 
Molecular chaperones selectively bind to hydrophobic residues 
and/or unstructured backbone regions, features that are normally 
exposed in non-native states but are shielded in the native state [112-
113]. When binding to non-native conformations, chaperones ‘hold’ the 
proteins in an ‘on-pathway’ conformation avoiding harmful interactions 
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that could lead either to aggregation, or to conformational trapping 
(e.g. Hsp104 and sHSPs). In addition to being able to block deleterious 
interaction, some chaperones are also able to promote the correct 
folding (Hsp70 system) [112, 114]. Apart from these two remarkable 
features, the Hsp60/CCT/Clp/Hsp104 chaperone machinery can also 
reverse intra-molecular misfolding, by unfolding and disrupting small 
aggregates [115]. For a growing number of proteins the chaperone 
activity has to be combined with isomerase activity (PDIs and PPIases) 
in order for the correct fold to be guaranteed [116].  
Two molecular chaperone systems are involved in the protection 
against the proteotoxic effect inherent to misfolding diseases: the Hsp 
70 and the chaperonins. The members of the Hsp70 family exist in the 
cytosol of eukaryotes as well as in their organelles such as 
endoplasmatic reticulum and mitochondria [117]. Comprising a wide 
range of functions such as assisting de novo folding, assembling of 
newly synthesised proteins into macromolecular complexes, avoiding 
aggregation, dissolving and refolding aggregated proteins, protein 
trafficking and assistance in the proteolytic degradations of terminally 
misfolded proteins, this family of molecular chaperones is not only 
constitutively expressed but their expression is also induced/increased 
under stress conditions [117-119]. Hsp70’s have two domains, an N-
terminal ATP-binding domain (NBD) and a C-terminal substrate 
binding domain (SBD) and both are essential for its chaperone activity. 
The binding of ATP to the NBD domain induces an "open" 
conformation that allows for the substrate to be recognised. When a 
substrate binds to the SBD domain, ATP is hydrolysed and the SDB 
domain conformation "closes", stabilising the chaperone-substrate 
complex. ADP is then released and the binding of another ATP 
molecule to the NBD will induce the opening of the SBD domain and 
consequently the substrate will be released. This cycle of binding and 
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release of the substrate promotes folding and at the same time 
prevents aggregation [114, 120]. The molecular process by which 
Hsp70’s induce conformational changes is still not clear, but a 
mechanism involving entropic pulling is hypothesised [121]. According 
to this mechanism, when Hsp70 binds to the substrate it locally 
stabilises it in the unfolded state. Disaggregation is favoured and, once 
the substrate is released, it can fold into the native state. Co-factors 
(NEF) and co-chaperones (Hsp40/DnaJ) participate and regulate 
Hsp70 chaperone activities. While co-factors control the Hsp70 cycles 
by facilitating the ADP release and rebinding of ATP, co-chaperones 
control the specificity of Hsp70’s by targeting the substrates to the 
chaperone [52, 81]. Bag-1, a co-chaperone of this system, binds to the 
proteosome directing proteins for degradation, and thus has a crucial 
and regulatory role in protein degradation [122].  
The Hsp70 machinery has been implicated in the pathogenesis of 
misfolding and age-related diseases [123]. Hsp 70, as well as other 
chaperones and components of the ubiquitin-proteosome system, 
have been found in inclusion bodies/plaques characteristic of 
neurodegenerative diseases associated to protein misfolding [124]. In 
addition, although Hsp70 machinery is active in polyglutamine cell 
models it is unable to prevent protein aggregation. Together, these 
observations suggest that Hsp70 machinery is indeed activated during 
misfolding pathologies, however its capacity is likely to be exceeded. 
[125-127]. Ageing cells show a decreased transcription of the Hsp70 
machinery and a decreased DNA binding activity of the transcription 
factor HSF-1 (the regulator of Hsp expression), thus these cells are 
more prone to the accumulation of toxic misfolded proteins [128-131]. 
In agreement, the most severely affected neurons in Huntington’s 
disease, a pathology associated to protein misfolding and aggregation, 
show reduced Hsp70 expression levels [132-133], highlighting the 
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importance of this chaperone system in the regulation of neuronal 
susceptibility towards degeneration.  
Chaperonins are large (~800kDa), doubled ring complexes 
enclosing a central cavity (Fig. 1.8). Conserved throughout evolution, 
chaperonins are divided in 2 subgroups [52, 117]. Group I (Hsp60’s) 
occurs in bacteria (GroEL), mitochondria and chloroplasts.  GroES 
(bacteria) or Hsp10 family cooperate with this group by acting as a lid 
of the ring complex. Chaperonins have a crucial role in the regulation 
of protein homeostasis and a single point mutation (V98I) on 
mitochondrial Hsp60 severely impairs its regulatory function in some 
cell types leading to the development of hereditary spastic paraplesgia 
(Table 2) [134-135]. Group II is present in archea and eukaryotic 
cytosol (TRiC/CCT), and, is GroES independent since their lid function 
is embedded into the chaperonin ring in the form of specialised -
helical extensions. TRiC promotes the folding of newly synthesised 
peptides (that may be presented by the Hsp70 and/or the co-
chaperone prefoldin), its expression is transcriptionally and functionally 
linked to protein synthesis and is not stress induced [136-137]. The 
group II has been extensively implicated in the development of 
neurodegenerative diseases, especially in Huntington's disease. 
Several experimental evidences suggest that TRiC modulates 
huntingtin aggregation [123, 138]. The TRiC polypeptide binding region 
has diverged during evolution to create substrate binding specificity. Its 
substrates tend to be large hydrophobic proteins with -strands and 
high aggregation propensity, which are characteristics present in 
polyQ- expanded huntingtin as well as other amyloidogenic proteins 
[139-141]. The concerted action with Hsp70 optimises TRiC 
neuroprotective properties [142]. 
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Figure 1.8: The GroEL-ES chaperonin. A) Crystal structure of the aymetric GroEL-ES 
complex (PBD 1AON). B) Working model summarising the conformational changes in 
a substrate protein upon transfer from Hsp70 system (DnaK, DnaJ and GrpE) to 
GroEL and during GroEL-GroES-mediated folding (ATP dependent cycles). (1) 
Substrate protein may be delivered to the GroEl by the Hsp70 system in a non-
aggregated but kinetically trapped state. Upon binding to GroELit undergoes local 
unfolding to an ensemble of expanded and more compact conformations. (2) ATP-
dependent domain movement of the apical GroEL domains results in stretching of 
tightly bound regions of substrate and in release and partial compaction of less stably 
bond regions. (3) Compaction is completed upon substrate encapsulation by GroES. 
(4) Folding in the chaperonin cage. (5) Substrate release upon GroES dissociation. (6) 
Rebinding of incompletely folded states. N, Native state and I, folding intermediate. 
From [52].  
 
The mechanism of action of chaperonins is to some extent identical 
to the observed for the Hsp70 family. Similarly, it depends on ATP 
hydrolysis and folding is promoted by substrate binding/releasing 
cycles. However, chaperonins promote folding through cycles of global 
protein encapsulation that may involve mechanical stress and this 
constitutes the main difference in terms of the mechanism of action of 
these two chaperone systems. Non-native substrates bind, through 
hydrophobic interactions, to apical domains of the unoccupied ring; the 
co-chaperone and ATP then bind to the ring and the substrate is 
encapsulated inside. The binding of a co-chaperone induces 
conformational changes on the GroEL ring, which result in strong 
upward and outward motions of the ring, causing a significant 
expansion of the distance between the encapsulated polypeptide 
binding regions [52]. Thus, the substrate is subject to stretching forces 
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that can induce unfolding as it was observed for lysozyme and 
rhodanese [143-145]. The mechanism of action and the nature of 
group II binding sites are not yet understood.  
1.2.2. Rescuing of Misfolding Defects by Small Molecules- 
Chemical Chaperoning 
An increasing number of studies describe the use of low molecular 
weight compounds to overcome folding defects in proteins involved in 
conformational disorders (Table 1.2). These small molecules, often 
also called chemical chaperones, can have a direct impact on the 
protein stability and solubility and can also regulate or substitute the 
folding activities of molecular chaperones [146]. The effect of these 
molecules can be particularly relevant in the context of 
misfolding/conformational diseases, namely when partial rescuing of 
the perturbed protein is enough to obtain the minimal activity required 
or at least to partially attenuate the observed defects [147-150]. In 
some particular cases, chemical chaperoning is likely to lead to a 
concrete pharmacological use especially in lysosomal storage 
disorders such as Gaucher’s disease [151-152]. Many of these small 
compounds are known to serve as organic osmolytes and other 
compatible solutes, synthesised or uptaken by living organisms from 
micro-organisms to plants and animals, to minimise protein 
denaturation, allowing the adaptation to harsh environments or stress 
[153-155]. These molecules fall into six major categories: small 
carbohydrates including sugars (e.g. trehalose), polyols and 
derivatives (e.g. glycerol, inositol, sorbitol, and o-methyl-inositol), 
amino acids and derivatives (e.g. glycine proline taurine and ectoine), 
methylamines (TMAO and glycine betaine), methylsulfonium solutes 
(DMS) and hydrophobic compound (4PBA) [156-157]. The mechanism 
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by which osmolytes promote protein folding and increase 
thermodynamic stability has been extensively studied. These chemical 
compounds do not bind directly to proteins, their mode of action is not 
specific and it can be described by the “solvophobic” effect. The 
interactions of the osmolyte with the peptide backbone are 
unfavourable causing a preferential exclusion of osmolytes from the 
water-protein interface leading to a preferential hydration of the protein 
surface. The presence of osmolytes also results in an increased 
solvent density that restrains the proteins’ free movements, increasing 
its compactness [158-161]. This non-specific mechanism of the 
chemical chaperones action allows them to intervene in different 
stages of the folding process [162-164]. Chemical chaperones can 
stabilise the native state, preventing aggregation or degradation, direct 
the folding pathway or promote refolding of misfolded/destabilised 
proteins [165]. It should be noted that, since their mechanism of action 
is not specific, the same compound may have different effects if 
present in different stages of folding process or opposite effects for two 
different proteins. Both cytosolic and endoplasmic reticulum (ER) 
folding can be modulated by chemical chaperones. Their actions allow 
restoring a protein function by stabilising the protein conformation or by 
correcting trafficking defects [152, 166-167]. Also, these compounds 
have been shown to be able to promote the assembly of complexes 
through the stabilisation of intermediates states, to stabilise 
aggregation prone proteins and to induce structure in intrinsically 
unstructured proteins, thus regulating biochemical processes [147, 
168-169]. Apart from this direct action on the folding reaction, certain 
chemical chaperones can also regulate molecular chaperones and the 
unfolded protein response system [146, 170]. A subgroup of chemical 
chaperones, the pharmacological chaperones, is often distinguished. 
Opposite to the above described general and unspecific effect of 
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chemical chaperones, these compounds have a specific action on a 
given target protein. This subgroup comprises competitive inhibitors, 
ligands, agonists/antagonists and protein's co-factors such as metals 
and flavins. Copper may be regarded as a pharmacological 
chaperone: its use may prevent the trafficking impairments associated 
to Menkes' disease. Mutations in the copper transporter P-type 
ATPase (MNK) leads to its ER retention and the development of 
Menkes disease. MNK disease-related mutant, G1019D, accumulates 
in the ER, but if the cells expressing this mutant are supplemented with 
copper, the protein is efficiently processed in the Golgi and reaches 
the plasma membrane. Thus, copper, MNK ligand, may act as a 
pharmacological chaperone by promoting its proper trafficking [171]. 
 
1.2.3. Protein Quality Control and Disease Prevention 
The concerted action of molecular chaperones and protein 
degradation systems constitutes the cellular protein quality control 
(Fig.1.9). In Eukaryotes, two different degradations systems are 
present. While cytosolic proteins are degraded by the ubiquitin-
proteasome system (UPS) [172-173], mitochondrial proteins are 
degraded by ATP-dependent proteases [174]. Degradation of proteins 
is an essential endpoint that contributes to protein homeostasis. 
Chaperones and proteases/proteasome actions have to be concerted 
in order to prevent early degradation and, at the same time, to 
guarantee that extensively damaged proteins are efficiently degraded 
before aggregation. Two other pathways are also involved in protein 
degradation and proteostasis: the lysomal and the autophagic 
trafficking pathways (reviewed in [175]). 
 
Chapter 1 
30 
 
 
 
Figure 1.9: Protein Quality control. Cells have a pool of misfolded or unfolded proteins. 
These non-native states result from the biosynthesis of normal (but unable to fold 
without the assistance of molecular chaperones) or aberrant proteins (mutated), the 
chaperones cycles and as the result of stress conditions (such as thermal fluctuations 
and increased oxidative stress). Non-native proteins are recognised by the cell's 
protein quality control. Exposed hydrophobic regions are recognised by chaperones 
(all families) and by ATP-dependent proteases. Chaperone binding and release of 
folding intermediates may allow proteins to reach the native state or they may return to 
the non-native proteins pool where they can rebind to chaperones or bind to 
proteases. Protease binding followed by the ATP-dependent unfolding and 
subsequent degradation removes the protein from the non-native proteins pool. After 
being unfolded by the protease, if the protein is repaired it will be released prior to 
degradation. In eukaryotes the degradation pathway in the cytosol involves the 
ubiquitination system. Non-native proteins are recognised and ubiquitinilated and 
targeted to the proteasome where they are degraded. Similar to what is observed for 
the proteases after unfolding reaction inside the chambers of the proteasome the 
protein may be deubiquitilated and return to the pool of free cytosolic proteins avoiding 
degradation. Chaperones main action is to avoid aggregations, however, some 
chaperones can also promote disaggregation. Protein aggregates are relatively 
resistant to proteolysis so, in order to be degraded, aggregates have to be dissolved 
first. Misfolded or partially folded proteins can aggregate and if the protein quality 
control fails aggregated proteins accumulate leading to disease. Adapted from [76]. 
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The main difference between the action of proteases and 
proteasomes relies on their mechanisms of substrate recognition. In 
mitochondria, ATP-dependent proteases selectively bind to non-native 
proteins by recognising, like chaperones, exposed hydrophobic 
regions and/or unstructured regions. In the cytosol, proteins are 
marked for proteolysis by the covalent attachment of polyglubiquitin 
chain(s) which are recognised by the 26S proteasome [176-177]. 
Ubiquitination is a multistep process involving three enzymes that 
select the targets for degradation and facilitate ubiquitination. 
Modulator proteins, such as E3 ligases and chaperone co-factors 
(CHIP and Bag1) link chaperones to the UPS which supports the idea 
of direct communication between folding and degradations systems 
[122].  
In the mitochondria, the fact that chaperones and proteases bind to 
the same substrates could result in competition, but since chaperones 
are more abundant, probabilistically non-native proteins will bind to the 
latter before interacting with proteases [178]. After being released from 
chaperones, non-native proteins can either acquire the native fold (that 
is not recognised by the protein quality control elements) or remain in a 
non native state and then interact again with a chaperone or a 
protease [179]. When encountering a protease, the most likely 
scenario is protein degradation. However, a fraction of the proteins that 
are unfolded by the chaperone component of the proteolitic complex 
may be in fact released [180]. 
 Mitochondrial ATP-dependent proteases derive from the bacterial 
proteases and are highly conserved in Eukaryotes [181]. These 
proteases degrade misfolded or non-assembled proteins to peptides 
which are either exported or further degraded by oligopeptidases. The 
AAA proteases are localised in the inner membrane, while Lon and 
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ClpXP are present in the matrix [182-185]. AAA proteases are 
integrated in the mitochondrial inner membrane; m-AAA catalytic 
domain is turned to the matrix while i-AAA catalytic domain is in the 
intermembrane region. These proteases overlap in substrate specificity 
and the fact that they are inversely inserted into the membrane allows 
for the efficient degradation of damaged membrane proteins 
independently of their topology. AAA proteases also dislocate the 
substrate proteins allowing their degradation in a hydrophilic 
environment through an ATP-dependent process [186]. Matrix 
proteases have a chaperone domain preceding the proteases domain. 
ClpXP has a barrel like structure with the two heptameric rings of ClpP 
(the proteolitic core) flanked on both sides by the hexameric rings of 
ClpX. The barrel has a series of aqueous chambers connected by an 
axial chamber, thus, the proteolytic domain on ClpP is isolated and 
inaccessible to other proteins (this isolation of the proteolytic site is 
identical to the observed in the proteasome). The ClpX has ATPase 
and chaperone activities and their aqueous chamber may function 
analogously to what is described for the GroEL family: in addition to 
preventing aggregation it can also promote disaggregation [92-94]. Lon 
functional organisation is still unknown; in vivo it was shown that 
proteolytic inactive Lon can protect substrates from other proteases, 
which suggests the existence of binding sites or chambers that 
sequester the substrate proteins from the surrounding medium [187]. 
Also, proteolytic inactive yeast Lon was shown to be able to promote 
the assembly of inner membrane complexes but its chaperone activity 
is ATP-dependent [187]. Lon degrades misfolded proteins in the 
matrix, including thermally denatured proteins and oxidatively 
damaged proteins such as aconitase [182-183, 185]. Although the 
mitochondrial protein quality control is quite robust, it has limited 
capacity and oxidatively modified proteins and aggregated aconitase 
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accumulate in the mitochondrial matrix of aged cells which may 
contribute to the age-related mitochondrial decline [83, 127]. 
The degradation and the chaperone machineries are responsible for 
repairing and removing most forms of aberrant proteins, avoiding 
protein aggregation. Both systems are induced by stress conditions 
such as temperature and their expression levels increase in parallel, 
guaranteeing the balance between them. Mutations on either 
proteases or chaperones result in an imbalance of protein 
homeostasis, accumulation of insoluble proteins (inclusion bodies) and 
increased cellular sensitivity to stress [178, 188]. These observations 
highlight the importance of chaperones and proteases on protein 
homeostasis.  
If these two systems fail, proteins aggregate, triggering deleterious 
biological processes that compromise the cell homeostasis. Protein 
aggregation has been linked to many diseases including diabetes II, 
Alzheimer's and Creutzfeldt-Jakob's diseases [55, 189]. Aggregates 
may form structures that can disrupt some cellular functions (such as 
pores in membranes reducing the potential across the membrane 
[190]), serve as seeds for the aggregation of other unrelated proteins 
or engaged and block molecular chaperones and proteases, 
decreasing their availability to other substrates. Protein aggregation is 
a progressive process that starts with non-specific interaction leading 
to the formation of oligomeric species. Small oligomers can evolve to 
more organised structures such as 'protofilaments' and ultimately well-
defined fibbers (amyloid fibbers) are formed [191-192].  
1.2.4. Mitochondrial Dysfunction and Neurodegeneration 
Mitochondria are essential and extremely specialised organelles, 
with a plethora of function including energy production and cellular 
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homeostasis [193]. Mitochondrial dysfunction has severe cellular 
consequences and is associated with several neurodegenerative 
diseases (Table 1.2). Mitochondria harbour the respiratory chain, 
whose efficient function constitutes the cell’s main driving force (it 
produces more than 15 times the ATP generated by anaerobic 
glycolysis). In addition, these intricate organelles are also involved in 
fatty acid oxidation, steroid metabolism, intermediate metabolic 
pathways, calcium homeostasis and free radical scavenging. Although 
most mitochondrial proteins are encoded by the nuclear genome, 
mitochondria also have their own genome (mtDNA). The mtDNA 
encodes 13 polypeptide components of the respiratory chain as well as 
all the components necessary to ensure intramitochondrial protein 
synthesis [194].  Mitochondrial morphology is complex and plastic, 
mediated by conserved cellular machineries mitochondria undergoes 
constant fusion and fission events that constitute a reticulated 
mitochondrial network and allow the adaptation of these organelles to 
different physiological demands. Mitochondria change shape, size and 
location and this dynamic behaviour, together with their plastic 
morphology, contribute to their functional optimisation, which ensures 
an accurate response to their changing intracellular needs [195]. 
Despite all the functions described so far that contribute to maintain 
and improve cellular metabolism and viability, mitochondria are also 
involved in cell death. The intermembrane space contains pro-
apoptotic factors (cytocrome c, Smac/DIABLO and endonuclease G) 
and insults to the mitochondria may cause the release of those factors 
to the cytosol and consequently promote apoptosis. For instance, if 
cytochrome c is released to the cytosol, it will bind to Apaf1 and co-
caspase 9 to form the apoptosome initiating a downstream cascade 
that results in cell death [196].  
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Table 1.2: Proteins associated to neurodegenerative diseases that involve 
mitochondrial dysfunction/decline. 
 
Protein Function Disease Clinical Features 
APP 
Unknown. Precursor of A 
peptide the primary 
component of senile plaques Alzheimer’s disease 
Most common dementia. 
Confusion, language 
breakdown and social 
withdrawal. Presenilins 
1 and 2 
Component of -secretase 
which cleaves APP to yield A 
-Synuclein 
Unknown, but interacts with 
tubulin. Primary component of 
Lewy bodies 
Parkinson’s 
Disease 
Progressive rigidity, 
bradykinesia and tremor. 
Parkin Ubiquitin E3 ligase 
PINK1 
Mitochondrial kinases, 
although the function is 
unknown seems t protect 
against cell death 
LRRK2 Kinase. Function unknown 
DJ-1 
Protects the cell against 
oxidant-induced cell death 
HtrA2 
Serine protease in the 
mitochondrial intermembrane 
space. Degrades denatured 
proteins within mitochondria. 
Degrades the inhibitor of 
apoptosis proteins and if 
released to the cytosol 
promotes apoptosis 
SOD1 
Converts superoxide to 
hydrogen peroxide 
Amyotrophic lateral 
sclerosis 
Progressive weakness, 
atrophy and spasticity of 
muscle tissue 
Huntingtin 
Unknown. Maybe involved in 
vesicular transport regulation 
during  neurotransmitter 
release 
Huntingtons’s 
Disease 
Uncoordinated body 
movements, decline in 
cognitive abilities and 
reduction in life-spam 
Frataxin 
Mitochondrial iron chaperone 
that promotes biogenesis and 
repair of Fe-S clusters. Also 
involved in Heme biosynthesis 
and iron detoxification. 
Friedreich’s Ataxia 
Ataxia and neuropathy due 
to degeneration of 
spinocerebellar tracts and 
dorsal-root ganglia; diabetes 
and cardiomyopathy 
Paraplegin 
Subunit of hetero-oligomeric 
m-AAA protease in 
mitochondrial inner membrane Hereditary spastic 
paraplegia (HSP) 
Slowly progressive 
weakness and spasticity of 
the legs 
Hsp 60 
Mitochondrial matrix 
chaperonin 
Opa1 
Mitochondrial dynamin-like 
GTPase required for inner 
membrane fusion and cristae 
morphology 
Autosomal 
dominant optic 
atrophy (DOA) 
Optic neuropathy causing 
progressive visual loss 
MFN2 
(subtype 2A) 
Mitochondrial outer membrane 
Dynamin-like GTPase that 
mediates fusion Charcot-Marie-
Tooth disease 
Neuropathy of motor and 
sensory nerves. Weakness 
of the foot and lower leg 
muscles. 
GDAP1 
(Subtype 4A) 
Mitochondrial outer membrane 
protein that promotes fusion 
Pantothene 
kinase 2 
Mitochondrial, catalysis the 1st 
step in coenzyme A synthesis. 
Neurodegeneration 
with brain ion 
accumulation 
(NBIA) 
Progressive dementia, 
rigidity, involuntary 
movements, spasticity and 
retinal degeneration 
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Mitochondria have developed an elaborate protective mechanism, 
composed by 3 systems that enable them to overcome the diverse 
challenges threatening their function and integrity. The first comprises 
a highly conserved intra-organellar proteolysis system: the 
mitochondrial protein quality control; molecular chaperones and 
energy-dependent proteases evaluate the folding and assembly of 
mitochondrial proteins and remove excess and damaged proteins from 
the mitochondria [181, 184]. The second relies on the dynamic nature 
of the mitochondrial population: damaged mitochondria can be 
repaired/restored by fusing with healthy neighbouring mitochondria 
[195, 197]. The last defence system consists on the removal of 
damaged mitochondria which enables the survival of the cell. Once the 
damage to the mitochondria is too extensive, fusion no longer occurs; 
instead, mitochondria are fragmented and selectively removed from 
the cell through an autophagyc process named mitophagy [198-199]. 
This is a cytoprotective system since it eliminates mitochondria without 
the release of the pro-apototic factors that would destroy the cell.  
In spite of these protective mechanisms, mitochondria dysfunction 
still occurs and is associated with ageing and neurodegenerative 
diseases [200-203]. Ageing is the greatest risk factor in many 
neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s 
disease or amyotrophic lateral sclerosis. Also, many of the specific 
proteins implicated in neurodegenerative diseases interact with 
mitochondria.  
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Figure 1.10: Mitochondrial quality control (QC) mechanisms. Intraorganellar protein quality 
control ensures the correct folding and assembly of mitochondrial proteins and the 
degradation of excess or damaged proteins. If the protein quality control fails, 
mitochondrial function can be restored by fusion and fission processes. Ultimately, if the 
mitochondrial damage is too extensive, mitochondria are fragmented and removed through 
mitophagy preventing the release of pro-apoptotic proteins. If these 3 systems fail, pro-
apoptotic proteins (e.g. cytochrome C) are released leading to apoptosis. Adapted from 
[181]. 
 
 
Aging leads to the accumulation of mitochondrial DNA mutations, 
especially large-scale deletions and point mutations, and also to an 
increase in oxidative stress [204-205]. Proofreading-deficient POLG 
mice present a marked increase in mtDNA mutations, much like in 
ageing cells, and consequently exibit decreased ATP production  and  
decreased activity of respiratory enzymes. At 25 weeks of age, these 
mice began to present pathologies frequent in ageing humans and 
their lifespan is significantly reduced. In functional mitochondria the 
amount of reactive oxygen species (ROS) produced through the 
multiple electron carriers is balanced by the extensive mitochondrial 
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network of the anti-oxidant defences. However, once mitochondria are 
damaged, which is believed to occur with ageing, the balance is lost 
and more ROS is produced, leading to further mitochondrial 
disfunction [194]. Overexpressing superoxide dismutase, methionine 
sulphoxide reductase or catalase (three antioxidant enzymes) in 
Drosophila has been shown to prolong flies’ lifespan, highlighting the 
role of ROS in ageing-related mitochondria 
disfunction [206].  A study performed in human ageing brains, 
suggests that mitochondrial 
disfunction is associated to the 
down-regulation of genes 
involved in synaptic 
transmission, vesicular transport 
and mitochondrial function. In 
addition, the promoter region of 
these genes has also shown an 
increased sensitivity towards 
oxidative stress, either to their 
G/C-rich sequences or their 
inability to undergo transcription-
coupled repair [128].  
 For example, Huntington’s 
disease (HD) involves the loss 
of long projection neurons in the 
cortex and stradium. This 
disorder is associated with a 
plygluthamine extension on 
huntingtin protein. The gene 
coding for this protein normally 
has less than 36 CAG 
Figure 1.11: Molecular mechanism 
associated to the development of Huntington 
disease.  Complex II activity is decreases in 
HD brains. Mutated HTT (with gluthamine 
expansions) associated to the outer 
mitochondrial membrane increases the 
sensitivity towards Calcium-induced 
cytochrome C release (apoptosis). Mutant 
HTT also translocates to the nucleus where it 
binds and induces p53 expression (Apoptotic 
pathway involving BAX or NOXA/PUMA from 
the Bcl-2 family). Deletion of PGC-1 or 
missense mutations on Htr2 are also 
associated to a HD phenotype [200].     
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trinucleotide repeats but disease related genes show an extension of 
over 40 repeats [200]. Several evidence, namely increased levels of 
lactate in patient’s cortex and basal ganglia and decreased activities of 
complexes II and III in human HD brains, suggest that the pathological 
process may result from mitochondrial dysfunction [207].  Different 
mechanisms could explain how mutant huntingtin (HTT) results in 
mitochondrial disfunction and thus the pathological process is still 
unclear. In vivo experiments with HD mouse models, have suggested 
that HTT may interact directly with the mitochondria. The presence of 
the polyglutamine expansion results in lower mitochondrial membrane 
potentials that depolarise at low calcium loads [208-209]. Alternatively, 
HTT may not interact directly with the mitochondria, but it may alter 
transcription of several proteins involved in mitochondrial homeostasis 
[210]. It is known that HTT interacts with p53, CREB-binding protein 
and SP1. For instance, binding of HTT to p53 increases its levels 
leading to the up-regulation of downstream targets, BAX and PUMA, 
and ultimately to mitochondrial depolarisation [211]. 
Parkinson’s disease (PD), another age-related neurodegenerative 
disease, is also associated to mitochondrial dysfunction. However, the 
aetiology of this disease is far more heterogeneous and the mutation 
of several genes has been associated to PD [212]. Independently of 
the mutated gene, complex I inhibition and increased oxidative stress 
are prevalent, highlighting the role of mitochondrial dysfunction in PD 
pathogenesis. At the molecular level, this disorder is characterised by 
the selective loss of dopamine-secreting neurons in the substantia 
nigra and the accumulation of cytoplasmatic inclusions - Lewy Bodies. 
-synuclein is the major component of Lewy Bodies, but ubiquitin is 
also present [200]. Among the nuclear genes so far associated to PD, 
six are involved in mitochondrial functions: -synuclein, parkin, DJ-1, 
phosphatase and tensin homologue (PTEN)-induced kinase 1 (PNK1), 
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leucine-ric-repeat kinase 2 (LRRK 2) and HTRA 2. -synuclein 
overexpression impairs mitochondria function and increases oxidative 
stress and the sensitivity towards MPTP (a complex I inhibitor) [213]. 
Parkin migrates to the outer mitochondrial membrane, avoids the 
release of cytochrome c, and may also enhance mitochondrial 
biogenesis by interacting with the mitochondrial transcription factor A 
[214-215].  
 
 
 Figure 1.12: Molecular mechanisms associated to the development of Parkinson’s 
disease (PD). Many of the genes associated to the development of this disease are 
associated to the mitochondria. Complex I activity is decreased which increases the 
amount of ROS and decreases the mitochondrial ATP production. mtDNA mutations 
are increased and some patients have mutations on the mtDNA polymerase gene 
which results in multiple mtDNA mutations. Mutation on -synuclein and parkin are also 
associated to PD. While -synuclein mutations lead to its aggregation causing 
citotoxicity, a 'gain-of-function', mutations on parkin are deleterious by causing a 'loss-
of-function' since this protein encodes an ubiquiting E3 ligase and has an anti-apoptotic 
activity. Dj-1 interacts with -synuclein, parkin and Pink1, and acts as a redox sensor 
preventing cells death. Pink1 is also believed to prevent cell death. Mutations on 
LRRK2 are associated to familial late-onset PD. HTR2 is a putative quality control 
agent within the mitochondria and pro-apoptotic factor when released into the cytosol, 
mutations on its gene have been associated to PD. Adapted from  [200]. 
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DJ-1 when oxidised down-regulates the PTEN-tumor suppressor 
protecting cells from oxidative-stress-induced cell death [216]. The 
mitochondrial kinase PINK1 also has an anti-apoptotic role and which 
is reduced by PD-related mutations [217-218]. Genetic evidence 
suggest that DJ-1, PINK 1 and parkin function in a sequential way on 
the same pathway supporting this hypothesis; the physical 
associations between Dj-1 and -synuclein, Dj-1 and parkin, and Dj-1 
and PINK 1 have been reported.  Mutations in the LRRK2 are the most 
common known cause of familial late-onset PD and, in addition, are 
also responsible for 1-2% of sporadic cases [219]. HTRA2 was most 
recently associated with PD: HtrA2 is believed to be one of the 
proteins involved in mitochondrial protein quality control system; 
however, when this protein is released to the cytosol, it acts like a pro-
apoptotic factor [220-221]. 
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2.1. Friedreich’s Ataxia 
Friedreich’s ataxia (FRDA; OMIM: 229300) is the most common 
hereditary ataxia. This movement disorder was first described in 1863 
by Prof. Nikolaus Friedreich, Professor of Medicine 
in Heidelberg, and his clinical observations already 
comprised the essential characteristics of the 
disease [1].  In his original report he described the 
disease as a “degenerative atrophy of the posterior 
column of the spinal cord leading to progressive 
ataxia, particularly associated with clumsiness in 
walking, accompanied by sensory loss, lateral 
curvature of the spine, foot deformity and heart 
disease”.  
 The cause of the disease remained unknown for 
over 130 years and even the rigorous diagnostic criteria and the 
autosomal recessive pattern of heritance were only established 
between 1976 and 1981 [2-3]. The authors of these studies, while trying 
to describe the unifying features of FRDA, came across a quite rare 
observation for a recessive disorder. The pathological manifestations of 
the disease are rather variable, especially concerning the age onset, 
rate of progression, severity and extent of disease. Also these studies 
have allowed for the collection of clinically homogeneous families that 
were subsequently used in biochemical studies and, after 1985, in 
genetic studies. In 1996, the gene associated with FRDA and its most 
common mutation, an intronic GAA triplet expansion, were finally 
identified [4], allowing for genotype-phenotype correlations, 
pathophysiological studies and new approaches to treatment. 
 
Figure 2.1:  The 
German pathologist 
and neurologist, 
Prof. Nikolaus 
Friedreich (1825-
1882). 
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In spite of being a rare disorder, FRDA is the most common inherited 
ataxia across Europe. Among the European Caucasian population, 
Friedreich's ataxia carrier frequency is estimated to be 1 in every 85 
individuals, with a disease prevalence of 1-2 cases per 40,000 
individuals [5]. The disease seems to be restricted to individuals of 
European, Middle Eastern, North African and Indian origin [6-7].  
Located on chromosome 9q13, the FRDA gene codes a small protein: 
frataxin [4].  Although ubiquitously expressed, frataxin expression levels 
are higher in tissues with a high ATP demand such as heart, spinal cord 
and dorsal root ganglia. This differentiated expression correlates with 
FRDA clinical features: neuronal degeneration and cardiomyopathy [8].  
The expansion of a GAA repeat within the first intron of FRDA gene 
was found to be the cause of over 90% of FRDA cases [4-5]. This is an 
autosomal recessive disease, meaning that FRDA only occurs when the 
GAA extension is present in both alleles coding for frataxin. A normal 
allele has between 6 and 12 repeats while disease associated alleles 
have between 40 and 1000 repeats (600 to 900 in most cases) [4, 9-
10]. The number of non-pathogenic GAA repeats is also variable, and 
includes subgroups with up to 14 to 34 repeats. GAA expansions, just 
like other disease-related expansions, are unstable and prone to further 
expansion when transmitted from parent to child. Thus, non-pathogenic 
large expansions constitute a reservoir for disease-related expansions 
[4]. In FRDA, GAA expansions and contractions are equally likely after 
maternal transmission but more likely after paternal transmission 
contractions. This pattern is common to disorders resulting from triplet 
expansions in non-coding regions; in addition to FRDA, fragile X and 
myotonic dystrophy are also included in this group [11]. For disorders 
resulting from a triplet expansion in a coding region, such as 
Huntington’s disease, an opposite pattern after paternal transmission is 
observed, as triplet expansions are more likely [12].  
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The origin of the GAA expansion responsible for FRDA is now 
described by a two step-model. First, the duplication of the ancestral 
normal expansion (~9 GAA repeats) lead to the formation of large 
alleles with ~18 GAA repeats [9]. A second mutational event resulted in 
an unstable expansion with more than 34 repeats. According to this 
model, all large alleles originated from the same haplotype and the 
carriers of the expanded allele have passed through a population 
bottleneck, most likely the ice age refuges.  The northern Spain refuge 
is a good candidate since the prevalence of FRDA in this region is the 
highest registered to date, explaining the prevalence observed in 
Western Europe.  
 
 
Figure 2.2: Schematic representation of frataxin gene highlighting the identified 
mutations. Boxes represent frataxin gene exons, while bars represent its introns. 
Above the gene representation, truncating mutations are described, X represents 
nonsense mutations. Below the gene representation, missense mutations are 
described; G130V and I154F are the most common and where identified in several 
families. The expansion mutation in intron 1, present in all FRDA patients, is also 
represented. Adapted from [9, 13].  
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It has been shown, in vivo and in vitro, that frataxin levels correlate 
inversely with the length of the expansion [13]. In peripheral blood 
leukocytes from FRDA patients, the levels of frataxin range between 5% 
and 30% of the normal levels [14-16]. The reduced amounts of mRNA 
depend on the length and orientation of the expansion and this 
reduction likely results from a disruption on transcription [17-18]. 
Sakamoto [19] has suggested that GAA repeats being “sticky” would 
self associate forming triple helix structures. These DNA triplexes could 
trap RNA polymerase suppressing frataxin gene expression. Normally, 
the formation of triplex structures is avoided by the presence GGA 
repeats within the GAA expansions.  
Some patients (~4% [20]) are not homozygous for the triplet 
expansion but are compound heterozygous having the triplet expansion 
in one allele and a loss-of-function mutation on the other. Mutations 
identified so far are represented in Fig. 2.1 and include missense, non-
sense or splice mutations. Deletions involving large portions of the gene 
were only rarely detected [4, 21-22]. A patient with two point mutations, 
one in each allele, has not so far been identified, either because this 
would be lethal or just because carriers of point mutations are less 
common [4-5, 13, 17, 20, 23]. Identified FRDA-related missense 
mutations are summarised in Table 2.1; predicted constrains as well as 
the phenotype associated to each mutation are also described [13, 17, 
20, 23-28].  While all homozygous patients present a typical and severe 
phenotype, some of the heterozygous patients show milder 
manifestations of the disease meaning that, in spite of the mutation, 
frataxin still retains some residual activity [21].  
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Table 2.1: Clinical point mutations described in heterozygous patients. 
Point mutation Yeast E. coli Effect Phenotype Ref 
Leu106  Ser Leu84 Ile17 
Internal cavities with 
loss of packing energy 
Severe [23] 
Asp122  Tyr Ile99 Asp29 
Change of a surface 
conserved negative 
charge (function) 
Moderate [13] 
Gly130  Val Gly107 Gly37 
Steric strain by replacing 
a Gly that is in a 
conformation not 
allowed to other 
residues 
Mild [13] 
Asn146  Lys Asn122 Asn52 
Disruption of an 
hydrogen bond  on a -
hairpin 
Severe [25] 
Ile154  Phe Ile130 Val60 
Steric strain by replacing 
a buried hydrophobic 
residues by a larger one 
Severe [13] 
Trp155  Arg Trp131 Trp61 
Replacement of a bulky 
highly conserved 
aromatic chain by a 
positively charged 
residue 
Severe [7] 
Leu156  Pro Leu132 Leu62 Disruption in -sheet 
hydrogen bonds 
Severe [13] 
Agr165  Cys Arg141 His70 
Replacement of a 
conserved positively 
charge residue with an 
exposed Cys that might 
form intermolecular 
disulphide bridges 
Mild [20] 
Trp173  Glyc Trp149 Trp78 
Internal cavities with 
loss of packing energy 
Severe/ 
Mild 
[13] 
Leu182  His Leu158 Phe87 
Electrostatic strain by 
replacing a buried 
residue with a 
hydrophilic one 
Moderate [13] 
Leu182  Phe Leu158 Phe87 
Steric strain by replacing 
a buried hydrophobic 
residues by a larger one 
Moderate 
[13, 
20] 
His183  Arg Thr159 Trp88 
Electrostatic strain by 
replacing a partially 
uncharged buried 
residues with a bulky 
charged one 
Moderate [13] 
Leu186  Arg Leu162 Leu91 
Electrostatic strain by 
replacing a buried 
hydrophobic residues by 
a charged hydrophilic 
Severe [25] 
Leu198  Arg Gln174 Val103 
Electrostatic strain by 
inserting a positive 
charge on the C-terminal 
tail likely will decrease 
protein stability. 
Severe [29] 
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Due to the limited number of patients with the same mutation, it is not 
possible to establish a firm genotype-phenotype correlation. Mutation 
G130V constitutes an exception; this mutation arose from a single 
ancestral mutation but is present in several families and correlates to a 
mild phenotype. Although associated to early onset of the disease the 
progression is very slow [13, 17, 20, 23].  
2.1.1. Friedreich’s Ataxia: a Mitochondrial Disease 
Although FRDA is a neurodegenerative disease, extraneural organs 
are involved in its pathogenesis which suggests that mitochondria are 
involved in FRDA development. The co-localisation of frataxin with 
mitochondrial markers confirmed that frataxin is indeed a mitochondrial 
protein [30-32]. However, there have been reports of cytosolic frataxin, 
where it interacts with the cytosolic Aconitase/IRP1 switch controlling it 
[33-34]. 
The study of the molecular features associated to FRDA 
pathogenesis were first addressed using the yeast system as a model. 
Deleting yeast frataxin homologue resulted in the inhibition of growth, 
reduced mitochondrial respiration, iron accumulation and increased 
sensitivity towards oxidative stress [35-36]. Interestingly, human frataxin 
could complement yeast frataxin deletion, suggesting a high functional 
conservation throughout evolution. Studies on cardiac biopsy samples 
from FRDA patients revealed deficiencies on respiratory complexes I, II 
and III, and on aconitase [37]. These deficiencies correspond to deficits 
of iron-sulphur proteins and suggest a link between the lack of frataxin 
and iron-sulphur clusters biogenesis impairment. These results were 
further confirmed and supported by the analysis of autopsy samples 
and by in vivo quantification of the ATP production rate after exercise 
[38]. Whether iron deposits detected in FRDA patients [35, 39] 
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constitute a primordial cause of FRDA has been a matter of debate. 
Without excluding a direct role of frataxin on iron metabolism, murine 
models support the hypothesis that iron accumulation is a secondary 
effect of FRDA [40].  Homozygous deletion of the frataxin gene in this 
model leads to embryonic lethality, but this effect is not associated to 
iron accumulation. Furthermore, conditional mouse models of FRDA 
showed that cardiac hypertrophy and respiratory chain dysfunction were 
observed several weeks before mitochondrial iron accumulation was 
detected [41]. A recent report, using muscle creatine kinase conditional 
frataxin knockout mouse models, also supports this view of iron 
accumulation as a secondary effect of FRDA [42]. When analysing the 
gene expression in the conditional mutants, Richardson and co-workers 
observed that frataxin deficiency causes the down regulation of key 
enzymes involved in iron mitochondrial utilisation pathways, which 
contributes to mitochondrial iron loading and also alters the systemic 
iron metabolism [42]. In addition, frataxin knockout also causes the 
upregulation of transferrin receptor-1 and mitoferrin2 increasing 
respectively the iron cellular and mitochondrial uptake, which further 
contribute to the iron accumulation characteristic of FRDA-like cells [42].  
Oxidative stress also plays a crucial role in FRDA pathogenesis. The 
first evidence of this relationship came from studies on yeast model and 
on cultured cells from FRDA patients, when it was demonstrated that 
both these cells have higher sensitivity towards hydrogen peroxide [35, 
43]. Furthermore, cultured mouse cells expressing low levels of frataxin 
show increased production of free radicals. Accordingly, FRDA patients 
show markers of increased oxidative stress like urinary 8-hydroxy-2’-
deoxyguanosine and increased levels of plasma glutathione–S-
transferase activity and melondialdehyde [44].  The activation of stress 
pathways in frataxin deficient cells such as the c-Jun N-terminal kinase 
pathway further supports the pathogenic role of mitochondria 
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dysfunction and oxidative stress in FRDA [45].  A recent report shows 
that the increased oxidative stress associated to FRDA results from 
SOD's reduced, at least partially, the activity in FRDA-like cells [46]. 
Reduced levels of frataxin lead to the activation of AFT1 which, in time, 
results in a deprivation of cytosolic copper and reduced Cu,Zn-SOD 
activity [47]. In addition, frataxin depletion also induces a decrease in 
manganese uptake contributing to mitochondrial SOD inactivation (Mn-
SOD) [48].  Experimental evidence suggests that supplementing FRDA-
like cells with copper and manganese has a positive effect, restoring 
SOD's activities and preventing both oxidative damage and inactivation 
of magnesium-binding proteins [46]. Thus, the effect of frataxin 
deprivation on oxidative stress balance does not result entirely from its 
activity but also from side effects of its depletion.  
 
2.1.2. Treatments Available 
Treatment approaches that aim at reverting the mitochondrial 
pathogenesis associated to the disorder have been extensively 
explored [49]. These approaches have focused on improving 
mitochondrial function, reducing the amount of reactive species and of 
iron accumulation. A first approach involved the use of iron chelators 
such as desferrioxamine or phlebotomy, but, since iron chelators 
replaced iron instead of protecting against its toxic effect and studies on 
mouse models suggested that iron accumulation is a secondary event 
of FRDA and not the causative pathological mechanism [50], this 
approach was to some extent dropped. A second approach has focused 
on reducing the load of reactive species observed in FRDA patients. A 
combination of coenzyme Q10, a potent antioxidant and electron 
carrier, and vitamin E, an antioxidant, as well as the use of idebenone, a 
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short-chain benzoquinone structurally identical to coenzyme Q10, has 
been tested. A trial with ten FRDA patients has revealed that the 
treatment with coenzyme Q10 and vitamin E improves most FRDA 
symptoms but has no effect on either posture, gait or hand dexterity 
degeneration [51-52]. Treatment with idebenone has been quite 
promising and several clinical trials have already been performed [53-
59]. Idebenone is well tolerated and 6 months of treatment with either 
intermediate (15mg/kg/d) or high-doses (45mg/kg/d) seems to 
completely prevent the disease progression and also improve the 
functional impairments by an amount equivalent to 1 year of disease 
progression [53-64]. In Canada, idebenone has received a conditional 
approval for the symptomatic treatment of FRDA while in Europe and 
the US additional clinical trials have been requested and two phase III 
trials are now being performed, one in Europe and one in the US [49]. In 
2007, a promising trial combining idebenone treatment with and an iron 
chelator, hydroxypyridinone deferiprone (DFP), was published. This was 
a 6-month trial involving patients that had been treated with idebenone 
(30mg/kg/d) for at least 2 years. Patients continued the idebenone 
treatment and started to receive 20 or 30 mg/kg/d of DFP. Neuropathy 
and ataxic gait were reduced and no side effects were observed [65]. 
Although these results must still be regarded with caution they open a 
new and promising strategy. 
In contrast to the above described approaches to FRDA treatment, 
gene-therapy strategies address the cause of the disease and aim to 
increase the cellular levels of frataxin; however, the discovery of 
treatments for FRDA following this approach are still in an early stage. 
Treatments combining drugs that facilitate chromatin opening, such as 
histones deacetylase (HDAC) inhibitors and DNA-demethylation agents, 
have shown positive results reverting fragile X syndrome defects [66], 
given the similarities and parallels between this pathology and FRDA is 
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likely that the same approach may also be useful for FRDA treatment. 
Different compounds have been tested and some are likely to reverse 
the heterochromatin induced by the GAA repeats, such as BLM-210 
and HDAC ibhibitor that leads to an increase (approximately two-fold) in 
frataxin message level [67]; others are more likely to increase the 
proteins level due to specific transcription factor activation such as 
Cisplatin [68], 3-nitroproprionic acid [69], hemin [70] and erythropoietin 
[71]. Although the identification of these compounds that effectively 
enhance frataxin levels in the cell may represent a turning point on the 
way FRDA therapeutics are addressed, caution must be taken since we 
are still at the beginning of accessing this possible therapeutic 
approach. Many of the biochemical mechanisms involved have not yet 
been fully elucidated and, in addition, these molecules may also be 
harmful.  
 
 
2.2. Frataxin: a Highly Conserved Mitochondrial Protein 
Frataxin is highly conserved throughout evolution, having 
homologues in mammals, Caenorhabditis elegans, yeast and Gram-
negative bacteria. The different homologues share a sequence identity 
of ~25% and a similarity of 40-70% (Fig. 2.3). Human C-terminal 
domain is similar to CyaY proteins of -purple bacteria suggesting that 
that FRDA gene evolved from a CyaY gene of the mitochondrial 
ancestor [72]. While bacteria only have the conserved C-terminal 
domain, Eukaryotes have an additional N-terminal tail that constitutes 
the mitochondrial import signal [32].  
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Figure 2.3: Alignment of eukaryote and bacterial frataxins sequences displayed with 
Clustal X colours to emphasise conserved sequence features [73]. On the 2D 
structure line, ..... helices and   .. -sheets. The residues whose mutation leads to 
FRDA in heterozygous patients are marked with    .
 
 
Eukaryotic frataxin homologues are nuclear encoded proteins and 
are thus synthesised in the cytosol as precursors with an N-terminal 
presequence that targets frataxin to the mitochondrial matrix. Once 
imported, the precursor frataxin is matured by the mitochondrial 
processing peptidase (MPP) through a two-step process [74-76] (Fig. 
2.4).  MPP is responsible for the maturation of most nuclear encoded 
protein, however, the maturation process usually involves only one step 
[77]. Studies on the maturation process using an in vitro hybrid system - 
maturation of human frataxin by rat MPP - suggested that the second 
cleavage constitutes the maturation limiting step, since this second 
reaction is ~12 times slower than the first [75]. Frataxin presequence is 
~1.5-2 times the average length (20-40) [78-79] which might explain the 
need for two cleavages. N. crassa ATApase subunit 9, the other 
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described protein with a two step maturation process, also has a longer 
presequence [80].  
 There has been some 
controversy regarding 
frataxin cleavage sites 
during maturation, but 
a recent study in vivo 
using human cells has 
shown that 81-210FXN 
corresponds to frataxin 
mature form and 42-
210FXN to the 
intermediate form [81]. 
Furthermore, this 
study has also revealed that human frataxin may have an alternative 
cleavage site when the cleavage between residues 80 and 81 is 
impaired (maybe due to a mutation or a posttranscriptional 
modification). This alternative cleavage site leads to the formation of 56-
210FXN, which may suggest the existence of a proteolytic mechanism 
that can control the length of mature frataxin [81]. This idea is further 
supported by the fact that 56-210FXN is able to rescue frataxin deficient 
cells.  
As shown by studies on the yeast homologue, the mitochondrial 
Hsp70's, Ssq1 and Ssc1, are involved in frataxin import and maturation. 
While Ssc1 is crucial for the import, Ssq1 is believed to be involved in 
frataxin maturation [82-83]. Nevertheless, ssq1 mitochondria show 
levels of mature frataxin that are approximately 75% of the observed in 
normal mitochondrial, suggesting that the absence of this chaperone 
does not completely impair maturation [83]. Maturation studies have 
also revealed that mutation on the C-terminal domain can affect MPP 
 
Figure 2.4: Schematic representation of human frataxin 
processing by MPP (Arrows point out MPP cleavage sites). 
Precursor protein (1-210FXN) is targeted to the mitochondria 
and undergoes a two-step maturation process. The 1st step is 
slower leading to the formation of the intermediate 42-210FXN, 
the 2nd step leads to the formation of mature frataxin (81-
210FXN), however, if the normal cleavage site is blocked 
(between residues 80 and 81), alternative maturation can 
occur leading to the formation of 56-210FXN. Green corresponds 
to the highly conservative protein core [81]. 
MWTL…CGRRGLR…TPRRASS…YLMNLRKSGTLGHPGSLDETTY…KDA
1 42 56 81 210
Precursor (1-210) 23kDa
Intermediate (42-210) 19kDa
Mature Alternative (56-210) 17kDa
Mature (81-210) 14.2kDa
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processing efficiency but experimental data on this subject is 
controversial [75-76]. 
Extensive structural and 
biochemical studies have 
been performed in three of 
the frataxin’s homologues: 
human (FXN), yeast (Yfh1) 
and bacteria (CyaY). These 
studies have focused on the 
evolutionary conserved 
domain (the C-terminal 
domain) and aimed at a 
better understanding of 
frataxin’s cellular function and 
of the relation between 
reduced frataxin expression 
levels and FRDA 
development. Human frataxin 
(FXN) structure was the first 
to be solved (Fig. 2.5) [85-
86], followed immediately by 
the CyaY [87-88]. Four years 
later the Yfh1 structure was 
solved [89] and now many 
structures, including the 
structure CyaY bound to 
metals as well as Yfh1 
assemblies, have already 
been published [90-92]. 
 
Figure 2.5: Top. Molecular surface 
representation of Human frataxin. The molecule 
is oriented as shown in the middle Fig. The 
molecular surface was calculated and was 
shaded according to the electrostatic potential (-
10kt/e, red to +10 kt/e, blue). Individual residues 
within the acid ridge are labelled. Middle. Ribbon 
representation of human frataxin structure, -
helices are represented in blue, -sheets in grey 
and loops in green. The residues comprising the 
acidic ridge at the  surface are labelled 
(Putative iron binding region). Bottom. Side 
chains of highly conserved residues that project 
outward from the large, flat  sheet () create 
a 1008 Å2 conserved surface on frataxin. Adapted 
from [84]. 
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Initially FXN structure was solved considering only the residues 
comprising the protein core [84-86]; however, recently the FXN N-
terminal tail was studied by NMR revealing that this region is intrinsically 
unfolded and does not alter the protein structure, iron binding properties 
or the monodispersity of the evolutionary conserved domain (the core) 
[84-86].  
The orthologues sequence homology shown above (Fig. 2.3) is 
reflected on their identical folds. Five -strands form a flat antiparallel -
sheet that is solvent exposed on one side and is tightly packed against 
the two helices on the other. N- and C-terminal helices have their axes 
nearly parallel with respect to the main antiparallel -sheet. A second -
sheet intersects the helical and -sheet planes and is formed by the C-
terminus of the last -strand (5) of the antiparallel sheet and two 
additional strands (only one additional strand for Cyay and Yfh1); the 
loop between these two strands is less structured than the others. The 
main difference between these three orthologues is that the C-terminal 
extension that has variable lengths and hydrophobicities (Fig. 2.6). This 
extension is packed between the two helices filling the groove between 
them and its length correlates with the protein’s stability [93]. Both 
sequence and fold are highly conserved between frataxin orthologues, 
but the thermodynamic stability diverges significantly. The human and 
bacterial frataxin's (FXN and CyaY) are thermally stable with melting 
temperatures (Tm) of ~58ºC and ~51ºC respectively. Whereas 
interestingly, Yfh1 is only marginally stable in its metal free form (Tm = 
~35ºC even though the optimal growth temperature for yeast is 30ºC). 
The different thermo-stabilities show a correlation with the C-terminal 
tail length.  Elongating Yfh1 C-terminal tail with 3 amino acid residues 
from the FXN sequence increases its thermal stability by 6ºC. The 
opposite strategy, removing 3 and 12 residues from the CyaY and FXN 
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tails respectively, results in constructs with different properties from the 
original proteins. FXN is no longer soluble and CyaY thermal stability is 
significantly impaired, showing a Tm identical to the Yfh1, Tm=36.8ºC 
corresponding to a Tm=14ºC. In agreement with this hypothesis, no 
conserved function is associated to the C-terminal tail. 
 
 
CyaY 
C-terminus = 7 residues 
Tm =  51.0 ± 0.1 
Yfh1 
C-terminus = 4 residues 
Tm =  35.5 ± 0.1 
FXN 
C-terminus = 16 residues 
Tm =  58.0 ± 0.1 
Figure 2.6: Ribbon representation of frataxin's orthologues structure. This structural 
comparison highlights the similarities between the orthologues. Left. E. coli frataxin - 
CyaY (PDB # 1ew4). Middle. S.cerevisiae frataxin - Yfh1 (PBD # 2ga5). Right. 
Human frataxin - FXN (PDB # 1ekg). The C-terminus residues are coloured in black 
and their side chains represented by sticks[93]. 
 
Frataxin fold is not common and only recently a similar fold was 
identified on a protein outside frataxin's family. The crystal structure of 
the hydrophilic domain of respiratory complex I from Thermus 
thermophilus revealed that its subunit Nqo15 has a fold similar to 
frataxin. The sequence homology is low (11-13%), but the structures 
superimpose with RMS values of 2.5 and 3.3 Å for CyaY and FXN 
respectively. [94]. Nqo15 interacts with complex I mainly through the 
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exposed -sheet surface, the same region in that frataxin is proposed to 
be a protein-protein interaction site. Two putative roles are suggested 
for Nqo15 subunit; this subunit may function as an iron storage module, 
promoting the reconstitution of FeS clusters in the complex or/and it 
may stabilise the complex structure [94]. In addition to being structurally 
similar, the putative functions attributed to frataxin and this complex I 
domain are also related. The  sandwich motif structure is also 
recognised in the ferredoxin-like fold of some cytosolic copper 
chaperones (Human HAH1 [95], Yeast ATX1 [96] and BsCopZ [97]). 
These however, are smaller in size and their helices are tilted at 45º to 
each other.  
Solving frataxin structure has allowed for the identification of 
residues, among the conserved ones, that are more likely to be 
associated to the protein’s function. Conserved residues on the protein 
surface are likely to be involved in the protein function and while 
conserved buried residues are more likely to have a structural role [84, 
86].  A large number of highly conserved acidic residues between the 
1/1 interface constitute a negatively charged surface that covers a 
quarter of the proteins surface (Fig. 2.5 Top). This region is likely to be 
functionally relevant and the presence of numerous Asp and Glu 
suggests that it might constitute a metal binding site (Fig. 2.5 Middle).  
Surface exposed residues in the -sheet plane of frataxin are also quite 
conserved and are believed to be involved in the protein-protein 
interactions (Fig. 2.5 Bottom). On the other hand, highly conserved 
residues on the -sheet that contribute to the protein core, as well as 
conserved residues in the helical plane, are likely to have a structural 
role in frataxin.  Almost all mutations described in FRDA heterozygous 
patients involve conserved residues, which highlights either structural or 
functional roles [9, 13]. 
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The high evolutionary conservation among frataxin orthologues has 
enabled the development and use of disease models of a wide range of 
organisms, from the unicellular eukaryote Saccharomyces cerevisiae to 
mice. The yeast model system has been extensively used and 
contributed significantly to what is now known about frataxin function 
and its implication in FRDA [28, 98].  Unicellular models are particularly 
relevant for the study of genetic and environment modifiers of a 
phenotype and for unbiased drug screenings. On the other hand, multi-
cellular disease models contribute extensively to the understanding of 
the pathophysiology associated to FRDA. Different multicellular models 
have been developed using murine models, constitutive and conditional 
knockouts [41], GAA-based mouse models [99], C. elegans [100-102] 
and Drosophila models [103-105]. The last model allows investigators to 
use of conditional RNA interference technology to modulate frataxin 
expression [103]. 
2.3. Frataxin Function: What is Known so Far 
Early studies on frataxin have suggested that this small mitochondrial 
protein is involved in iron homeostasis but its exact role is still not clear. 
Organisms with low levels of frataxin expression show metabolic 
disturbances associated to intramitochondrial iron accumulation, 
decreased activity of iron-sulfur (FeS), reduced oxidative 
phosphorylation and oxidative stress hipersensitivity.  
2.3.1. An Iron Binding Protein 
Considering the phenotype caused by reduced levels of frataxin 
expression it was not surprising to find that frataxin is an iron binding 
protein [106-112]. Frataxin does not have any cavities or hydrophilic 
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pockets to harbour bound iron, instead iron binding involves carboxylate 
oxygens, from Asp and Glu, and nitrogens on imidazole rings from His. 
In support of this notion, iron binding studies by NMR together with 
mutagenesis studies have shown that the conserved acidic residues on 
the 1/1 interface, rich in Asp and Glu, constitute the putative iron 
binding surface. Table 2.2 enumerates the residues found to be 
involved in iron binding in three of frataxin's orthologues - CyaY, Yfh1 
and FXN (Fig. 2.6).  Ferrous iron to protein stoichiometries measured 
for these orthologues are 2, 2 and 7 Fe2+ per monomer respectively 
[108, 110-111]. While iron dissociation constants described for CyaY 
and Yfh1 are identical (~4 and 3M) [108, 110], the Kd determined for 
the human orthologue is ~10 fold higher (55M, Table 2.3).  
 
Figure 2.7: Human frataxin putative iron binding 
sites identified by NMR spectroscopy. Red. At a 
stoichiometry of 1Fe2+:1FXN the amide 
resonances of the following residues disappear: 
Asp112, Leu113, Asp115 and Val125; Pink. 
Increasing the stoichiometry to 2Fe2+:1FXN 
further alters the amide resonance of the 
following residues: Asp104, Ala107, Glu108, 
Phe110, Ala114, Thr119, Phe120, Asp122 and 
Asp124; Green. Additionally at a stoichiometry of 
6Fe2+:1FXN: Ser105, Phe109, Glu111, Lys116, 
Glu121 and Phe127. Increasing the iron 
concentration does not induce further changes in 
the amide resonances which is in agreement 
with the 6:1 iron stoichiometry determined for 
human frataxin [91]. 
 
Ferric iron binding has only been described for the bacterial and 
human orthologues [108, 111]. Human frataxin shows the same 
stoichiometry for iron III as for iron II, binding 6/7 irons per monomer but 
showing a higher affinity for ferric iron with a Kd of ~10M [111]. 
Monomeric Cyay is also able to bind ferric iron with a stoichiometry of 
6/7 irons per monomer. However, this orthologue presents additional, 
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but weaker, iron binding sites allowing CyaY to bind up to 25-26 iron 
atoms per monomer [108].  
Table 2.2: Residues identified as being involved in iron binding by NMR 
spectroscopy and the sequence number conversion between different species for 
this functional residues [89, 91, 113-114]. 
Residue Number In
CyaYa Yfh1a Dfhb mFXNb FXNa
- 
Ser4 
Glu5 
Phe6 
His7 
Arg8 
Leu9 
Asp11 
Gln12 
Leu15 
Thr16 
Glu18 
Glu19 
Arg20 
Leu21 
Asp22 
Asp23 
Trp24 
Asp25 
Gly26 
- 
Asp27 
Asp29 
Asp31 
Cys32 
Glu33 
Asn35 
Ile41 
Thr42 
Leu72 
Glu71 
Lys72 
Tyr 73 
His74 
Glu75 
Glu76 
Asp78 
Asp79 
Asp82 
His83 
Leu85 
Asp86 
Ser87 
Leu88 
Glu89 
Glu90 
Leu91 
Ser92 
Glu93 
Pro96 
Asp97 
Ile99 
Asp101 
Val102 
Glu103 
Ser105 
Leu111 
Glu112 
Gly70 
Ala71 
Thr72 
Tyr73 
Glu74 
Arg75 
Val76 
Ser78 
Asp79 
Asp82 
Ala83 
Cys85 
Asp86 
Tyr87 
Phe88 
Glu89 
Glu90 
Leu91 
Thr92 
Glu93 
Glu97 
Leu98 
Gly100 
Asp102 
Val103 
Ala104 
Tyr106 
Val112 
Asn113 
Glu89 
Thr90 
Ala91 
Tyr92 
Glu93 
Arg94 
Leu95 
Glu97 
Glu98 
Asp101 
Ser102 
Ala104 
Glu105 
Phe106 
Phe107 
Glu108 
Asp109 
Leu110 
Ala111 
Asp112 
Thr116 
Phe117 
Asp119 
Asp121 
Val122 
Ser123 
Gly125 
Ile131 
Lys132 
Glu92* 
Thr93 
Thr94 
Tyr95 
Glu96* 
Arg97 
Leu98 
Glu100* 
Glu101* 
Asp104 
Ser105 
Ala107 
Glu108 
Phe109 
Phe110 
Glu111* 
Asp112 
Leu113 
Ala114 
Asp115 
Thr119 
Phe120 
Asp122 
Asp124 
Val125 
Ser126 
Gly128 
Val134 
Lys135 
a The putative iron binding sites for these three species, E. coli, S. cereviseae and H. Sapiens, 
were determined using NMR spectroscopy. In Black are the residues identified by NMR as 
involved in iron binding, in grey are the corresponding residues that in other species were 
identified as  iron binding sites; 
b Dfh – D. melanogaster (fruit fly) and mFXN – M. musculus (mouse). Sequence number 
conversion for the residues identified as binding sites on the other three species; 
* Residues indentified in an additional study [114]. 
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CyaY and Yfh1 oligomerise in an iron-dependent way [106, 108], but 
their oligomerisation process is different. Contrary to what is observed 
for the CyaY, Yfh1 oligomerisation process is well defined and ordered, 
leading to the formation of high molecular weight oligomers. 
Nonetheless, magnesium and calcium salts, at concentrations found 
within the mitochondria, stabilise the monomeric iron-bound Cyay and 
Yfh1 [106-107, 110], suggesting that oligomerisation may not be 
important for frataxin cellular function.  
Table 2.3: Stoichiometry and dissociation constants determined, by both 
flurescence or ITC (isothermal titration calorimetry), for the interaction of frataxin 
with either ferrous or ferric iron. 
 n Kd (M) Ref. 
Fe2+    
CyaY 2 3.80 [108] 
Yfh1 2a 2.50 [110] 
Dfh 1 6.00 [115] 
46-210FXN 1 4.00 [116] 
78-210FXN 7 0.46 [114] 
78-210FXN 
(E100/E101/D104/E108/E111/D112A) 
2 0.21 [114] 
78-210FXN 
(D115/E1221/D122/D124A) 
4 0.32 [114] 
78-210FXN 
(E92/E96/E100/E101A) 
5 0.18 [114] 
81-210FXN 6/7 55.0 [111] 
Fe3+    
CyaY 6a n.d. [108] 
81-210FXN 6/7 11.7/10.2b [111] 
a Additional irons can bind without protein precipitation, Yfh1 binds up to 
~50FeII/monomer, while CyaY bind up to a stoichiometry of ~25-26FeIII/monomer; 
b As measured by fluorescence and ITC. 
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Human frataxin does not oligomerise in vitro, however it can 
assemble into holopolymers when expressed in E. coli or in Yeast [22, 
109], but this oligomerisation depends on protein-protein interactions 
involving the non-conserved N-terminal region. Contrary to what is 
observed for other frataxin orthologues, human frataxin oligomerisation 
is not iron dependent but oligomers can bind up to 10 irons per 
monomer. Oligomers can be found in mouse and human heart 
mitochondria when 56-210FXN construct is expressed, suggesting that 
indeed oligomerisation can occur in native conditions [117]. The protein 
core does not oligomerise (78-210FXN) [107, 109], but the identification of 
an alternative maturation site leading to the formation of 56-210FXN opens 
the possibility of oligomerisation in vivo.   If this process does occur in 
vivo its biological relevance is still questionable since iron storage in 
human cells is much more efficiently accomplished by ferritin. Due to 
the lack of mitochondrial ferritin in yeast, yeast may alternatively use 
frataxin as an iron storage protein.  
 
2.3.2. Iron-Chaperone  
Frataxin acts as an iron chaperone for two fundamental processes: 
the FeS clusters and the heme biosynthesis. Frataxin involvement in 
FeS clusters formation was first suggested by the decreased activity of 
FeS clusters containing enzymes in FRDA patients, as well as in yeast 
and conditional knockout mice [35, 41, 118-120]. FeS proteins 
participate in several essential cellular processes such as electron 
transport (respiratory chain), gene regulation, iron uptake and catalysis 
[121]. FeS clusters assembly in eukaryotes is performed in the 
mitochondria by the ISC machinery (Fig. 2.7) [122-123]. Correct FeS 
assembly involves Nsf1 (a cystein desulfurase) [123-124], Arh1 
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(ferredoxin reductase) [125], Yah1 (ferredoxin), Isd11 [125-127] and Isu 
[123, 128-130]. Briefly, Isu provides a platform for the assembly of FeS 
clusters prior to the delivery to an apo protein. The scaffold protein Isu 
is dynamic as it forms dimers and binds Nsf1 forming an 
heterotetrameric complex that allows for the transfer of sulphide. While 
Nsf1 delivers sulphur, frataxin acts as an iron chaperone delivering iron 
to the scaffold protein Isu.  
 
 
 
Figure 2.8: A model for FeS protein assembly in Eukaryotes. The assembly of FeS 
occurs inside the mitochondria, the ferrous iron is imported from the cytosol in a 
membrane potential-dependent manner (with proton-motive force (PMF) as a source 
of energy). Import is aided by the inner membrane carriers Mrs3 and Mrs4 (known as 
mitoferrin in mammals). FeS clusters assembly starts with sulphur liberation from 
cystein by the desulfurase complex Nsf1-Isd11 (1). The synthesis of transiently bound 
FeS clusters on the scaffold protein Isu1 (and Isu2 in yeast) further depends on the 
iron-binding protein frataxin as an iron donor, that undergoes an iron-stimulated 
interaction with Isu1-Nsf1(2) and electron-transport chain consisting of NADH, 
ferredoxin reductase (Arh1) and ferredoxin (Yah1), which possibly provides the 
electros for the reduction of sulphur to sulphide (3). The release of the FeS clusters 
from Isu and its transfer to apooriteins (APO) are facilitated by ATP-dependent Hsp70 
chaperone Ssq1, DnaJ-like co-chaperone Jac1, the nucleotide exchange factor Mge1 
and the monothiol glutaredoxin Grx5 (5). The nuclear and cytosolic FeS protein 
biogenesis require the mitochondrial ISC machinery assembly, export machinery and 
further involved the cytosolic FeS protein assembly machinery (CIA). Adapted from 
[123, 125, 131-134]. 
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It was demonstrated that frataxin deficiency in human HeLa cells and 
Yeast compromises the maturation of both cytosolic and mitochondrial 
FeS cluster proteins [135-138]. This is the first defect to be detected 
once frataxin expression is impaired by iRNA [139], suggesting a 
specific role of frataxin on the biosynthesis FeS clusters.  
Frataxin is involved in the early stages of FeS clusters biosynthesis 
and experimental evidence suggests that frataxin delivers iron to the 
scaffold protein Isu [111] [141]. In 
vitro frataxin-Isu interaction is iron 
dependent and Table 2.4 presents 
the binding parameters assessed for 
this interaction.  
Moreover, frataxin is also involved 
in FeS clusters’ protection and repair. 
It interacts with aconitase in a citrate 
dependent fashion, delivering iron to 
aconitase ([3Fe-4S]1+) and enabling 
the repair of its FeS cluster and its 
enzymatic reactivation [140].  
Recently, a study using the E. coli orthologue, CyaY, has suggested 
an alternative and rather controversial role of frataxin on the FeS 
biosynthetic pathway [142]: Pastore and co-workers have suggested 
that frataxin may work as an inhibitor of FeS assembly and as an iron 
sensor. According to this new putative function, CyaY would, through a 
negative regulation mechanism, act as a gate-keeper of FeS clusters 
assembly, fine-tuning the assembly of the clusters to meet the 
concentration of apo-protein acceptors (Fig. 2.10). 
 
 
 
    
 
Figure 2.9: Frataxin can play a dynamic 
role in the regulation of aconitase during 
oxidative stress. It can protect the 
aconitase labile [4Fe-4S]2+ from 
disassembly and facilitate FeII transfer to 
the [3Fe4S]1+ cluster of aconitase 
reactivating its enzymatic activity [140]. 
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Figure 2.10: Schematic representation of the alternative molecular mechanism of frataxin 
in the cell proposed by Pastore and co-workers (proposed through the study on the 
bacterial mechanism). (A) Normal iron concentrations, FeS clusters are assembled by the 
IscS-IscU complex (corresponding to the Isu-Nsf1 complex). (B). Excess of iron in respect 
to the concentration of final accepters will be rebalance by slowing down the FeS clusters 
assembly and avoid unnecessary overproduction of these labile clusters. (C). When 
frataxin is down-regulated or produced in insufficient concentrations, as in FRDA, there is 
no regulation of the clusters assembly. FeS clusters will be produced in excess and iron 
excess will result in FeS clusters surplus which being very unstable will degraded 
generating Fenton reactions. Fe3+ will precipitate and form insoluble aggregates. Adapted 
from [142]. 
 
Frataxin also acts as an iron chaperone in another essential 
biosynthetic pathway - the Heme synthesis. Considering that 
prokaryotic frataxin in not part of a specific operon, frataxin involvement 
in more than one pathway is conceivable. Heme synthesis comprises 
several steps and the last involves ferrochelatase. Frataxin catalyses 
the insertion of ferrous iron into the porphyrin ring, leading to the 
formation of functional heme. In Eukaryotes, ferrochelatase is 
associated to the matrix side of the inner mitochondrial membrane and, 
in addition to iron, it can chelate other divalent ions being zinc the 
predominant alternative. Studies using the yeast model have shown that 
the absence of frataxin (Yfh1 deleted strain) leads to severe deficiency 
in cytochromes b, c and (a+a3). Interestingly, when using a system 
where the induction of Yfh1 could be controlled, it was observed that the 
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cytochrome c deficiency could be reversed once frataxin expression 
was reversed [143]. Later, it was shown that reduced levels of frataxin 
lead to a down regulation of mitochondrial transcripts and a kinetic 
inhibition of the heme biosynthetic pathway [144]. Altogether these 
results suggest an involvement of frataxin in heme assembly. Dancis 
and co-workers, through the use of Surface Plasmon Resonance 
(Biacore), have first reported a direct interaction between frataxin and 
ferrochelatase (Kd~40nM) [143].  
 
Table 2.4: Stoichiometry and dissociation constants determined, by both 
flurescence, ITC or Biacore, for the interaction between frataxin and its protein 
partners Isu and ferrochelatase. 
 n Kd (M) Ref. 
Isu1a    
46-210FXN 1.0 5.40 [116] 
78-210FXN 1.0 0.03 [114] 
78-210FXN 
(E100/E101/D104/E108/E111/D112A) 
0.9 0.05 [114] 
78-210FXN 
(D115/E1221/D122/D124A) 
1.0 0.09 [114] 
78-210FXN 
(E92/E96/E100/E101A) 
0.9 0.11 [114] 
81-210FXN 1 0.67b 
0.45 
[111] 
Dfh 0.9 0.21 [115] 
Ferrochelatase    
Yfh1 - 0.04 [143] 
81-210FXN 0.5c 0.17 [112] 
a Measured Apo D37A Isu . Mutation D37A on Isu was found to stabilize The Isu-bound FeS 
clusters; 
b Measured for Apo Isu; 
c Frataxin monomer binds to ferrochalatase homodimer. 
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However, this study could not report any direct evidence of frataxin-
mediated iron delivery to ferrochelatase, since interaction was detected 
in the absence of iron. Later, Cowan and co-workers characterised this 
interaction for the human system and have shown that holo-frataxin 
could be a potential iron donor to ferrochelatase for the insertion of iron 
into the protoporphyrin ring during heme synthesis (Kd=~17nM, Table 
2.3) [112]. The interaction between frataxin and ferrochelatase could 
only be detected by ITC and fluorescence when iron was present, 
similarly to what it had been described for the Isu-frataxin interaction 
(Table 2.4) [112].  
 
 
Figure 2.11: Top. Ribbon representation of the structure of human frataxin, putative iron 
and ferrochelatase binding sites are coloured and their side chains are presented by 
sticks. red:  iron binding sites; green: ferrochelatase biding sites;orange:  iron and 
ferrochelatase binding sites. Bottom: Alignment of the sequence of CyaY, Yeast and 
human frataxin; red boxes highlight the putative iron binding sites;  green boxes with a 
green underline identify the putative ferrochelatase binding sites; orange boxes with a 
green underline identify the residues that constitute putative iron and ferrochelatase 
binding sites [91, 113-114]. 
 
CyaY_ECOLI ---------------------------------------MND---------------------------- 3
Yfh1_YEAST ---MIKRSLASLVRVSSVMGRRYMIAAAGGERARFCPAVTNKKNHTVN--------------------TF  48
FXN_HUMAN MWTLGRRAVAGLLASPSPAQAQTLTRVPRPAELAPLCGRRGLRTDIDATCTPRRASSNQRGLNQIWNVKK  70
Ruler 1.......10........20........30........40........50........60........70     
CyaY_ECOLI -----------------------SEFHRLADQLWLTIEERLDDWDG----DSDIDCEINGGVLTITFE-N   45
Yfh1_YEAST QKRFVESSTDGQVVPQEVLNLPLEKYHEEADDYLDHLLDSLEELSEA-HPDCIPDVELSHGVMTLEIPA- 115
FXN_HUMAN SQSVYLMNLRKSGTLGHPGSLDETTYERLAEETLDSLAEFFEDLADKPYTFEDYDVSFGSGVLTVKLGGD  139
Ruler .........80........90.......100.......110.......120.......130.......14
CyaY_ECOLI GSKIIINRQEPLHQVWLATKQ-GGYHFDLKGDEWICDRSGETFWDLLEQAATQQAGETVSFR-------- 106
Yfh1_YEAST FGTYVINKQPPNKQIWLASPLSGPNRFDLLNGEWVSLRNGTKLTDILTEEVEKAISKSQ----------- 174
FXN_HUMAN LGTYVINKQTPNKQIWLSSPSSGPKRYDWTGKNWVYSHDGVSLHELLAAELTKALKTKLDLSSLAYSGKDA 210
Ruler 0.......150.......160.......170.......180.......190.......200.......210
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Table 2.5: Residues identified as being involved in ferrochelatase binding by NMR 
spectroscopy and the sequence number conversion between different species for 
this functional residues [89, 113]. 
Residue Number In
CyaYb Yfh1a Dfhb mFXNb FXNa 
Trp14 
Leu15 
Thr16 
Ile17 
Glu18 
Glu19 
Arg20 
Leu21 
Asp22 
Asp23 
Trp24 
Asp25 
Gly26 
- 
- 
Asp29 
Asp31 
Cys32 
Glu33 
Thr40 
Ile41 
Ser47 
- 
Leu57 
His58 
Trp61 
Ile79 
Ser83 
Trp88 
Asp89 
Leu90 
Leu91 
Glu92 
Gln93 
Gln97 
Gly100 
Glu101 
Thr102 
Leu81 
Asp82 
His83 
Leu84 
Leu85 
Asp86 
Ser87 
Leu88 
Glu89 
Glu90 
Leu91 
Ser92 
Glu93 
Ala94 
His95 
Ile99 
Asp101 
Val102 
Glu103 
Thr110 
Leu111 
Thr118 
Lys123 
Asn127 
Lys128 
Trp131 
Val150 
Asn154 
Thr159 
Asp160 
Ile161 
Leu162 
Thr163 
Glu164 
Lys168 
Ser171 
Lys172 
Ser173 
Leu81 
Asp82 
Ala83 
Leu84 
Cys85 
Asp86 
Tyr87 
Phe88 
Glu89 
Glu90 
Leu91 
Thr92 
Glu93 
Asn94 
Ser96 
Gly100 
Asp102 
Val103 
Ala104 
Thr111 
Val112 
Gly119 
Thr127 
Asn129 
Lys130 
W133 
Ile156 
Ser160 
His165 
Glu166 
Leu167 
Leu168 
Gln169 
Gln170 
Gly174 
Lys177 
Ser178 
Gln170 
Leu100 
Asp101 
Ser102 
Leu103 
Ala104 
Glu105 
Phe106 
Phe107 
Glu108 
Asp109 
Leu110 
Ala111 
Asp112 
Lys113 
Tyr115 
Asp119 
Asp121 
Val122 
Ser123 
Thr130 
Ile131 
Thr138 
Thr146 
Asn148 
Lys149 
Trp152 
Val171 
Asn175 
His180 
Glu181 
Leu182 
Leu183 
Ala184 
Arg185 
Lys189 
Asn192 
Thr193 
Lys194 
Leu103 
Asp104 
Ser105 
Leu106 
Ala107 
Glu108 
Phe109 
Phe110 
Glu111 
Asp112§ 
Leu113§ 
Ala114 
Asp115§ 
Lys116 
Tyr118 
Asp122 
Asp124 
Val125 
Ser126 
Thr133 
Val134 
Thr141 
Thr149 
Asn151 
Lys152 
Trp155 
Val174 
Asn178 
His183 
Glu184 
Leu185 
Leu186 
Ala187 
Ala188 
Lys192 
Lys195 
Thr196 
Lys197 
a The putative ferrochelatase binding sites for, S. cereviseae and H. Sapiens, were determined using 
NMR spectroscopy. In Black are the residues identified by NMR as involved in ferrochelatase 
binding, in grey are the corresponding residues that were identified as  iron binding sites on the other 
specie; b CyaY - E. coli, Dfh – D. melanogaster (fruit fly) and mFXN – M. musculus (mouse). 
Sequence number conversion for the residues identified for the other  two species;§ Residues whose 
chemical shifts were already broadened beyond detection during the iron titration before 
ferrochelatase addition but that are believe to constitute the interface for ferrochelatase binding [113]. 
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The identification of frataxin residues involved in the ferrochelatase-
binding surface was performed by NMR spectroscopy for both yeast 
and human orthologues (Table 2.5 and Fig. 2.11) [89, 113]. These 
studies suggested that frataxin’s helical plane, primarily the conserved 
and exposed helical residues including the 1 iron binding residues, 
constitutes the interface for frataxin–ferrochelatase interaction. 
Furthermore, 6-loop-2 residues are also involved in the interface for 
ferrochelatase binding. These residues on the 6-loop provide an 
hydrophobic patch on the interface surface which could suggest that 
this region maybe target the binding of frataxin the hydrophobic exterior 
of ferrochelatase.  
 
Frataxin participates in 
two important and essential 
biosynthetic pathways thus 
there must be a control 
mechanism that 
determines which pathway 
holo-frataxin targets. After 
determining the frataxin 
affinity constant for Isu and 
ferrochelatase interactions, 
Yoon and Cowan have 
suggested a simple regulation mechanism (Fig. 2.12). When present in 
normal concentrations, holo-frataxin will primarily deliver iron to the 
more needed biosynthetic pathway. However, if frataxin levels are 
reduced, such as in FRDA patients, frataxin will first meet heme 
biosynthetic needs at the cost of the FeS clusters biosynthetic pathway 
leading to a drastic decrease in the amount of FeS clusters. 
 
 
Figure 2.12: Model for the regulation of frataxin 
iron chaperon activity, FeS clusters biosynthesis 
vs Heme biosynthesis. Under normal growth 
conditions frataxin (FXN) concentration is 
sufficient to both biosynthetic pathways. 
However, when frataxin (FXN) expression levels 
are reduced the FeS suphur biosynthetic pathway 
should be more significantly affected due to the 
different affinities of holofrataxin to Isu1 and 
ferrochelatase. Adapted from [112]. 
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2.3.3. A Ferritin-Like Behaviour 
In the absence of iron, Yfh1 is monomeric, but in the presence of 
oxygen and ferrous iron it undergoes iron-dependent oligomerisation. 
Anaerobic conditions fully inhibit oligomerisation [145] and other metals, 
such as calcium, cobalt, magnesium and manganese, as well as ferric 
iron are unable to promote Yfh1 assembly [106]. Oligomerisation follows 
according to the progression    3  6   12   24  48, where 
monomer to trimer transition constitute the rate limiting step [106, 145] 
(Fig. 2.12).  Giving the similarities between this mechanism and the 
assembly process described for ferritin [146] it is suggested that frataxin 
may act as an iron storage protein. When ferrous iron to protein 
stoichiometries are high, Yfh1 forms a 48-multimeric homooligomers 
binding up to 50 iron atoms per monomer [145, 147-148].  This multimer 
is ~1.1MDa and keeps iron in a soluble, stable and available form [106]. 
However, anaerobic conditions, high concentrations of other divalent 
ions and physiological salt concentrations impair the assembly process 
[106-107, 110].  Yfh1 self-assembly is driven by two sequential iron 
oxidation reactions: first, the protein forms trimers containing 
ferroxidation sites (residues H74, D78, D79, D82 and H83) that catalyse 
iron II oxidation [148-149]; when all ferroxidase sites are occupied, the 
protein starts an autoxidation process that overcomes ferroxidation. The 
trimers then coalesce through a stepwise process yielding higher order 
multimers [90, 150]. It is suggested that at least part of the H2O2 
produced by the ferroxidase reaction will react with the protein [148]. 
Structural studies on frataxin oligomers suggest a gating mechanism 
involving two conformations for Yfh1 trimer that enables frataxin to 
either deliver iron to its protein partners or transfer it to the oligomer 
core (iron detoxification role) [90]. These studies have also confirmed 
the remarkable similarities between the structural organisation of Yfh1 
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oligomers with those of the iron-storage protein ferritin. Although the 
biological significance of human frataxin oligomerisation capacity is 
debatable, if indeed this mechanism is relevant, FRDA-related 
mutations may cause its impairment.  Analysis of the structure of Yfh1 
trimer, the oligomerisation building block, suggests that four of the 
identified FRDA clinical mutations, G130V (Yfh1-G107), D122Y (Yfh1-
I99), W155R (Yfh1-W131) and R165C (Yfh1-R141), are likely to impair 
its formation. [90]. 
Mutagenesis studies have allowed the identification of three residues 
critical for the oligomerisation capacity of Yfh1: the mutation of residues 
86, 90 and 93 to alanines abolishes Yfh1 oligomerisation [151]. 
However, further studies have revealed that mutating only residue 93 is 
enough to almost completely abolish oligomerisation [152]. Under 
normal conditions mutations that compromise oligomerisation are 
asymptomatic which lead to the belief that this feature was dispensable 
in vivo [151]. However, Isaya group has shown that, under stress 
conditions, oligomerisation impairment becomes harmful, diminishing 
yeast lifespan, and lethal if SOD1 gene is deleted [152]. 
A recent study suggests that reversible Yfh1 iron dependent 
oligomerisation represents a mechanism that allows frataxin to promote 
mitochondrial FeS biosynthesis while limiting iron toxicity [153]. 
Similarly, as noted previously for CyaY, FeIII-loaded oligomeric Yfh1 
may deliver iron for the FeS cluster assembly. This study suggests that 
Yfh1 oligomeric form is the one interacting with Nfs1-Isd11 and Isu. 
However, low levels of oligomerisation are enough to guarantee FeS 
cluster assembly. The interaction between frataxin and Isd11 (a 
component of the Nsf1/Isu complex of mitochondrial FeS cluster 
biogenesis) had already been reported [129, 154]; Isd11 is thought to 
mediate the interaction of frataxin with the Nsf1/Isu complex as Isd11 
deficiency results in many of the deficiencies described for frataxin 
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depletion. Interestingly, the frataxin-Isd11 interaction is inhibited by 
physiological concentrations of ferrous iron but this effect can be 
reversed by iron chelators. Other metals also inhibit the interaction with 
the exception of nickel that increases it [154]. 
 
 
 3 6 24 
Figure 2.13: Yfh1 iron induced oligomerisation. The excess of iron induces Yfh1 
oligomerisation; the trimers constitute the building block of the supramolecular 
assembly and its formation is the rate limiting step of the process and involves two 
oxidation reactions: a ferroxidase reaction followed by an autoxidation. The trimer (3) 
is stabilised by the interactions between the loops marked in red, the N-terminal 
extension, in green, plays a crucial role in the stabilisation of the trimer and in addition 
is believed to be involved in the packing of the trimers within 24 . Iron binds to the 
channel at the 3-fold axis of the trimer, close to residues D143. Two putative 
conformations of the channel suggest a gate mechanism that controls whether iron 
stays in the channel to be delivered to frataxin partners or whether it is transferred to 
the detoxification sites (oxidation) at the exit of the channel. Adapted from [90]. 
 
2.3.4. Anti-Oxidant Activity 
The relationship between oxidative stress and FRDA (and hence 
frataxin) function is rather controversial. The fact that, in vivo, reduced 
levels of frataxin lead to an increase of the oxidative stress is well 
accepted [100, 155-159], however, the mechanism that allows frataxin 
to maintain the oxidative balance is still a matter of debate 
[84,89,137,138]. In the yeast system, the dynamic oligomerisation 
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behaviour seems to explain how yeast frataxin holds the oxidative 
balance [117, 152, 160]. According to a mechanism proposed by 
Isaya’s lab, the presence of ferrous iron and oxygen triggers Yfh1 
oligomerisation, preventing the existence of free iron which would result 
in the formation of oxigen reactive species through Fenton reaction. In 
vitro, the presence of Yfh1, CyaY or Dfh1 (drosophila orthologue) 
inhibits the production of OH• through Fenton chemistry [115, 149, 161] 
and this effect seems to result from the presence of ferroxidase sites.  
In vivo, it was shown that overexpressing frataxin increases cellular 
tolerance to stress conditions, such as increased iron concentrations, 
addition of Paraquat or H2O2, prolonging cells life span and preventing 
oxidative damage to proteins. [162]. This protective effect has been 
observed for human, drosophila and yeast frataxin [163-165]. The 
antioxidant protection resultant from overexpressing human frataxin has 
been linked to increased levels of glutathione and its peroxidase [166]. 
Interestingly, decreasing the levels of frataxin (yeast model) also leads 
to an enhanced activity of glutathione peroxidase, thus it seems that 
frataxin may also control cellular oxidative balance by regulating the 
cellular thiol content and the thiol-dependent response to oxidative 
stress [167]. 
Other studies suggest that frataxin may also act primarily as an 
activator of oxidative phosphorylation (OXPHOS) [168]. In human cell 
lines, overexpressing frataxin leads to an increase of Ca2+ uptake and 
respiration, which in turns results in an increased mitochondrial 
membrane potential (m increased 2.5 fold) and elevated cellular ATP 
content (1.9 fold increase). This hypothesis is in agreement with the fact 
that FRDA patients have reduced ATP production in the skeletal muscle 
and with the cellular respiration defects described in Yfh1 deficient 
yeast. Considering this hypothesis, frataxin may act as an anti-oxidant 
directly but may also prevent oxidative stress by regulating oxidative 
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phosphorylation. Still regarding frataxin's putative role in OXPHOS, 
direct physical interactions between  frataxin and succinate 
dehydrogenase and yeast ETF orthologue have been reported [169]. 
These suggest that frataxin may be involved in the entrance of electrons 
into the electronic transport chain and that its absence could lead to the 
incorrect use of electrons by complex II and the consequent 
accumulation of semiquinone. These results also suggest that the 
decreased succinate dehydrogenase activity associated to reduced 
levels of functional frataxin may not be a secondary effect but a direct 
effect. 
Unravelling the mystery of frataxin function has been an intense and 
interesting quest that is still far from finished. Frataxin seems to have a 
wide and dynamic role on mitochondrial physiology and function and 
even the identification of the primary pathological consequences of its 
reduced expression is controversial.  
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3.1. Summary 
To better understand the pathological mechanism associated to 
FRDA development in heterozygous patients, we have evaluated 
whether two particular FRDA mutants, FXN-I154F and FXN-W155R, 
retain frataxin fold. A detailed comparison of the conformational 
properties of the wild-type and mutant proteins combining biophysical 
and biochemical methodologies was undertaken. We show that FRDA 
mutants retain the native fold under physiological conditions but are 
differentially destabilised, as reflected both by their reduced 
thermodynamic stability and higher tendency towards proteolytic 
digestion. The I154F mutation has the strongest effect on the fold 
stability, as expected from the fact that the mutated residue contributes 
to the hydrophobic core formation. Functionally, the iron-binding 
properties of the mutant frataxins are found to be partly impaired. The 
apparently paradoxical situation of having clinically aggressive frataxin 
variants which are folded and are only slightly less stable than the wild-
type form in a given adverse physiological stress condition is discussed 
and contextualised in terms of an hypothetical mechanism that could 
determine the pathology of heterozygous FRDA. 
 
3.2. Introduction 
At the present time, at least 15 missense frataxin point mutations 
have been described in FRDA patients [1]. Reports on these mutations 
indicate that they do not interfere with splicing and the fact that some 
compound heterozygous individuals have atypical milder phenotypic 
expressions of the disease is suggestive of the cellular presence of 
frataxin with a partly reduced function [1-2]. Although mapping these 
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mutations on to the available three-dimensional structures of frataxin [3-
5] can provide a framework for predicting their effect on the protein 
structure, the exact impact of these clinically relevant missense 
mutations on the folding pathway of frataxin remains to be 
experimentally and quantitatively addressed. 
In the present chapter, studies on the structural stability and folding 
properties of human frataxin and on two mutant variants comprising 
clinically relevant point mutations, I154F and W155R, are reported. 
These modifications involve highly conserved amino acids and previous 
studies have suggested that these two mutations represent two extreme 
possibilities, but both lead to an aggressive phenotypic development of 
FRDA [1]. The first one, I154F is one of the most common clinically 
occurring mutations and affects a residue which is part of the protein 
core. This mutation is therefore expected to directly affect the stability of 
the protein fold and should be structurally important. The second 
mutation involves the conserved Trp155, which is part of an invariant 
surface in the exposed region of the β-sheet. The aromatic ring of 
Trp155 is fully solvent-exposed, suggesting a role of this residue in the 
interaction with frataxin protein-partners. The mutation is expected to be 
functionally important since conservation of surface residues usually 
implies that they are involved directly in protein function; this putative 
functional role attributed to Trp155 has been recently confirmed [6]. 
Using the yeast homologue, Foury and co-workers have evaluated the 
putative contribution of 12 conserved residues in frataxin -sheet for the 
interaction with Isu1. Their report shows that, in fact, frataxin (Yfh1) 
interaction with Isu1 is mediated by its -sheet surface and Trp-131 
(corresponding to FXN-Trp155) through its aromatic side chain is directly 
involved contributing to the Yfh1-Isu1 binding energy  [6].   
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3.3. Materials and methods 
Gene Expression and Protein purification 
The constructs were expressed in E. coli (competent cells BL21 DE3 
from Novagen) as fusion proteins with a His and a GST tag with 
cleavage site for tobacco etch virus (TEV) or PreScission protease as 
previously described [4-5, 7-8]. The constructs contained the gene 
coding for the truncated form of frataxin (91-210), hereon simply FXN. 
This form of frataxin has been compared with longer constructs (FXN61-
210 and FXN75-210) and the mature form (FXN81-210); it has been shown 
that additional residues at the N-terminus are unstructured and flexible, 
which suggests that these residues are intrinsically unfolded and provide 
limited information about the protein fold [5, 9]. Both mutants were found 
to be stable in solution, although susceptible to precipitate upon slow 
freezing; however, thawed proteins that had been fast frozen retained 
their spectroscopic properties and melting temperatures. 
Spectroscopic methods 
UV/Vis Spectra were recorded at room temperature in a Shimadzu 
UVPC-1601 spectrometer equipped with cell stirring. Fluorescence 
spectroscopy was performed on a Cary Varian Eclipse instrument (ex 
=280nm, em =340nm, slitex: 5 nm, slitem: 10 nm unless otherwise noted), 
equipped with cell stirring and peltier temperature control. Far-UV CD 
spectra were recorded typically at 0.2 nm resolution on a Jasco J-715 
spectropolarimeter fitted with a cell holder thermostated with a Peltier.  
Chemical denaturation 
The chemical denaturation curves were measured using the dilutions 
method and two solutions with the same protein concentration were 
prepared: one with no denaturation agent and the other with a high 
concentration of denaturation agent. These were combined in different 
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proportions yielding different denaturant concentrations. After mixing, the 
solutions were equilibrated for two hours. Transitions curves were 
determined by plotting the average emission wavelength versus 
denaturant concentration, correcting for the pre- and post-transitions [10-
12]. A non-linear least-square analysis was used to fit the data to a two 
state model [11]: the fits to the unfolding transitions were made using 
Origin (MicroCal). 
Thermal denaturation 
Thermal unfolding was followed by monitoring the intrinsic tryptophan 
fluorescence (exc= 280 nm, em=340 nm, slitex= 5 nm and slitem=10 nm) 
and the ellipticity (mrw at 222 nm) variations. It has been previously 
demonstrated [13] that identical melting temperatures are obtained for 
frataxin by both CD and fluorescence spectroscopies, thus ruling out 
artefacts resulting from changes of fluorescence quantum yield with 
temperature. Further, DSC experiments confirmed melting temperatures 
(data not shown). In all experiments, a heating rate of 1ºC/min was used 
and the temperature was changed from 20 to 90ºC. Data was analysed 
according to a two-state model [11] and the fits to the unfolding 
transitions were made using Origin (MicroCal). For pH variations, the 
buffers used were 30mM acetate (pH 4.9), 40mM phosphate (pH 6.0, pH 
7.9 and pH 11.6), 10mM HEPES (pH 7.0) and 40mM glycine (pH 8.9 
and 9.7). The reversibility of the reaction was investigated by downward 
temperature ramps, as well as repetition of the upward ramps after 
cooling down of the sample to 25C.  
Fluorescence quenching 
Quenching experiments were performed using a neutral quencher – 
acrylamide (Bio-Rad) and an ionic quencher KI (Fluka). The samples 
were excited at 295nm in order to ensure that the light was absorbed 
almost entirely by tryptophanyl groups and the fluorescence intensity 
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decrease at 340nm was followed. Results were analysed according to 
the Stern-Volmer equation [14]. 
Trypsin limited proteolysis 
Frataxins were incubated with trypsin (bovine pancreas trypsin, 
sequencing grade, Sigma) at 37°C in 0.1 M Tris-HCl pH 8.5, in a 100 
fold excess over the protease. Aliquots (~0.5 nmol protein) were 
sampled at different incubation periods and the reaction stopped by the 
addition of 0.2% (v/v) of trifluoroacetic acid (TFA). The products of the 
proteolysis reaction were analysed by reverse-phase HPLC (Waters 
Alliance System 2695) using a C18 Column 150 x 3.9 mm (DeltaPak, 
Waters) run at a 0.5 ml.min-1 flow rate, monitoring the absorbance at 
214nm. The peptidic profiles were obtained running a three-step 
gradient from (A) 0.1% (v/v) TFA to (B) 80% (v/v) Acetonitrile + 0.1% 
(v/v) TFA: 0-37% (in 65 min), 37-75% (in 30 min) and 75-100% (in 20 
min). The column was regenerated with 0.1% (v/v) TFA.  
3.4. Results  
3.4.1. Frataxin Chemical and Thermal Unfolding 
To evaluate the effect of the introduced clinical mutations on the 
human frataxin fold, the chemical and thermal unfolding reactions of 
human frataxin were investigated in detail. Frataxin unfolding can be 
monitored either by fluorescence or by far-UVCD spectroscopy; in the 
present study, intrinsic tryptophan fluorescence changes were routinely 
used to monitor unfolding transitions (see Experimental section). Under 
most denaturation conditions tested, frataxin unfolding was found to be 
highly reversible. FXN exhibits considerable stability over the 
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physiological pH range: its thermal unfolding transition is reversible and 
essentially invariant between pH 6.0 and 9.0 (Table 3.1). 
 
Table 3.1 – Parameters for FXN thermal denaturation as a function of pH. 
pH Tm (ºC) Hm (kcal.mol
-1) Tm
 (ºC) Refolding (%) 
4.9 59.0  0.1 65.7  0.4 -7.3  0.1 20 
6.0 65.4  0.2 88.8  0.5 -0.9  0.3 80 
7.0 62.5  0.2 59.8  0.3 -3.8  0.3 95 
7.9 66.3  0.1 89.2  0.4  - 100 
8.9 62.1  0.2 86.5  0.8 -4.2  0.3 100 
9.7 59.0  0.1 67.4  0.3 -7.3  0.1 20 
 
 
However, below pH 5.0, which is the isoelectric point of FXN as well 
as at higher pH values, an increasing extent of irreversibility was 
observed as a result of protein aggregation. At lower pH values, this is 
expected, considering the decreased solubility of the unfolded form of a 
protein near its isoelectric point [11, 15]. Chemical denaturation 
experiments were performed at pH 7.9 using urea, GdmCl and GuSCN 
as denaturants. The obtained curves were analysed assuming a two-
state mechanism, and the unfolded fraction was plotted as a function of 
denaturant concentration; from the data in the transition region, and 
using the linear extrapolation model, the thermodynamic parameters 
GH2O and m were determined (Fig. 3.1 and Table 3.2). Frataxin 
conformational stability ranges from 5.7–8.5 kcal · mol-1. 
 
Table 3.2 - Parameters for the chemical denaturation of wild type 
FXN, pH 7.9 
Denaturant [D]1/2 (M) 
m  
(cal.mol-1.M.-1) 
GH2O  
(cal.mol-1) 
GuSCN 
GdmCl 
Urea 
1.1 
2.1 
4.3 
5354  327 
4009  235 
1353  063 
5675  407 
8539  541 
5833  299 
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Figure 3.1: Chemical denaturation curve for FXN at pH 7.9. Fxn typical 
denaturation curves with (○) GdmCl, (□) GuSCN, (∆) urea.  
 
 
3.4.2. Conformational Dynamics 
The impact of the clinical mutations on the frataxin fold and dynamics 
was evaluated from fluorescence quenching studies. Fluorescence 
quenching experiments were performed at 25ºC using acrylamide and 
iodide (Fig. 3.2 and Table 3.3). Acrylamide is a neutral quencher 
molecule, therefore it accesses the protein interior more easily and it 
quenches buried residues, whereas iodide is negatively charged and 
interacts with the protein's surface. The Stern–Volmer constant for the 
FXN-I154F mutant is comparable with that of the wild-type for both 
quenchers, which suggests that this structural core mutation does not 
result in protein misfolding.  
With respect to the FXN-W155R variant, a lower Stern–Volmer 
constant was determined, which is in agreement with the fact that the 
two remaining tryptophan residues are not exposed, and the protein 
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matrix will strongly slow down the penetration of the quencher 
molecules.  
For all frataxins studied, the accessibility of the tryptophan residues is 
increased in the presence of GmdCl, corresponding to a disrupted 
tertiary structure. Thus, quenching experiments show that, under 
physiological conditions, the mutant frataxins have a globally stable wild-
type-like fold and breathing dynamics. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Stern–Volmer plots of acrylamide and iodide quenching of frataxin 
tryptophan fluorescence. Plots of F 0/F against concentration of acrylamide (A) and 
iodide (B) for the native wild type Fxn (○), FXN-W155R (∆) and FXN-I154F (□). See 
Table 3.3 for parameters. 
 
Table 3.3 – Effect of FRDA mutations on quencher accessibility, Stern-
Volmer constants using different quenchers.  
 
 
Protein 
Ksv (M
-1)
Acrylamide
(close symbols) 
KI 
(open symbols) 
Wild Type 11.2 ± 0.2 5.0 ± 0.2 
W155R 4.5 ± 0.1 3.2 ± 0.1 
I154F 10.5 ± 0.2 5.9 ± 0.2 
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3.4.3. Limited Proteolysis Experiments 
The conformational 
differences between wild-type 
and the mutant frataxin forms 
were accessed by monitoring the 
progression of trypsin-mediated 
proteolysis. Trypsin was selected 
for this comparative mapping as 
it cleaves with high specificity at 
the C-terminal side of lysine and 
arginine, unless the following 
position is occupied by a proline 
residue [16]. Inspection of the 
protein sequence identifies 11 
possible digestion sites for the 
wild-type and I154F proteins and 
an additional one for the W155R 
mutant, as a result of the inserted arginine residue. A comparison of 
these limited proteolysis experiments allows for the evaluation of the 
degree of destabilisation of the mutant forms with respect to the native 
protein. A destabilised fold will have more accessible cleavage sites due 
to increased flexibility and therefore undergo faster proteolysis. The 
obtained peptide maps show clearly that both mutant frataxins are 
destabilised with respect to the wild-type protein, as evidenced by the 
appearance of a substantially higher number of peptides during the 
same incubation period (Fig. 3.3). This observation indicates that the 
clinical mutant frataxins under study contain partly destabilised regions 
which make them more prone to degradation. 
 
 
Figure 3.3: Peptide maps resulting from 
partial tryptic digestions. Wild-type and 
mutant variants (FXN-I154F and FXN-
W155R) after being incubated with trypsin 
for 100 min at 37◦C. 
 
I154F
wild type
W155R
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3.4.4. Iron-Binding is Impaired by Protein Destabilisation 
Iron binding was also investigated, as this may provide useful insights 
into the biological impact of the clinical variants. Frataxin is known to be 
able to bind six to seven irons per monomer, albeit with low affinity [17-
18]. The FRDA-associated mutant frataxins were investigated with 
respect to their ability to bind iron, as well as the wild-type protein, which 
was used as a positive control. Iron binding monitored by fluorescence 
spectroscopy showed that progressive iron binding destabilises the 
mutants, resulting in protein precipitation. Although this occurs both with 
Fe(II) and Fe(III) and under pH-controlled conditions, the ferric ion 
seems to have a more destabilising effect and precipitation is observed 
above an iron/frataxin ratio of 2:1. Concerning ferrous ion binding, 
precipitation was only observed at iron/frataxin ratios ranging from 5:1 to 
7:1. Thus, although none of these FRDA-associated mutations is directly 
involved in the proposed iron binding region [17, 19], its binding may 
have a negative functional impact as it probably induces structural 
modifications which destabilise the frataxin fold, leading to the formation 
of iron induces precipitates. In any case, iron-mediated colloidal 
precipitation of the mutant frataxins cannot be ruled out at this stage. 
 
3.4.5. Frataxin Mutants Thermodynamic Stability 
The conformational properties of the two FXN mutants were 
investigated spectroscopically using fluorescence and far-UV CD. The 
differences in conformational stability between the wild-type FXN and 
the two mutants were determined from the analysis of their chemical and 
thermal denaturation transitions, at pH 7.0 (Table 3.4). 
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For both mutants, cooperative unfolding transitions were observed 
and, under the experimental conditions used, the unfolding reactions 
were found to be reversible. Concerning chemical unfolding, the order of 
the midpoint unfolding urea concentrations was determined to be FXN 
wild-type>W155R>I154F (Table 3.4). The slightly higher m values 
determined for the two mutants also show that a larger fraction of buried 
residues is exposed upon unfolding. The midpoint denaturation 
concentrations determined for the mutants were about one unit below 
that observed for the wild-type and this corresponded to a destabilisation 
of 1.4–1.7 kcal as a result of the mutations. Thermal unfolding 
experiments also revealed that the mutant FXN-I154F is more 
destabilised than the FXN-W155R having a Tm   approx. 16ºC lower than 
the wild-type protein, whereas the mutant W155R shows a decrease of 
only approx. 5ºC. Taken together, these data reveal that both mutations 
under study reduce the thermodynamic stability of frataxin and that the 
mutation FXN-I154F is more destabilising. 
3.5. Discussion 
Under chemically or thermally destabilising conditions, the two 
mutants, FXN-I154F and FXN-W155R, show distinct behaviours, but 
they are both folded at physiological temperature and pH. Mutant FXN-
W155R, which from frataxin structure and sequence conservation 
analysis was suggested to have its functional properties impaired, shows 
Table 3.4 - Parameters for urea denaturation of wild type and mutant forms (FXN-I154F 
and FXN-W155R). Comparing the differences in stability. 
Protein GH2O  
(kcal.mol-1) 
m  
(kcal.mol-1.M-1) 
[Urea]1/2 
(M) [Urea]
 a
 1/2  
Tm 
(ºC) 
Tm 
(ºC) 
Wild type 5.8  0.3 1353  63 4.3   66.3  0.1 
W155R 5.1  0.2 1483  78 3.4 -0.9 -1713 61.4  0.4 
I154F 5.9  0.2 1836  67 3.2 -1.1 -1401  50.7  0.1 
a difference between the [urea]1/2 for the wild-type and the mutant forms.
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only some destabilisation when compared to the wild type protein. 
Inversely, a significant perturbation was detected for the FXN-I154F 
mutant whose fold is substantially destabilised. While this is reasonable 
since the mutation affects a buried residue which takes part of the 
hydrophobic core [5], the destabilisation effect only becomes evident 
under stressing conditions. Accordingly, I154F partly retains its iron-
binding capability, as does W155R, which nevertheless depends 
strongly on the specific three-dimensional scaffold. These are curious 
observations since the severe effects of both mutations in FRDA 
patients were initially thought to exert a much stronger effect on the 
frataxin fold.  
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4.1. Summary  
In the present study, we analysed, in vitro, the consequences of 
disease-related mutations on the stability and dynamics of human 
frataxin. In addition to the FXN-I154F and FXN-W155R mutant variants, 
two other, FXN-G130V and FXN-D122Y, were investigated for the first 
time. CD spectroscopy analysis has demonstrated a substantial 
decrease in the thermodynamic stability of the variants during chemical 
and thermal unfolding (wild-type > W155R > I154F > D122Y > G130V), 
which was reversible in all cases. NMR showed that the clinical mutants 
retained a compact and relatively rigid globular core despite their 
decreased stabilities.  Protein dynamics was studied in detail, revealing 
that the mutants have distinct propensities towards aggregation. Limited 
proteolysis assays coupled with LC-MS allowed the identification of 
particularly flexible regions in the mutants; interestingly, these regions 
included those involved in iron-binding. In agreement, the iron 
metallochaperone activity of the Friedreich’s ataxia mutants was 
affected: some mutants precipitate upon iron binding (I154F and 
W155R) and others have a lower binding stoichiometry (G130V and 
D122Y). Our results suggest that, in heterozygous patients, the 
development of Friedreich's ataxia may result from a combination of 
reduced efficiency of protein folding and accelerated degradation in vivo, 
leading to lower than normal concentrations of frataxin.  
4.2. Introduction 
In preliminary studies, we addressed the question of whether 
prevalent mutations that result in classical FRDA phenotypes were 
correlated with complete impairment of the frataxin fold [9]. We showed 
that, although destabilised, the two tested mutations (W155R and I154F) 
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result in proteins that should be folded under physiological conditions. 
What physical property contributed to the pathogenic mechanism? Two 
possible working hypotheses are that, in the mutants, the efficiency of 
folding is reduced compared to that of the wild-type protein and that the 
mutants have an enhanced susceptibility towards degradation. Either 
scenario, or a combination of both, is likely to lead to frataxin 
concentrations lower than normal. To address this important question, 
which bears direct relevance for our understanding of FRDA, we 
performed a comparative study of the protein dynamics of frataxin 
variants carrying mutations of clinical interest. We focused on how the 
frataxin mutations I154F, W155R, D122Y and G130V encompass 
structural perturbations that may compromise protein–protein 
interactions [1-3], impair functional activity (in terms of iron binding and 
metallochaperone activity) [4] and increase post-translational proteolytic 
susceptibility. We also addressed in detail how mutations affect the 
protein dynamics. This study is expected to contribute to a better 
molecular and structural understanding of the disease mechanism, 
especially when taken in combination with recent data obtained in vivo in 
human cells for some of these mutations [3]. 
4.3. Materials and Methods 
Protein purification 
All constructs were expressed in Escherichia coli competent cells 
(BL21 (DE3)) and the protein was purified as previously described [5-7]. 
As in previous studies, the protein used corresponded to the conserved 
C-terminal domain (amino acids 91–210). The mutants were stable in 
solution, although susceptible to precipitate upon slow freezing. 
Nevertheless, thawed proteins that had been fast frozen retained their 
spectroscopic properties and melting temperatures. 
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 SDS/PAGE 
After cell harvesting, 100 mg of cells from each bacterial growth were 
resuspended in 1.5 mL of lysis buffer (20 mM Tris–HCl, pH 8, 150 mM 
NaCl, 40 mm Imidazole, 1 mm phenylmethanesulfonyl fluoride, DNaseI 
and lysozyme) and lysed on the French press. After lyses, the samples 
were centrifuged at 168000 g for 45 min. The pellet fraction was 
resuspended in 1.5 mL of 6M GuHCl. The protein concentration of both 
the pellet and the soluble fraction was determine using Bradford reagent 
in order to prepare aliquots with the same protein concentration 
(0.2mg·ml-1) to further apply on the gel. A 15% SDS/PAGE was 
performed at 200 V and 25 mA. Proteins were visualised by Coomassie 
blue staining. 
Western blotting 
Proteins separated using SDS/PAGE were transferred from the gel 
onto poly (vinylidene difluoride) membrane for 1 h at 45 mA using a ECL 
semi-dry blotter (GE Healthcare, Piscataway, NJ, USA). 
Immunochemical detection of the His-tagged GST frataxin fusion protein 
was achieved by incubation with anti-GST produced in rabbit (Sigma, St 
Louis, MO, USA). The antibody was diluted (1:1000) in NaCl/Pi-Tween 
containing nonfat milk. After washing with NaCl/Pi-Tween, the 
membrane was incubated with secondary anti-rabbit sera, conjugated 
with horseradish peroxidase (Sigma) and developed with ECL (GE 
Healthcare). 
Spectroscopic methods 
UV/visible spectra were recorded at room temperature in a Shimadzu 
UVPC-1601 spectrometer (Shimadzu, Kyoto, Japan) equipped with cell 
stirring. Fluorescence spectroscopy was performed on a Cary Varian 
Eclipse instrument (Varian NMR, Inc, Palo Alto, CA, USA) (ex = 280 nm, 
em = 340 nm, slitex: 5 nm, slitem: 10 nm, unless otherwise noted) 
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equipped with cell stirring and Peltier temperature control (MJ Research, 
Watertown, MA, USA). Far-UV CD spectra were recorded typically at 0.2 
nm resolution on a Jasco J-715 spectropolarimeter (Jasco Inc., Tokyo, 
Japan) fitted with a cell holder thermostated equipped with a Peltier. 
Trypsin limited proteolysis and LC-MS analysis 
Frataxins variants were incubated with trypsin (bovine pancreas 
trypsin, sequencing grade; Sigma) at 37 ºC in 0.1M Tris–HCl (pH 8.5), in 
a 100-fold excess over the protease. Aliquots (approximately 0.5 nmol of 
protein) were sampled at different incubation periods and the reaction 
stopped by the addition of 0.2% (v/v) of trifluoroacetic acid. The products 
of the proteolysis reaction were analysed by reverse-phase HPLC [6]. 
The column was regenerated with 0.1% (v/v) trifluoroacetic acid. MS 
analysis was carried out at the ITQB Mass Spectrometry Service 
Laboratory (Oeiras, Lisbon, Portugal). 
Iron-binding assays 
Iron binding stoichiometry was quantitated by iron dependent 
fluorescence measurements, essentially as described previously [6]. 
Briefly, tryptophan fluorescence was measured in 1 mL quartz cuvettes 
with continuous stirring. The excitation and monitoring wavelengths were 
290 and 340 nm, respectively. The binding stoichiometry for ferrous and 
ferric ion are identical (six or seven irons per frataxin, [4]) and therefore 
binding of ferric iron was routinely monitored. For the measurements, a 
10 M solution of apo frataxin was titrated with ferric ion from a stock 
solution of FeCl3, over the concentration range 0–120 M. The 
quenching of tryptophan fluorescence induced by the binding of ferric 
ions was used to calculate the fraction of binding sites occupied. The 
stoichiometry, p, and apparent dissociation constant, Kd, were then 
obtained as previously described by Winzor and Sawyer [8] 
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NMR spectroscopic methods 
15N T1, T2 and NOE NMR relaxation measurements were performed at 
600 MHz and 25 ºC on approximately 0.4 mm samples. Both T1 data and 
T2 data were acquired with ten relaxation delays (10, 100, 200, 300, 400, 
500, 600, 700, 800, 100ms and 10, 20, 35, 50, 65, 80, 100, 125, 150, 
250ms, respectively). Experimental steady-state NOE values were 
determined from the peak intensity ratios of amide signals obtained by 
recording interleaved 2D Watergate 1H-15N HSQC spectra with and 
without a proton saturation delay of 4 s and a repetition delay of 4.2 s. T1 
and T2 relaxation times were obtained by fitting the data with atwo-
parameter single exponential decay function. The T1 and T2 values of 
residues 115, 116, 127, 130, 171, 176, 177, 200, 207, 209 and 210 differ 
by more than one standard deviation from the mean value and therefore 
were not considered in the correlation time calculations.  
The errors on the T1 and T2 measurements were estimated to have an 
average value of 3%, whereas the error on the NOE measurements is 
approximately 5%. The 15N heteronuclear relaxation rates were 
interpreted using the program TENSOR2 [9]. The internuclear distance 
rNH was assumed to be 1.02 Å. The dipolar and chemical shift anisotropy 
interactions were assumed to be collinear. 
Frataxin degradation assay 
Cells were transformed with vectors enabling the over expression of 
FXN (wild type or mutants) and a protease system. Double transformed 
cells were grown in LB medium at 37ºC to OD600=0.6 and then plasmid-
derived protein expression was induced by addition of IPTG (0.5mM). 
Following a 45min induction, general protein synthesis was inhibited by 
the addition of rifampicin (300g/ml) and chloramphenicol (100g/ml) at 
t=0 [10-11]. Samples were withdrawn at the mentioned intervals. Cells 
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were lysed and applied on a 15% SDS/PAGE; further, the intensity of 
the bands corresponding to frataxin were quantitated.   
4.4. Results 
4.4.1. Mapping Frataxin Mutations on the Structure 
The four mutations D122Y, G130V, I154F and W155R were mapped 
onto the human frataxin structure (Fig. 4.1). Three of them are 
replacements of exposed residues. The mutation D122Y is located at 
the very beginning of the 1 strand and is an integral part of the turn 
connecting 1 to 1. The side chain of D122 could potentially form an H-
bond with the amide group of the spatially contiguous G138. Being in a 
turn, the exact nature of this residue could influence the folding process. 
Furthermore, a stabilising surface ionic interaction of D122 with the 
nearby K135 residue is disrupted upon mutation. Similarly, G130 is in 
the tight turn formed by G128, S129 and G130 between strands 1 
and2 and both  and  are positive. Its mutation into a valine must 
disturb the turn conformation, resulting in severe local strain. I154 is a 
buried residue that directly sits into the hydrophobic core; its 
replacement by another, albeit bulkier, but still hydrophobic residue does 
not disrupt the fold completely [6]. Finally, W155 is an exposed and 
extremely conserved residue that has been suggested to be relevant for 
protein-protein interactions. However, because W155 packs against a 
nearby arginine (R165), its mutation to an arginine results in a repulsive 
interaction arising from two spatially contiguous positively charged 
residues. 
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I154F W155R
  
G130V D122Y
Figure 4.1: Mapping of frataxin clinical mutations onto the protein structure. The 
figures were drawn using the protein databank file 1EKG. 
 
 
4.4.2. Protein Dynamics of Wild-type Human Frataxin  
The dynamical properties of wild-type human frataxin were 
established by NMR 15N relaxation experiments, looking specifically at 
regions around the mutated positions (Fig. 4.2A).  This technique has 
proven to be very successful in providing information about molecular 
internal motions.  
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Figure 4.2: Comparison of the HSQC spectra for the four frataxin mutants. (A)D122Y; (B) 
G130V; (C) W155R; and (D) I154F. The spectra were recorded at 600 MHz and 25 ºC. 
 
 
Overall, longitudinal (T1) and transverse (T2) relaxation rates and NOE 
values are rather uniform along the protein sequence, in agreement with 
what is expected for a compactly folded globular protein. Such a flat 
behaviour is consistent with the presence of only short and rather stiff 
turns between secondary structure elements. The Lipari–Szabo model-
free formalism was used to analyse the data [12]. Smaller than average 
T1/T2 and small or negative NOE values, which suggest the presence of 
internal motions on the nano- and picosecond timescale, were observed 
at both termini and especially at the C-terminus. This suggests a higher 
mobility of these regions compared to the rest of the molecule, in 
agreement with the larger rmsd of the solution bundle in these regions 
[13]. Residues in the loop between strands 4 and 5 (Thr149, Asn151 
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and Lys152), and at the end of strand 6 (Val174), have larger than 
average T1/T2 ratios and shorter T2. These features may indicate the 
presence of low-frequency motions, often associated with 
conformational exchange. The correlation time of the wild type at room 
temperature, as estimated from the T1 /T2 ratio, is 7.9 ns. This value is in 
good agreement with the value expected for a monomeric globular 
domain of equivalent size [13]. 
 
4.4.3. Conformational Dynamics of Frataxin Mutants 
The NMR spectra for the four frataxin mutants are all compatible with 
folded species, having appreciable peak dispersion (approximately 4 
p.p.m. and 30 p.p.m. dispersion in the 1H and 15N dimensions, 
respectively) (Fig. 4.2B–D). This is confirmed by far-UV CD because the 
spectrum of the mutants is overall identical to that of the wild-type 
frataxin (not shown). The NMR spectra obtained for FXN-W155R and 
FXN-G130V are very similar to that of the wild-type [14] and the 
spectrum for FXN-D122Y shows some local rearrangement of several 
resonances. The spectrum for FXN-I154F is of lower quality, suggesting 
the presence of a small but appreciable population of either degraded or 
unfolded protein.  
 
Table 4.1: Relaxation rate constants, NOE and correlation time. T1 and T2 as well, as 
steady-state 1H-15N NOE and c, were measured or frataxin variants. 
Protein T1 (ms) T2 (ms) NOE c (ns) 
WT 544.3 106.9 0.76 7.9 
D122Y 578.2 115.5 0.76 7.7 
G130V 634.5 98.4 0.77 7.5 
I154F 712.1 97.7 0.75 8.5 
W155R 746.6 90.6 0.71 9.2 
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Accordingly, it was relatively easy to assign the spectra for the FXN-
W155R, G130V and D122Y mutants from that of the wild-type, whereas 
the spectrum for FXN-I154F could only be tentatively assigned. T1 and T2 
as well as steady-state 1H-15N NOE and correlation times (c) were 
determined and analysed for the wild-type and the mutant frataxins 
(Table 4.1 and Fig. 4.4). 
 
 
Figure 4.3: Effect of frataxin clinical mutations on the protein aggregation 
propensity. Top: SDS/PAGE gels obtained from E. coli lysates expressing GST-
frataxin fusion proteins (Mr = 39.2 kDa). Frataxin identity was confirmed by 
Western blot analysis (not shown). For each protein variant, the electrophoretic 
separations of total protein in both the soluble (s) and insoluble (p) fractions are 
shown. Bottom: Semi-quantitive analysis of the relative proportion of frataxin 
present in the soluble and insoluble fractions, obtained from densitometric 
analysis of gel bands (n = 3). 
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 Apart from I154, whose resonance is not observable because of 
overlap, the other mutation sites have average T1 /T2 and NOE values. 
We observed a progressive increase of the average T1 values, with a 
concomitant decrease of the average T2, which follows the order wild-
type < D122Y < G130V < I154F < W155R. In agreement, the correlation 
times extend from 7.5 to 9.2 ns for FXN-W155R (Table 4.1 and Fig. 
4.4). This strongly suggests that the mutants have a different tendency 
towards aggregation. Such behaviour is fully consistent with what had 
been noticed at the protein purification level because expression of 
frataxin mutants always results in formation of aggregates and inclusion 
bodies.  
This was further investigated by carrying out a semi-quantitative 
analysis of frataxin expression in cell extracts by SDS/PAGE (Fig. 4.3) 
and Western blot analysis (not shown). Expression systems have been 
used as a tool to study the foldability and conformational destabilisation 
of human proteins [15], including other mitochondrial proteins [10, 16]. 
The data obtained for the different frataxin variants showed that these 
have different tendencies to aggregate (Fig. 4.3). Although wild-type 
frataxin remains, to a considerable extent, mostly soluble after 
expression, the same is not observed for the mutant variants. For those, 
the percentage of frataxin that remains soluble after expression is 
considerably lower, and the FXN-I154F and FXN-W155R mutants are 
mostly expressed in an insoluble form (79% and 68%, respectively; Fig. 
4.3). This analysis shows that, although all the variants are also found in 
the soluble fraction, their tendency to misfold in the confined cellular 
environment could result in an appreciable quantity of aggregated and/or 
destabilised protein. On the other hand, the average NOE values remain 
comparable among variants, indicating that the internal flexibility of the 
protein is essentially invariant. 
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Figure 4.4: Representative relaxation parameters measured for the 
FXN-W155R mutant. The data were collected at 600 MHz and 25 ºC. 
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4.4.4. Structural Flexibility  
Limited proteolysis experiments were used to further identify and 
characterise the sites of enhanced flexibility or of local unfolding in the 
frataxin mutants. The rationale for this approach is that chain flexibility is 
determinant in the proteolytic reaction because digestion of rigid 
secondary structure elements is extremely disadvantageous 
thermodynamically [17]. Frataxin nicking reactions were carried out at 
physiological temperature (37ºC), the reaction products were separated 
by reverse phase HPLC and the resulting peptides identified by MS. A 
comparison of the obtained tryptic maps clearly shows that mutant 
frataxins are destabilised relatively to the native protein (Fig. 4.5). 
 All frataxin mutants exhibit an increased proteolytic susceptibility 
compared to the wild-type, as shown by the higher number of obtained 
peptides during identical proteolysis periods (Fig. 4.5). Furthermore, the 
complexity of the tryptic maps is not identical between mutants: overall, 
FXN-I154F and FXN-W155R are more easily accessible to the protease 
having more degradation sites and peaks, whereas the FXN-G130V and 
FXN-D122Y mutants have simpler tryptic maps (Fig. 4.5).  
Some additional differences are observed between the mutants, 
which are suggestive of the local impact that the different mutations 
have on the protein structure and dynamics. For example, the G130V 
and D122Y mutations are highly flexible in the loop between strands 3 
and 4, as shown by the appearance of a peak corresponding to the 
Q153-K164 segment (approximately 36 min; Fig. 4.5), which is absent in 
the other mutants. On the other hand, the 1 helix in the FXN-I154F and 
FXN-W155R mutants has a decreased rigidity compared to the native 
protein and the remaining mutants. Proteolysis within a regular 
secondary structure element such as helices is very unfavourable and 
Chapter 4 
128 
 
does not occur unless some disorder or local breathing is present, as 
appears to be the case in the FXN-I145F and FXN-W155R mutants. 
 
 
Figure 4.5: Trypsin limited proteolysis of frataxin at pH 8.5. Top: Secondary 
structure wiring diagram. The fragments resulting from thetryptic digestion are 
highlighted by boxes. Bottom: Peptide maps resulting from partial tryptic digestion: 
wild-type and mutant variants (FXN-D122Y, FXN-G130V, FXN-I154F and FXN-
W155R) (data from the wild-type and the last two mutants are redrawn from the 
previous chapter [9]) after being incubated with trypsin for 90 min at 37ºC. Boxes 
highlight the peaks that are only present on the tryptic digestion of FXN-D122Y and 
FXN-G130V or FXN-I154F and FXN-W155R. 
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Table 4.2: Kinetic constants observed for all the identified peaks. Time course of 
trypsin limited proteolysis: appearance of the peaks with different elution times was 
monitored for all the proteins understudy and the data was fitted to a first order 
reaction.  
 
  k obs  (x 10
-3 min-1)
Peak 
(min) 
Wt D122Y G130V I154F W155R 
32 D91-R97 - - 28.1 ± 8.1 25.6 ± 11.2 
40 L136-K147 25.0± 1.4 37.9 ±12.5  25.4 ± 11.0 
23 L198-K208 22.7 ± 2.6 45.6  ± 5.1 - - 
36 Q153-K164 26.7 ± 2.0 48.1 ± 8.3 - - 
26 Y166-K171 26.7 ± 2.6 42.7 ± 8.1 14.5 ± 3.8 39.8± 9.8 
66 N172-K192 24.5 ± 2.7 32.2 ± 2.9 26.4 ± 6.3 39.6 ± 21.1 
42 L198-K208 26.9 ± 4.0 25.0 ± 5.1 - 18.5 ± 10.6 
4.4.5. Proteolytic Degradation Kinetics 
To investigate whether particular regions of frataxin have different 
degradation rates, we analysed the proteolysis kinetics of the different 
frataxin variants (Fig. 4.6; Table 4.2).  
Under the tested conditions the FXN-G130V and FXN-D122Y 
variants are found to undergo proteolysis at higher rates. By contrast, for 
the FXN-I154F and FXN-W155R mutants, proteolysis is restricted to 
particular regions of the protein: fast degradation is observed at 
cleavage sites within helix 1 (R97), at strand 5 (R165) and on the loop 
between strands 5 and 6 (K171). The FXN-W155R mutant is also 
cleaved at a faster rate at the protein termini and at the loop between the 
2 and 3 strands, probably as a result of the destabilisation of the 
3/4 inter-strand interactions, which likely increases the flexibility of the 
contiguous loop and its cleavability (K135). A comparison between these 
two mutants suggests that the conformational strain introduced by these 
mutations results in a more localised destabilisation, affecting the 
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stability of the first helix and eventually perturbing the ridge of negatively 
charged residues that cluster along the first helix and the first strand, 
which are known to be involved in iron binding [18]. 
 
 
 
Figure 4.6: Top. Time course of trypsin limited proteolysis. The appearance of the 
peptide eluting at 66 min (Fig. 4.5) was monitored for wild type (■) and mutant 
variants:  FXN-D122Y, (◊); FXN-G130V, (□); FXN-I154F, (○); FXN-W155R, (∆) during 
incubation with trypsin at 37ºC. Solid traces are fits to first-order reaction rates. 
Bottom. Comparative plot of proteolysis rates per identified fragment. The observed 
proteolysis rates of the four frataxin mutant variants are compared for the different 
digested fragments. The rates determined for the native frataxin have been subtracted 
in each case. 
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4.4.6. Degradation by Lon and ClpXP 
In order to evaluate whether frataxin variants are more prone to 
degradation by the mitochondrial proteases Lon and ClpXP, we have co-
expressed frataxin together with either one of the protease systems. 
Frataxin concentration/amount was evaluated during a time period 
following the inhibition of protein synthesis (Fig. 4.7) [10-11]. 
 
Figure 4.7: Degradation rate of wild type, FXN-D122Y and FXN-I154F proteins in cells 
co-overexpressing Lon (A) or ClpXP (B) proteases at 37ºC. The quantity of frataxin, 
either wild type or mutant variants, present in the cells was evaluated by SDS/PAGE. 
We have evaluated the degradation rate of wild type and two of the 
mutant variants – FXN-D122Y and FXN-I154F. Lon co-expression leads 
to more efficient degradation rates and even the wild type protein is 
degraded. The decay of wild type protein is only observed 80min after 
the protein expression is blocked; by contrast, mutants’ degradation is 
readily observed. After 140min the wild type registered a decay of ~20%, 
while D122Y and I154F showed a decay of ~50% and ~70% 
respectively.  
Co-expression of ClpXP had no effect on the amount of wild type 
protein but lead to the degradation of the mutant variants and after 
180min, both mutants showed a decay of ~30-40%. Controls co-
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expressing frataxin proteins with proteolytically inactive proteases (Lon-
S679A and ClpXP-S111A) showed that the decreased on the amount of 
frataxin proteins was a direct effect of a higher number of functional 
proteolytic units and not just a secondary effect of the co-overexpression 
per se. Overall, these results support what was suggested by the limited 
proteolysis experiments: frataxin FRDA variants are indeed more easily 
degraded by the mitochondrial proteolytic systems. 
 
4.4.7. Clinical Mutations Impact on Stability and Iron Binding 
 To compare the effect of the mutations on the folding 
thermodynamics of frataxin, we studied their stabilities against chemical 
unfolding in the presence of urea as measured by far-UV CD and Trp 
fluorescence emission. As observed for the wild-type protein, the mutant 
variants show cooperative unfolding transitions (Fig. 4.8). The results 
obtained revealed that the two newly studied mutations (D122Y and 
G130V) are those leading to higher frataxin destabilisation, in agreement 
with what has been proposed for G130V [19]. The protein stability 
decreases according to the order: FXN-wild-type > FXN-W155R > FXN-
I154F > FXN-D122Y > FXN-G130V and corresponds to a G) in the 
range -1.36 to -2.86 kcal·mol-1 (Table 4.3). 
This behaviour was compared with thermal unfolding, as recorded by 
far-UV CD. We measured the melting curves for FXN-G130V and FXN-
D122Y (Fig. 4.8) and compared the values with those previously 
obtained for FXN-I154F and FXN-W155R [6]. In agreement with the 
chemical unfolding data, the FXN-G130V and FXN-D122Y mutants 
showed the largest variations of melting transitions (Tm of approximately 
16 ºC and 23 ºC, respectively), while maintaining the reversibility of the 
unfolding reaction (> 95%).  
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Table 4.3 – Parameters for urea and thermal denaturation of wild type and mutant 
forms (FXN-W155R; FXN-I154F, FXN-D122Y and FXN-G130V). Comparing the 
differences in stability. 
 
 
Protein GH2O  
(kcal.mol-1) 
m  
(cal.mol-1.M-1) 
[Urea]1/2 
(M) 
[Urea]1/2
a 
 
(G) b 
(cal.mol-1) 
Tm 
(ºC) 
Tm 
(ºC) 
Wild typec 5.6  0.3 1407  41 4.3   66.30.1 - 
D122Y 4.3  0.2 1498  23 2.9 -1.4 -2110 50.40.1 -15.9 
G130V 3.1  0.3 1310  60 2.4 -1.9 -2863 43.20.1 -23.1 
I154Fc 5.8  0.3 1836  67 3.2 -1.1 -1657 50.70.1 -15.6 
W155Rc 5.1  0.2 1483  78 3.4 -0.9 -1356 61.40.4 - 4.9 
a Difference between the [urea]1/2 for the wild type and the mutant forms. 
b (G) = From [urea]1/2 x average of the three m values [20]. 
c Data from [6]. 
 
The impact of mutations in frataxin was also investigated with respect 
to its iron-binding properties. Independent experimental evidence 
suggests that frataxin acts as a cellular iron chaperone and human 
frataxin has been shown to bind six to seven irons, although with a low 
affinity [21]. 
 
 
Figure 4.8: Thermal (A) and chemical (B) denaturation curves at pH 7.0. filled squares, 
FXN-Wild-type; unfilled diamonds, FXN-D122Y; unfilled squares, FXN-G130V; unfilled 
circles, FXN-I154F; unfilled triangles, FXN-W155R (data from the wild-type and the last 
two mutants are redrawn from [9]. Lines represent fits to the two-state model [22]; for 
parameters, see Table 4.3. 
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We monitored the iron binding capacity by fluorescence spectroscopy 
using wild-type frataxin as a control. Under controlled pH conditions and 
at 25 ºC, the ferric binding capacity of FXN-D122Y and FXN-G130V 
appears to be partially impaired: the mutants are only able to bind four 
irons per molecule (data not shown). As previously reported, the 
mutants, FXN-I154F and FXN-W155R, precipitate upon ferric binding 
above the two iron per frataxin threshold [6]. 
4.5. Discussion 
In FRDA, the link between a point mutation in frataxin and the 
disease physiopathology remains unclear, and hypothetical scenarios for 
the impact of mutations include an effect on the folding efficiency, 
maturation, protein stability, proteolytic susceptibility or function. We 
have studied different point mutations found in compound heterozygotes 
FRDA patients. These mutations can be grouped according to FRDA 
symptoms: whereas the I154F and W155R mutations lead to severe 
FRDA, the mutations G130V and the D122Y account for milder clinical 
symptoms, although the latter has a very low prevalence [23]. From a 
structural point of view, our results demonstrate that none of the 
mutations significantly change the protein fold at room temperature. The 
heteronuclear single quantum coherence (HSQC) spectra obtained for 
the frataxin variants are typical of folded species and are very similar to 
those of wild-type protein. Furthermore, frataxin flexibility is not 
significantly altered by the insertion of the mutations. Despite retaining 
the fold, the four mutant variants present a reduced thermodynamic 
stability, which, in vivo, is likely to cause an increase in the molecular 
motions and enhance the susceptibility to aggregate and/or to be 
degraded by the cellular proteases. Limited proteolysis at 37ºC shows 
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that mutant frataxins have an increased susceptibility towards proteolytic 
degradation. In agreement co-expressing frataxin with Lon and ClpXP 
proteases at 37ºC shows that the FRDA-related variants are indeed 
more prone to degradation by the mitochondrial proteolytic systems.  
The increased correlation times measured for the mutants (Table 4.1) 
reflect a higher tendency towards aggregation. Furthermore, expression 
assays revealed that, in mutant frataxins, the soluble/insoluble protein 
ratio is decreased and this may play a role in the molecular 
pathogenesis of FRDA.  
The observed reduction in iron-binding could also be related to the 
increased molecular motions. The increased flexibility, combined with 
the enhanced propensity towards aggregation, could explain why some 
mutants precipitate upon iron binding (FXN-I154F and FXN-W155R) or 
have a lower binding stoichiometry (FXN-G130V and FXN-D122Y). 
Under adverse physiological conditions occurring in vivo, such as the 
oxidative stress observed in FRDA model cells [24-27], these effects 
could also lead to a perturbation of frataxin structure and dynamics, 
which could lead to its inactivation or misfolding, further reducing the 
cellular concentration of functional frataxin. 
Altogether, the clinical effects in heterozygous FRDA patients are 
likely to result from a combination of effects, such as a reduced 
efficiency of protein folding (resulting in an increase of the aggregation 
rates), an accelerated degradation in vivo (leading to decreased frataxin 
levels); misfolding and conformational destabilisation contribute to a 
decrease in the levels of functional frataxin. In this scenario, FRDA in 
heterozygous patients carrying frataxin single point mutations could be 
considered to possess a type of protein misfolding disorder [28]. 
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5.1. Summary 
In vitro studies on frataxin clinical mutants suggested that, in 
heterozygous FRDA patients, the pathological process may arise from a 
combination of effects such as reduced efficiency of protein folding, 
accelerated degradation, misfolding and conformational destabilisation 
[3-4]. Here we have analysed the effect of different classes of chemical 
chaperones in two of the stages of the protein folding process: during 
early folding events and on the conformation and stability of the folded 
native-like frataxin. The experiments were performed using the wild type 
frataxin and two clinical variants – FXN-I154F and FXN-D122Y. The 
wild type was used as a control and 4-phenyl butyrate, trehalose 
(sugar), trimethylamine-N-oxide (methylamine) and glycerol (polyol), 
were tested for their potential chaperone-like function on frataxin clinical 
variants.  Interestingly, the effect of the small compounds is mutant 
dependent. Considering the impact on early folding events, it is 
observed that, while FXN-D122Y folding efficiency is only modestly 
improved, FXN-I154F folding efficiency improves significantly with the 
amount of expressed soluble protein, increasing up to ~3fold in the 
presence of glycerol. Opposite, when analysing the effect on the protein 
native-like conformation and stability, the observed effects are more 
dramatic for the FXN-D122Y while only modest for the FXN-I154F. The 
presence of chemical chaperones stabilises FXN-D122Y considerably 
(∆Tm up to ~7.8ºC) with trehalose and TMAO inducing thermal stability 
values identical to the ones observed for the wild type protein. In 
addition, FXN-D122Y conformational defects were also more 
successfully rescued. For Overall, our data shows that folding defects in 
FRDA frataxin variants may be partially rescued by the presence of 
chemical chaperones and that these compounds may become useful  
therapeutics.  
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5.2. Introduction 
An increasing number of studies describe the use of low molecular 
weight compounds, called chemical chaperones, to overcome folding 
defects in proteins involved in conformational disorders [1-4]. This 
therapeutic strategy has been explored for many diseases such as 
cystic fibrosis [5-9], phenylketonuria [10-11], Huntington's [12] and 
Gaucher's disease [13]. The presence of chemical chaperones reverts, 
at least partially, the mistrafficking, misfolding and aggregation of the 
disease-protein ameliorating the pathological behaviour.  
Chemical chaperones do not bind directly to proteins; their 
interaction with the peptide backbone is unfavourable, causing a 
preferential exclusion of the compound from water-protein interface and 
leading to a preferential hydration of the protein surface. Furthermore, 
the presence of these small molecules also results in an increased 
solvent density that restrains the proteins’ free movements, increasing 
its compactness. In addition it is also described that, during protein 
synthesis, these compounds minimise the formation of intermediate 
states that could lead to folding dead-ends [14-17] and they may also 
induce the response of molecular chaperones [18]. 
Here, the possible use of chemical chaperones to rescue the folding 
defects and to modulate the misfolding and aggregation propensity of 
frataxin clinical mutants (FXN-D122Y and FXN-I154F) is addressed. 
Compounds from different classes were selected: 4-Phenylbutyrate 
(4PBA, a low molecular weight fatty acid), glycerol (a polyol), trehalose 
(a sugar) and Trimethylamine N-oxide (TMAO, a methylamine).  
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Sodium 4-Phenyl Butyrate (4PBA) 
 
Glycerol 
 
Trehalose 
                  
 
 
 
Trimethylamine N-oxide (TMAO) 
 
 
Figure 5.1: Chemical structures of the small compounds here analysed for their 
potential chaperone-like action on frataxin clinical variants. 
 
 
We have evaluated the effect of chemical chaperones on two 
different stages of the folding process: during the early folding events 
and on the conformation and stability of the folded protein. The effect on 
early folding events was accessed by comparing the protein folding 
efficiency in the presence and in the absence of the small compounds. 
The folding efficiency was quantified through the ratio of soluble versus 
insoluble protein during protein expression. Previously we have shown 
that frataxin clinical variants present smaller soluble/insoluble ratios [19] 
and here we aim to characterise impact chemical chaperones may have 
on this ratio. If a compound improves the mutants foldability (increases 
the soluble/insoluble ratio) this may lead to an increase of frataxin 
cellular levels, which may be sufficient to revert at least part of the 
pathological process associated to frataxin deficiency. 
Furthermore, we will evaluate the impact of chemical chaperones on 
the protein conformational properties and also their potential stabilising 
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effect. Frataxin conformational variations will be evaluated thorough the 
chaperonin sink assay [20]. GroEL promiscuously binds a wide range of 
hydrophobic folding intermediates, partitioning them from solution and 
thus preventing or arresting off-pathway aggregation.  Due to the 
mutants’ increased propensity towards aggregation and their decreased 
stability and folding efficiency, these are likely to partition onto GroEL. 
Thus, we aim to evaluate whether the presence of chemical chaperones 
can modulate the conformational destabilisation observed for the 
mutants, reducing or preventing their partitioning onto GroEL. If the 
partitioning onto this molecular chaperone is modulated, it is likely that, 
in vivo, the proteins’ recognition by proteases may also be modulated 
since the same features are recognised by GroEL and the protease 
systems. With this strategy, we aim to identify compounds that may 
extend the mutants cellular lifetime and like this increase the cellular 
levels of mutant frataxin. 
 Moreover, since the mutants’ stabilisation may improve their 
functionality we have evaluated the potential stabilising effect of small 
compounds. In order to achieve this, differential scanning fluorimetry 
has been performed (DSF) [21-22]. Through this technique the protein 
unfolding is followed using a fluorescent dye (Sypro orange was used 
here). Upon unfolding, the protein exposes its hydrophobic region which 
corresponds to a lower dielectric environment to which Sypro orange is 
sensitive. The lower the dielectric medium, the higher the quantum yield 
of the dye which means that, as the protein unfolds, Sypro orange 
fluorescence increases. After reaching a plateau, the fluorescence 
intensity starts to decrease probably due to aggregation of the 
denatured protein-dye complex.  
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5.3. Materials and Methods 
Accessing folding efficiency 
Cells were transformed with vectors enabling FXN (wild type or mutants 
conserved C-terminal domain) overexpression and grown in LB medium 
at 37ºC up to  an OD600=0.6. Plasmid-derived protein expression was 
induced by addition of IPTG (0.5mM) and, at the same time, chemical 
compounds were added to the medium. Aliquots were withdrawn at the 
mentioned expression time (2 or 4H). Cells were lysed and soluble and 
insoluble fractions were separated through high speed centrifugation 
(45 min at 168 000 g). Both fractions were loaded on to a 15% 
SDS/PAGE and after staining with Roti-blue a semi-quantitive analysis 
of the relative proportion of frataxin present in the soluble and insoluble 
fractions was obtained from densitometric analysis of gel bands (n = 3).  
Protein purification 
All constructs were expressed in Escherichia coli competent cells 
(BL21 (DE3)) and the protein purified as previously described [23-25]. 
As in previous studies, the protein used corresponded to the conserved 
C-terminal domain (amino acids 91–210). The vector here used lead to 
the expression of recombinant proteins with only a poly-His tag. The 
mutants were stable in solution, although susceptible to precipitate upon 
slow freezing. Nevertheless, thawed proteins that had been fast frozen 
retained their spectroscopic properties and melting temperatures.  
GroEL partitioning assay 
GroEL immobilised onto Sepharose 4 fast flow beads (2mM) was 
resuspended in buffer A (50mM Tris pH7.5, 50mM KCl, 5mM MgCl2, 
0.5mM EDTA and 1mM DTT) with 1M urea. Protein sample was then 
added (1:1 to the GroEL) and the reaching mixture was incubated with 
constant shaking at 45ºC. Every 40 min the reaction mixture was spin 
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down and an aliquot of the non-partitioned mixture was withdrawn [26-
27]. Aliquots were applied on a 15% SDS/PAGE and the amount of 
proteins quantified.  
 
Differential scanning fluorimetry (DSF). 
The effect of the chemical chaperones on the proteins thermal 
stability was evaluated through DSF [21-22]. The fluorescent dye Sypro 
orange (λex 300nm and λem 470/570nm) was used as a probe to follow 
protein unfolding. In all experiments, the heating rate of 1.5ºC/min. Data 
were analysed according to a two-state model [28]. The fits to the 
unfolding transitions were made using Origin (MicroCal).   
 
5.4. Results 
5.4.1. Effect on Early Folding Events 
Frataxin clinical mutations decrease the protein folding efficiency 
[19]. Here, we have analysed whether the small compounds understudy 
could rescue folding efficiency of frataxin clinical mutants (FXN-D122Y 
and FXN-I154F) if present during early folding events. In order to test 
this hypothesis, a bacterial system was used in which the foldability and 
conformational destabilisation of the frataxin proteins was monitored 
[19, 29-31]. Small molecular weight compounds (4PBA, Trehalose, 
TMAO and glycerol), at different concentrations, were added to the 
culture medium at the same time that protein expression was induced.  
 
 
Small Molecules as Modulators of FRDA FXN Variants 
147 
 
 
 
 
Figure 5.2: Effect of chemical chaperones on early folding events. A. SDS/PAGE gels 
obtained from E. coli lysates expressing frataxin. For each protein variant, the soluble (s) 
and insoluble (p) fractions are shown. B. Semi-quantitative analysis of the relative 
proportion of frataxin present in the soluble and insoluble fractions, obtained from 
densitometric analysis of gel bands (n = 3), allowed the determination of the protein 
expressed in the soluble form. 
 
After inducing protein expression for 2h and 4h, aliquots were 
withdrawn and the soluble and insoluble fractions analysed. It was 
observed that some compounds can rescue mutants folding efficiency 
and that the extent of this rescue is concentration dependent (Fig. 5.2 
and 5.3). Three of the tested compounds show different degrees of 
rescue depending on the mutant considered. Interestingly, while both 
TMAO and glycerol increase considerably the folding efficiency of the 
mutant FXN-I154F (over a two-fold increase), their impact on FXN-
D122Y folding efficiency is very small.  This suggests that the misfolding 
pathway observed for the two mutants should be different. 4PBA 
increases significantly the folding efficiency of both mutants and this 
increase is concentration dependent up to 7.5mM (Fig. 5.3B).  
However, 4PBA may not be acting as a chemical chaperone since 
different reports show that this compound can affect the expression 
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levels of chaperones and their mRNA’s stability [32-33], as well as alter 
the expression levels of other proteins, since 4PBA inhibits histone 
deacetylases [34]. 
 
Figure 5.3: Variation of the folding efficiency induced by the presence of chemical 
chaperones. After the densitometric analysis of the gel bands the ration between the 
amount of soluble protein present in the presence and absence of the compounds were 
determined. The Log2 of this ration is here present to highlight the variation observed. A. 
Effect of increasing concentrations of Trehalose and TMAO. B. Effect of increasing 
concentrations of Glycerol and 4PBA. (n=2) 
 
Comparative gel analysis of the control and osmolytes added cell 
lysates did not show any differences in terms of protein expression, 
meaning that the addition of osmolytes does not seem to have induced 
the expression of molecular chaperones, thus disfavouring the 
possibility that the effects observed are a result of an increased 
expression of the chaperone system and not a direct effect of the 
presence of the osmolytes during the early folding events.  
5.4.2.  Probing Conformational Variations: GroEL Sink Assay 
Further, we have used the chaperonin sink assay to evaluate the 
efficiency of osmolytes in correcting folding defects. Nucleotide-free 
GroEL, has a high affinity towards hydrophobic intermediates and 
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promiscuously binds to them, allowing its efficient and stable capture. 
Here, GroEL is used as tool to probe frataxin conformational alterations, 
more specifically as a detection platform to examine the dynamic shift  
towards stable/well folded populations in the presence of various folding 
osmolytes. Previously, we have shown that frataxin mutants present a 
higher flexibility and higher tendency towards aggregation [19], thus it is 
likely that mutants will be more easily captured by GroEL. Immobilised 
and in solution, GroEL show an identical capacity to bind unfolded and 
partially folded substrate proteins [27, 35]. Here we have used GroEL 
covalently bound to Sepharose 4 fast flow beads, since this preparation 
allows an easy and immediate evaluation of the partitioning of any given 
substrate protein onto 
GroEL.  The substrate 
protein and GroEL beads 
are put in buffered solution 
with a 1:1 stoichiometry; 
after a short spin down the 
solution is analysed 
(through an SDS-PAGE 
gel) and the protein in 
solution, correctly folded, is 
quantified. On the other 
hand if a protein is not 
correctly folded and has 
exposed hydrophobic 
regions, it will partition onto 
the GroEL beads and its 
concentration in solution 
will decrease.  
 
Figure 5.4: Partition of frataxin variants onto 
GroEL beads. Top. SDS/PAGE analysis of the 
reaction mixture aliquots withdrawn after spin 
down of the mixture. Bottom. Densitometric 
analysis of the gels bands, the initial point (before 
the proteins were incubated at 45ºC) corresponds 
to 100%. 
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The partition assays were performed for wild type frataxin and its clinical 
variants FXN-D122Y and FXN-I154F. In order to accelerate the 
partitioning reaction, the reaction mixtures were incubated at 45ºC in the 
presence of 1M urea. Under these conditions, even after an incubation 
of 160 min, the wild type frataxin remains in solution, thus FXN is well 
folded and stable. However, the mutants already start to partition onto 
GroEL after being at 45ºC for 40min and after 160min only ~60% of the 
initial protein remained in solution. These results confirm that the 
mutants show an increased destabilisation relative to the wild type (Fig. 
5.4).  
 
Figure 5.5: Modulating the partitioning GroEL partitioning of FRDA-related frataxin 
variants. (A) D122Y and (B) I154F. As is Figure 5.3, here we analysed the non-
partitioned fraction along a 160min incubation time at 45ºC and in the presence of 1M 
urea. 
 
 Next, we have evaluated whether the presence of the different 
chemical chaperones under study could correct the mutants’ 
conformational impairment, thus slowing down the partitioning or even 
preventing it (Fig. 5.5). In agreement to what had already been 
observed for the effect of chemical chaperones on early folding events, 
the same compound showed different efficiencies depending on the 
mutant variant considered. For instance, while the presence of 500mM 
TMAO significantly reduces the observed partitioning of the mutant 
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FXN-I154F, it has a negligible effect on the FXN-D122Y partitioning.  
The analysis of the partitioning profiles in the presence of the different 
compounds showed that FXN-D122Y partitioning can be prevented by 
trehalose (25mM) and also slowed down by both glycerol (2%) and 
4PBA (5mM). However, FXN-I154F partitioning can only be rescued by 
TMAO (500mM); the other three chemical chaperones either have no 
effect (glycerol and trehalose) or even accelerate partitioning. 
5.4.3. Stabilisation of Frataxin’s Native State.  
The analysis of the thermal denaturation curves in the presence of 
chemical chaperones has revealed that that all frataxin variants, 
including the wild type, can be stabilised by most small compounds 
under study (Fig. 5.6 and Table 5.1). However, the extent of the 
stabilisation and the effect of each compound depends on the variant 
considered.  
 
 
Figure 5.6: Stabilisation induced by the presence of chemical chaperones. A. 
Variations on the Tm values of FXN wild type (black), D122Y (Gray) and I154F 
(white) mutants by 5mM 4PBA, 500mM Trehalose, 750mM TMAO and 25% 
Glycerol. B. TMAO efficienctly increases the Tm values of all FXN variants in a 
concentration dependent way. (■) FXN wild type, (○) D122Y and (∆) I154F. 
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The stabilising effects of the different compounds are more 
pronounced for the FXN-D122Y mutant and the addition of trehalose 
and TMAO to this mutant increases its thermal stability to Tm values 
close to the wild type intrinsic stability. By contrast, the stabilising effects 
on the FXN-I154F mutant are modest with TMAO and glycerol showing 
the most significant effects (maximum ∆Tm = ~3.1 and 2.6ºC, 
respectively). 
 
Table 5.1: Melting temperatures determined by the two state fits to the unfolding 
curved obtained by the DSF experiments.  
 Wild Typea D122Ya I154Fa 
Tm (ºC) ∆Tm Tm (ºC) ∆Tm Tm (ºC) ∆Tm 
Control 55.1 ± 0.1 - 48.8 ± 0.1 - 39.1 ± 0.1 - 
4PBA 
(mM) 
0.1 54.5 ± 0.1 -0.6 49.5 ± 0.1 3.3 38.9 ± 0.1 -0.2 
0.5 54.8 ± 0.1 -0.3 49.3 ± 0.1 3.1 38.7 ± 0.1 -0.4 
1.0 54.8 ± 0.1 -0.3 49.4 ± 0.1 3.2 38.9 ± 0.1 -0.2 
2.5 55.3 ± 0.1 0.2 49.4 ± 0.1 3.2 38.9 ± 0.1 -0.2 
5.0 55.8 ± 0.1 0.7 49.0 ± 0.1 2.8 40.3 ± 0.1 1.1 
10.0 56.0 ± 0.1 0.9 48.3 ± 0.1 2.1 37.9 ± 0.1 -1.2 
Trehalose 
(M) 
0.025 54.6 ± 0.1 -0.5 50.1 ± 0.1 3.9 39.6 ± 0.1 0.5 
0.050 54.9 ± 0.1 -0.2 50.7 ± 0.1 4.5 39.5 ± 0.1 0.4 
0.125 55.3 ± 0.1 0.2 50.3 ± 0.1 4.1 38.3 ± 0.1 -0.8 
0.250 56.5 ± 0.1 1.4 50.3 ± 0.1 4.1 39.6 ± 0.1 0.5 
0.500 57.8 ± 0.1 2.7 53.4 ± 0.1 7.2 40.3 ± 0.1 1.2 
0.750 60.2 ± 0.1 5.1 54.1 ± 0.1 7.9 39.3 ± 0.2 0.2 
TMAO  
(M) 
0.05 50.1 ± 0.1 0.5 48.8 ± 0.1 2.6 39.7 ± 0.1 0.6 
0.2 51.3 ± 0.1 1.0 50.1 ± 0.1 4.0 38.4 ± 0.1 1.3 
0.5 52.0 ± 0.1 3.0 51.3 ± 0.1 5.1 40.9 ± 0.1 1.8 
0.75 54.0 ± 0.1 4.8 52.0 ± 0.1 5.8 42.2 ± 0.1 3.1 
1 48.8 ± 0.1 5.8 54.0 ± 0.1 7.8 41.6 ± 0.2 2.5 
Glycerol 
(%) 
0.4 55.1 ± 0.1 0 47.1 ± 0.1 0.9 39.2 ± 0.1 0.1 
4 54.6 ± 0.1 -0.5 44.5 ± 0.1 -1.7 37.8 ± 0.1 -0.3 
10 54.9 ± 0.1 -0.2 46.6 ± 0.1 0.4 - - 
20 55.4 ± 0.1 0.3 50.2 ± 0.1 4.0 41.7 ± 0.1 2.6 
25 54.7 ± 0.1 -0.4 50.0 ± 0.1 3.8 - - 
a The control Tm are lower than the previously determined by CD or fluorescence spectroscopies, to 
evaluate whether the variations observed where not due to an artefact induced by the presence of the 
dye, the Tm variation caused by 250mM trehalose was confirmed by florescence spectroscopy. 
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5.5. Discussion 
In spite of the basic mechanism responsible for the osmolyte effect, 
studies on the physical chemical origins of osmolyte action revealed 
that the mode of action of each osmolyte results from a combination of 
favorable or unfavorable interactions with backbone and side chains. 
This explains why some osmolytes are very effective in inducing 
structure while others are more likely to solubilise native proteins [14, 
36-39]. Besides the different effects of the different compounds, it is 
also shown here that the effect of a given chemical chaperone is 
variable depending on the mutant variant considered. In fact, while the 
FXN-I154F folding efficiency is impressively altered by the presence of 
chemical chaperones, their effect on FXN-D122Y folding efficiency is for 
most conditions marginally impressive.  
Although the mutations under study result in comparable decreased 
stabilities (∆Tm=~15ºC [19]), their impact on the protein conformation 
and structure are different and likely correlate to the different effect 
observed for each chemical chaperone. Residue I154 sits into the 
protein hydrophobic core and is completely buried, thus its mutation is 
likely to alter the protein compactness. However, mutating residue 
D122Y should have a less drastic effect on the overall conformation 
since this residue is at the protein surface on the α1/β1 transition [25, 
40]. Chemical chaperones disfavour backbone-water hydrogen bonds, 
favouring the scaffold hydrogen-bonds (structural); taking this into 
account and the fact that I154 is buried (the accessible surface of both 
backbone and side chains is for the native state zero), the presence of 
chemical chaperones during folding is likely to facilitate the insertion of 
a bulkier hydrophobic residue (phenylalanine) into the hydrophobic core 
of frataxin. However, the presence of chemical chaperones during the 
folding process of FXN-D122Y are likely to be small since the observed 
Chapter 5 
154 
 
reduced folding efficiency is likely to be caused by the impairment of 
two putative stabilising interactions (H-bond with G138 and a ionic 
interaction with K135) and not due to reduced compactness. On the 
other hand, the effect of chemical chaperones should stabilise the fold 
of the FXN-D122Y mutant fold since their presence will likely overcome 
the disruption of the stabilising bonds but, in contracts, their effects on 
stabilisation of the FXN-I154F should be very small.  
The results here presented suggest that FXN-D122Y conformational 
variation might be overcome by the presence of chemical chaperones 
and that in vivo increased concentrations of different osmolytes may 
rescue the protein conformational properties.  On the other hand, the 
FXN-I154F mutant should only be partially rescued and the presence of 
chemical chaperones may attenuate the phenotype observed. In vivo 
experiments using perhaps the well studied yeast model need to be 
performed but the approach here followed has revealed to be valuable 
for an initial screen of the potential rescuers of misfolding pathologies.  
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6.1. Summary 
 Frataxin is a mitochondrial protein that is defective in Friedreich’s 
ataxia (FRDA), resulting in iron accumulation and in an environment 
prone to Fenton reactions. Its cellular function, as well as its location, 
make frataxin a potential target for chemical oxidative modifications in 
the context of FRDA. Here, we analysed the impact of carbonylation 
and nitration on the structure and function of human frataxin. We found 
frataxin to be susceptible to carbonylation and nitration modifications in 
residues at the β-sheet surface (Tyr143, Tyr174, Tyr205 and Trp155). 
Frataxin functions are not significantly affected: frataxin-mediated 
protection against ROS is still observed as well as iron-binding 
necessary for the metallochaperone activity (5 Fe3+.mol-1, Kd=13-
36 µM). However, the protein is up to 1.0 kcal.mol-1 destabilised and the 
conformation opens. Interestingly, the strictly conserved Trp155, which 
is mutated in patients, may be a functional hotspot in frataxin. 
 
6.2. Introduction 
Frataxin function is not fully established but this essential protein was 
found to be involved in iron homeostasis, Fe-S cluster and heme 
biosynthesis, and metabolism of reactive oxygen species (ROS) [1-4]. 
The relationship between oxidative stress and FRDA is rather 
controversial. On the one hand, oxidative stress markers are used to 
monitor disease progression in patients [5-6], following the proposal that 
oxidative stress is involved in the pathogenic process [7-8]. On the other 
Chapter 6 
 
160 
 
 
 
hand, the fact that over-expression of antioxidant enzymes (SOD1, 
SOD2 and Cat) in fly and mouse models expressing low levels of 
frataxin fails to rescue the FRDA phenotype does not support the 
hypothesis that oxidative stress has a major role in FRDA pathogenesis 
[9-10]. Further, under aerobic conditions, the absence of frataxin in 
yeast results in aconitase degradation and accumulation of oxidatively 
modified proteins in both the cytosol and mitochondria, which lead to 
Pim1 expression and proteasome inhibition [11]. In any case, either 
directly or indirectly, frataxin seems to be important for maintaining the 
oxidative balance in the mitochondria. A question that remains to be 
answered is what happens to frataxin itself when iron accumulates in 
the mitochondria and oxidative stress arises. This is a pertinent point as 
frataxin is present in all FRDA patients, although at reduced levels. A 
priori, frataxin is a potential target for oxidative stress modifications, not 
only due to the fact that is localised in mitochondria, where oxygen and 
nitric oxide are available in a reducing environment, but also as a result 
of its iron-binding properties. Here we address whether human frataxin 
can be a target of oxidative stress related modifications, such as 
carbonylation and nitration, and if so, on which positions this occurs and 
what would be the structural and functional consequences of such 
modifications. 
6.3. Materials and Methods 
Protein production 
Frataxin (91-210) was expressed in Escherichia. coli (competent 
cells BL21(DE3) from Novagen) as fusion proteins with a His-tag and 
purified as previously described [12-13]. The frataxin core construct 
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FXN (91-210), previously shown to keep the protein fold, stability and 
functional properties of the mature variant [14], was used in this study.  
Metal-catalysed oxidation  
Frataxin (50µM) was incubated at 37ºC in 10mM Tris buffer pH 7.0 
supplemented with 0.2 mM FeSO4 and 2mM hydrogen peroxide (H2O2). 
The concentration of H2O2 was determined spectrophotometrically at 
240nm (ε240 = 0.0394 mM-1.cm-1). The reaction was stopped after 2h by 
addition of diethylene triamine pentaacetic acid (DTPA, final 
concentration 50mM) and catalase (final concentration 0.3 nM). 
Subsequently, the protein was applied on a desalting column to remove 
excess iron and H2O2 for further analysis. 
 
Fe2+ + H2O2  Fe3+ + 
.
OH + OH- 
 
 
Figure 6.1: Top. Iron Fenton reaction. Bottom. Tryptophan carbonylation. 
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Nitration reactions  
Frataxin (50µM) was incubated in 200 mM potassium phosphate pH 
7.0, 25µM DTPA and 500µM peroxynitrite (ONOO-) for 2h. Peroxynitrite 
was synthesised and stored at -80ºC as described in [15], just before 
each nitration reaction ONOO- was thawed and the concentration 
measured spectrophotometrically at 302 nm (ε302 = 1,670 M-1·cm-1). 
After the nitration reaction the excess of ONOO- was removed by 
passing the protein solution through a desalting column. 
 
 
Figure 6.2: Nitration reaction of Tyrosine by peroxynitrite. Modified peptides will 
present a characteristic mass shift of +(n×45) Da due to the addition of n×NO2 as a 
consequence of the nitration reaction. 
 
Analysis of protein modifications by mass spectrometry  
Modified and unmodified frataxin were resuspended in 0.5M 
triethylammonium bicarbonate pH 7.5 and digested using sequencing 
grade trypsin (Promega; 1:50 trypsin to sample ratio). Digested aliquots 
containing 200fmol of FXN were eluted independently on a 300µm x 
150mm Atlantis dC18 reverse phase (3µm, Waters Corporation, 
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Lancashire UK) capillary LC column via an Ultimate 3000 (Dionex, 
Surrey UK) capLC-MS. The LC-CapESI interface (typical voltage of 
4kV) was interfaced to both the maXis ESI-Q-UHR-TOF and HCT Ultra 
ESI-Q-Ion Trap (Bruker Daltonics, Coventry UK). Maintenance for ultra 
high resolution scans on the maXis (42k resolving power) and focus 
mass for the Ion Trap were achieved using Tunemix reference standard 
922 m/z (Agilent, Cheshire UK). All ion trap accumulations were 
dynamically controlled to either achieve 200000 ions or no less than 5 
Hz. Confirmatory SRM-MS/MS analysis of all identified modification 
sites were performed using CapLC MRM-MS/MS scans at a 250000 
charge limit. Data interrogation of site modifications and unmodified 
peptides were provided via manual spectra sequencing, and automated 
in-house Phenyx server v2.5 (Genebio, Geneva, Switzerland) database 
searching. Additional parameters and criteria for peptide matching are 
available as supplementary materials. 
Thermal stability  
Thermal denaturation experiments were performed as previously 
described, using 8 µM frataxin in 10mM HEPES pH 7.0 [12-13] and 
using circular dichroism and fluorescence spectroscopy to monitor 
conformational changes during heating. 
Limited proteolysis 
Frataxin (modified and control) was incubated with trypsin (bovine 
pancreas trypsin, sequencing grade, Sigma) at 37°C in 0.1 M Tris-HCl 
pH 8.5 in a 100 fold excess over the protease, during 90 min. Aliquots 
(~0.5 nmol protein) were subsequently analysed by reverse-phase 
HPLC as described in [12-13]. For comparing the extension of 
proteolysis among different preparations, the sum of the integrated peak 
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areas was determined for each tryptic map. The variations in the 
relative proteolytic susceptibility were determined from 
modified/unmodified ratios. 
Frataxin functional assays  
Iron binding to FXN was determined by monitoring quenching of 
tryptophan fluorescence (λexc=290 nm and λem=340 nm) during a 
titration of frataxin (10 µM) with Fe(III), which has allowed to calculate 
the fraction of binding sites occupied, as described in [4, 12-13]. The 
attenuation of Fenton chemistry by frataxin was assessed following the 
oxidative degradation assay described elsewhere [16-17]. 
 
6.4. Results 
6.4.1. Frataxin Carbonylation and Nitration  
We have investigated whether human frataxin can be a target for 
oxidative stress related modifications, such as carbonylation and 
nitration, by exposing frataxin to conditions mimicking oxidative stress. 
We have analysed the effects of the hydroxyl radical (OH•) and 
peroxynitrite (ONOO-) on human frataxin (FXN). While OH• attack to 
proteins leads to the formation of carbonyls (e.g. [18]), the reaction with 
ONOO- results in the nitration of amino acid side chains [18-20]. The 
differences between the exposed and unmodified FXN species were 
evaluated for nitration and carbonylation using tandem MS. Seven 
different unmodified tryptic peptides of FXN were identified, 
corresponding to 85% of the total protein sequence (Fig. 6.3). After 
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Tyr 205 
Tyr 174 
N 
N 
Tyr 143 
N 
A B C D 
E Trp 155 
N C 
carbonylation and nitration reactions no peptide fragmentation was 
detected. MS/MS and SRM-MS/MS analysis identified four potentially 
modified peptides with a +45 Da mass shift after peroxynitrite treatment. 
The +(n×45) Da mass shift is characteristic of the n×NO2 addition in 
nitrated peptides. Subsequent stepwise fragmentation (SPS SmartFrag) 
of these ions provided site-specific confirmation of four +45 Da amino 
acid positions.  
 
 
 
Figure 6.3: (A-D) Structure of the modified Trp and Tyr identified in frataxin 
subsequently to carbonylation and nitration. (A) 3-nitroyrosine; (B) 6-
nitrotryptophane; (C) 5-hidroxytryptophane; (D) N-formylkynurenin; (E) Ribbon 
representation of human frataxin structure (PDB ID: 1EKG). Modified residues are 
labeled and represented sticks. 
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Figure 6.4:  Mass spectra of Human frataxin peptide 153-QIWLSSPSSGPK-164.  LC-
MS/MS peptide sequencing and site-specific determination for nitration and 
carbonylation in doubly charged FXN peptide QIWLSSPSSGPK.  Intact peptide mass 
MS scans; UHR-TOF scans (A: unmodified, B: nitrated, C: carbonylated); Ion Trap 
scans (D: unmodified, E: nitrated, F: carbonylated). Fragment spectra (MS/MS) of 
QIWLSSPSSGPK in unmodified (I), Trp nitrated (II) and Trp carbonylated (III) form. The 
peptide nitration site and its associated ions exhibit a characteristic +45 Da mass shift 
on singly charged species, and +22.5 Da on doubly charged species. Carbonylated Trp 
(W) and associated ions show two distinct stages of modification resulting in a +16 Da 
(not shown) or +32 Da shift. Subfigure III shows the latter with the characteristic +32 
and +16 Da shifts on singly and doubly charged species. Remark: asterisks (*) denote 
ions carrying site of modification, yn and bn denotes the y and b collision induced 
fragment ion series. ++ denotes doubly charges ion series species.  
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Nitration was identified on three tyrosines (Fig.6.2, 3-nitrotyrosine; 
Tyr143, Tyr174, Tyr205) and on one tryptophan (6-nitrotryptophane, 
Trp155). We observed that the treatment with OH• resulted in less 
extensive modifications: only a single tryptophan residue (Trp155) was 
found to be carbonylated (Fig. 6.1 and 6.4). The carbonylation of 
Trp155 leads to the formation of 5-hydroxytryptophan and N-
formylkynurenine, two common modifications [20-22] which result in 
mass shifts of +16Da and +32Da, respectively. Interestingly, it was 
observed that Trp-155 is a target for both carbonylation and nitration. 
Considering that Trp-155 is strictly conserved among frataxin 
homologues, this observation suggests that this position could be a hot 
spot for oxidative stress modifications. 
 
6.4.2. Effect on Frataxin Functions 
Functionally, frataxin has been suggested to play a role in preventing 
the iron-mediated production of hydroxyl free radicals [16-17, 23], 
therefore we have analysed whether this role as an oxidative stress 
protector was impaired by oxidative stress related modifications. For the 
purpose, we have followed the production of OH• by the Fenton reaction 
using the deoxyribose assay as described [24]. In agreement with 
previous observations, we have noted that unmodified frataxin is able to 
reduce OH• production to nearly half of the values observed in its 
absence. This function is not affected by frataxin carbonylation nor by 
its nitration, as the modified frataxins retained the ability to prevent 
Fenton reactions at the same level as the unmodified frataxin (Fig. 6.5). 
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One of the other proposed roles of frataxin is that of an iron-chaperone. 
Human FXN binds 6-7 Fe3+.mol-1 at a Kd of 17 µM [4] and is involved in 
pathways leading to the biosynthesis of Fe-S clusters [4]. We have 
investigated if this function would be perturbed by the modifications and 
we have found that neither carbonylation nor nitration abolish iron 
binding, although the stoichiometry is slightly decreased to 5.5 ± 0.4 
Fe3+.mol-1 (n=5) for both cases and the binding affinities remain either 
unaltered in nitrated frataxin (Kd=14.0 ± 1.1 µM, n=2) or slightly 
decreased in the carbonylated protein (Kd=34.0 ± 2.0 µM, n=3). 
  
6.4.3. Impact on Frataxin Conformation and Stability  
The effect of the chemical modifications on the protein structure and 
stability was also investigated. The protein fold did not change upon the 
modifications but, on the other hand, there was an effect on protein 
stability: nitration has a rather significant effect (∆Tm=-5°C), whereas 
carbonylation reactions are less perturbing (∆Tm=-1.6°C) (Fig. 6.6 and 
Table 6.1). The modifications also decrease the refolding efficiency 
upon thermal denaturation, as the reactions are still reversible, but at 
lower yields.  
Table 6.1: Thermodynamic stability from thermal denaturation of modified frataxins. 
 
Frataxin 
variants 
Tm  
(ºC) 
∆Hm  
(kcal.mol-1) ∆Tm (ºC) 
∆Ga 
(cal/mol) 
∆(∆G)b 
(cal/mol) 
Refolding 
% 
Unmodified  60.0 ± 0.1 68.6 ± 1.8 - 4462 - 95 
Nitrated  55.0 ± 0.2 60.1 ± 2.8 -5.0 ± 0.3 3457 -916 70 
Carbonylated 58.4 ± 0.2 64.9 ± 3.5 -1.6 ± 0.3 4030 -313 40 
a ∆G at 25ºC for ∆Cp= 12 cal/mol/K; b ∆(∆G) =[∆(Tm)] x ∆Sm = [∆(Tm)] x (∆Hm/Tm), where ∆Sm and ∆Hm are 
values for the wild type. 
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We have investigated if the modifications would promote frataxin 
oligomerisation and aggregation that could affect the refolding reaction. 
However, we could not detect the formation of oligomers when nitrated 
and carbonylated apo frataxin (50µM) were analysed using gel filtration. 
To probe for the effect of chemical modifications on frataxin flexibility, 
we have carried out limited proteolysis experiments using trypsin. The 
susceptibility to degradation was evaluated comparing the HPLC tryptic 
peptide maps after a 90 minute digestion at 37°C (Fig. 6.6B). The data 
shows that, whereas carbonylation does not enhance proteolysis in 
comparison with unmodified frataxin, nitration does increase the 
flexibility and induces opening of the conformation, making more sites 
available for cleavage and yielding a higher number of peptides. 
 
 
Figure 6.6: Effect of oxidative related modification on frataxin thermal stability (A) 
and proteolytic susceptibility of (B) unmodified frataxin ( ■ ) carbonylated (○) and 
nitrated (▲) variants. (A) Thermal denaturation curves. Lines represent fits to a two 
state model [25], see Table 1 for parameters; (B) Peptide maps resulting from 
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HPLC analysis of partial tryptic digestions. The yy-axis represents absorbance at 
214nm and chromatograms are normalized for digested frataxin concentrations, 
which was always the same for comparison purposes. 
6.5. Discussion 
All Friedreich’s ataxia patients express frataxin, although at much 
reduced levels. Within their mitochondria, iron accumulation and the 
presence of oxygen and nitric oxide in a reducing environment make 
frataxin a likely target for oxidative damage. We have addressed this 
hypothesis and here we have shown that, under oxidative stress 
conditions, frataxin is indeed modified with some compromise of the 
conformational properties but without a functional impairment. Structural 
mapping of the modified residues showed that most of the modifications 
occur on the β-sheet, a region of the protein believed to be involved in 
protein-protein interactions (Fig. 6.3E). We have identified four targets 
of oxidative modifications: Tyr143, Tyr175, Tyr205 and Trp155. All are 
targets for nitration but Trp155 is the only carbonylated amino acid. In 
fact, it is interesting to notice that Trp155 is particularly susceptible to 
modifications since it is both carbonylated and nitrated. There are two 
factors that may account for this increased susceptibility of Trp155 
towards modifications. One could be that Trp is highly susceptible to 
oxidative stress modifications; however, the specific analysis of other 
residues (Trp168 and Trp173) showed that they are not modified, 
excluding a bias for Trp oxidation. The other more plausible aspect is 
that the location of this amino acid and its orientation specifically 
facilitate modification. Indeed, Trp155 is strictly conserved across 
frataxin homologues and is located at the protein surface with the 
aromatic ring turned to the outside. Further, one other interesting aspect 
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is that the Trp155Arg mutation is found among FRDA compound 
heterozygotes [26]. Previously, we have characterised the impact of this 
mutation at the protein level and we have noticed that it does not disrupt 
the frataxin fold, but does increase the susceptibility towards proteolytic 
degradation, and partly compromises iron binding [12-13]. So, it might 
be relevant in the FRDA context, that a residue whose mutations result 
in FRDA is also a hot spot for carbonylation and nitration modifications. 
Future work made possible by the observations here reported will 
hopefully allow for the establishment of the effect of oxidative 
modifications on the frataxin interactome. 
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7.1. Summary 
To better understand the functional characterisation of frataxin 
structure, we have here characterised eight frataxin variants involving 
mutations on two putative functional regions – the  acidic ridge 
and the conserved -sheet surface.  It is shown that frataxin iron binding 
capacity is quite robust: even when five of the most conserved residues 
from the putative iron binding region are mutated, the protein still binds 
iron (~2 iron atoms per monomer), although with decreased affinity.  
Furthermore, the data suggest that the acidic ridge is designed to favour 
function over stability. The negative charges have a functional role but, 
at the same time, also significantly impair frataxin’s stability. Removing 
five of those charges results in a thermal stabilisation of ~24ºC and 
reduces the inherent conformational plasticity. Mutations on the 
conserved -sheet residues have only a modest impact on the protein 
stability, highlighting the functional importance of residues 122-124.  
7.2. Introduction 
The human and yeast frataxin orthologs have a high degree of amino 
acid (65%) and structural identity. The phenotype observed as a 
consequence of frataxin’s deficiency is very similar in human and yeast 
cells [1-2]. Hence, the yeast model system has been frequently used to 
study frataxin’s function, as well as the pathological events associated 
with FRDA. Yeast frataxin, Yfh1, is not absolutely essential, but its 
absence causes severe growth defects and a reduction in the activity of 
Fe-S cluster–containing enzymes, such as aconitase [1-4]. Iron binding 
by frataxins, a requirement for a role as a metallochaperone, has been 
well documented by several laboratories [5-7]. Frataxins bind iron at 
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micromolar binding affinities with different stoichiometries: while 
monomeric human frataxin binds 6/7 iron ions (Kd ~  12-55M [7]), 
monomeric frataxin from Drosphila binds 1 ferrous iron (Kd ~6M, [6]) 
and yeast frataxin binds 2 ferrous irons (Kd ~2.5M, [5]). This variability 
suggests a certain plasticity of the frataxin fold in respect to binding iron. 
In fact, an NMR based investigation of the iron binding to Yfh1 at low 
stoichiometry (up to 2Fe:Yfh1) denoted changes in 10 distinct residues 
[8], which could indicate long range effects upon iron binding or lower 
affinity sites. More complex effects arise at higher Fe:Yfh1 
stoichiometries. Like human frataxin, Yfh1 undergoes iron-dependent 
oligomerisation, above a threshold of 2 irons per monomer, according to 
the progression    3  6   12   24  48 [9-10]. This property 
has been established as important for iron-induced oxidative stress 
protection, but not for Fe-S cluster biogenesis [3, 11].  
The first helix (1) and the edge of the first -strand (1) form a 
semi-conserved acidic ridge that constitutes the putative iron binding 
region of the protein [5, 8, 12]. A set of conserved residues in the -
sheet surface constitutes the other putative functional region of the 
protein, believed to be involved in the binding of frataxin to its protein 
partners [8, 13]. Recently it has been shown that mutations at the 
conserved -sheet residues 122-124 affect neither iron binding capacity 
nor the oligomerisation properties of frataxin, these mutations, however, 
do compromise the interaction with Isu [14].  To complement previous 
functional characterisation of YFH1 mutants, here we address the 
structural and conformational effects of eight functional mutants in yeast 
frataxin that alter either the acid ridge or conserved residues on the -
sheet surface. We found that the negatively charged residues in the 
acid ridge that are important for iron binding reduce Yfh1’s stability, 
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indicating a trade-off between functionality and stability. In addition, 
alterations in the conserved residues of the portion of the acid ridge 
found in the -sheet affected interaction with the scaffold protein Isu but 
did not affect overall protein stability. 
7.3. Materials and Methods 
Yeast strains, plasmids and media.  
Saccharomyces cerevisiae strains carrying YFH1 mutant or wild type 
genes on plasmids were created by sporulation and dissection of 
YFH1/yfh1 (W303 background) transformed with the plasmids. YFH1 
mutants were generated by site-directed mutagenesis using pCM189-
YFH1 as a template, having YFH1 under the control of the tetO 
promoter [15]. Constructs containing the following mutations were 
prepared: yfh1-D86A/E90A/E93A, yfh1-D101A/E103A, yfh1-
D86A/E90A/E93A/D101A/E103A, yfh1-N122A, yfh1-N122K 
(corresponding to the human clinical mutation N146K), yfh1-K123T, 
yfh1-Q124A and yfh1-N122A/K123T/Q124A.  Doxycycline was used at 
1 g/ml to reduce expression. Cells were grown in minimal synthetic 
media with –ura DO at 30ºC for 2 days.  
 
Aconitase activity in isolated mitochondria.   
Mitochondria were isolated, according to the method described in 
[16], from cells grown in synthetic minimal media (-ura) in the absence 
of doxycycline. Aconitase activity was measured in isolated 
mitochondria by monitoring the decrease in the absorbance of the 
substrate isocitrate at 240 nm as described in [17]. 
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Gene Expression and Protein purification.  
The mature form of Yfh1 (amino acids 52-174) with an N-terminal His 
tag and a thrombin cleaving site in between were cloned into pET-3a 
vector (Novagen, Madison, WI, USA) [3]. Protein expression was 
induced over 3h at 37ºC in BL21(DE3) E. coli by adding IPTG 
(isopropyl-b-galactopyranoside) at a final concentration of 0.5mM.  With 
the exception of Yfh1-K123T, which was expressed at much lower 
levels (approximately 30%), all other mutant variants had expression 
levels identical to those of the wild type Yfh1. The reduced expression 
levels of Yfh1-K123T had already been described when expressing this 
mutant in yeast [14]. Under the tested conditions, wild type Yfh1 was 
exclusively expressed as a soluble protein, as was most of the mutants. 
The only exceptions are Yfh1-86/90/93A, Yfh1-N122A and Yfh1-
N122A/K123/Q124A, in which ~15% of the expressed protein was found 
in the insoluble fraction. After harvesting the cells, they were lysed on a 
French press. Cell lysate was subjected to His-binding resin 
(Amersham) chromatography and the protein was eluted with a gradient 
to 500mM Imidazole in the binding buffer (50mM Tris-HCl Ph8.0, 
200mM NaCl, 10mM Imidazole). The His tag was cleaved using 
biotinylated thrombin and thrombin was removed by streptavidin 
agarose (Amersham). When necessary (purity less than 90%) the 
protein was further purified by applying the sample on a Superdex 75. 
At the end, the buffer was changed to 10mM HEPES, 50mM NaCl pH 
7.0 using Centricons (Millipore). Protein concentration was determined 
using the extinction coefficient 280nm = 15470 M-1.cm-1. The mature form 
of Isu1 (amino acids 35-165) with an His tag and a TEV cleaving site in 
between was cloned into pKLD37 vector. Protein expression was 
induced over 4h at 30ºC in C41 E. coli by adding IPTG (isopropyl--
galactopyranoside) at a final concentration of 1mM. The purification was 
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performed as described above for the Yfh1 variants. Protein 
concentration was determined using the extinction coefficient 280nm = 
14161.4 M-1.cm-1 
 
Spectroscopic methods.  
UV/Vis Spectra were recorded at room temperature in a Shimadzu 
UVPC-1601 spectrometer. Fluorescence spectroscopy was performed 
on a Cary Varian Eclipse instrument (ex =280nm, em =340nm, slitex: 5 
nm, slitem: 10 nm unless otherwise noted) equipped with cell stirring and 
Peltier temperature control. Far-UV CD spectra were recorded typically 
at 0.2 nm resolution on a Jasco J-715 spectropolarimeter fitted with a 
cell holder thermostated with a Peltier thermal cell.  
 
Thermal denaturation. Thermal unfolding was followed by ellipticity 
(mrw at 222nm) variations and by Trp fluorescence spectroscopy. In all 
experiments, a heating rate of 1ºC/min was used, and the temperature 
was changed from 10 to 90ºC. All reactions were found to be reversible 
under the tested conditions, as inferred from obtaining identical far-UV 
CD spectra of the proteins before the thermal ramping and after cooling 
down the heated sample; a second temperature ramp of the same 
sample also yielded identical melting transitions. Protein aggregation 
was not observed during thermal unfolding. Data was analysed 
according to a two-state model and the thermodynamic data parameters 
were determined as in [18]. 
 
Trypsin limited proteolysis and LC-MS analysis. Frataxins were 
incubated with trypsin (bovine pancreas trypsin, sequencing grade, 
Sigma) at 37°C in 0.1 M Tris-HCl pH 8.5, in a 150 fold excess over the 
protease. Aliquots (300 mol of protein) were sampled at different 
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incubation periods and the reaction was stopped by adding loading 
buffer with 5M BSA followed by a 10min incubation at 100ºC. The 
products of the proteolysis reaction were analysed by SDS-PAGE [19]. 
 
Iron-binding assays. Yeast frataxin oligomerises in an iron-
concentration dependent fashion but, at up to a stoichiometry of 2 irons 
per protein the protein, remains in the monomer form [8-10, 20]. To 
avoid side effects from different oligomerisation behaviours we have 
measured iron binding before oligomerisation takes place, i.e. up to a 
iron:protein ratio of 2. Trp fluorescence emission spectroscopy was 
used to monitor iron binding, which quenches Trp emission as the iron-
frataxin complex is being formed. As previously shown, these methods 
yield results identical to those obtained by isothermal titration 
calorimetry [7, 21]. For the purpose, the quenching of the Trp 
fluorescence (exc=290nm; em=340 nm) of a 50M solution of apo 
frataxin in 100mM HEPES pH 7.0, 50mM NaCl was measured upon 
stepwise addition of an iron citrate solution in 1 ml quartz cuvettes 
under continuous stirring. This data was used to calculate the fraction of 
binding sites occupied. The stoichiometry, p, and apparent dissociation 
constant, Kd, were then determined as described by Winzor and Sawyer 
[22]. 
 
Isu:Yfh1 interaction assay. Holo-Yfh1 was prepared using a 
stoichiometry of 2 irons per frataxin to avoid interference from oligomer 
formation. The formation of a Isu:holo-frataxin complex was followed 
monitoring frataxin Trp fluorescence, since yeast Isu does not contain 
any Trp residue. Thus, when Isu binds to holo-Yfh1, the Trp 
fluorescence emission (exc=290nm; em=340 nm) of the latter is 
quenched and this can be used to monitor binding. Holo-Yfh1 were 
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prepared in 100mM HEPES pH 7.0, 50mM NaCl. Aliquots of Isu were 
added to 2.5 mM holo frataxins under constant stirring. The 
stoichiometry, p, and apparent dissociation constant, Kd, were then 
obtained as described by Winzor and Sawyer [22]. 
7.4. Results 
7.4.1. Frataxin’s Cellular Function 
To gain a better understanding of the relationship between the 
structure and function of frataxin, we compared four Yfh1 variants. 
Three variants (Yfh1-D101/E103A, Yfh1-D86/E90/E93A and a 
combination of these two, Yfh1-86/90/93/101/103A) alter the putative 
iron binding region at the 1/1 acidic ridge and oligomerisation region 
(Fig. 7.1).  
 
Figure 7.1: Yfh1 ribbon structure generated using PyMOL (PDB accession #2ga5). 
Mutated residues are represented by sticks, labelled and highlighted in black. The 
present study has focused on the structural and conformational characterisation of the 
following variants: Yfh1-D86A/E90A/E93A, Yfh1-D101A/E103A, Yfh1-
D86A/E90A/E93A/D101A/E103A, Yfh1-N122A, Yfh1-N122K (corresponding to the 
human clinical mutation N146K), Yfh1-K123T, Yfh1-Q124A and Yfh1-
N122A/K123T/Q124A.  
Glu93
Glu90
Asp86
Asp101
Lys122
Gln123
Asn122
C‐term
Glu103
N‐term
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The fourth, Yfh1-N122A/K123T/Q124A (hereafter referred to as 
Yfh1-122-4), alters the conserved -sheet in the putative binding 
surface for interaction with Isu, the scaffold on which Fe-S clusters are 
built [14]. Since Yfh1 cellular levels can be significantly reduced before 
any growth defects are detected [23], wild type and mutant YFH1 genes 
were placed under the control of the tetO promoter in order to be able to 
modulate protein expression using doxycycline. In this way, in vivo 
function could be tested under both normal and reduced levels of 
expression. At normal Yfh1 expression levels (minus doxycycline) all 
mutant genes were able to support the same growth as observed for the 
wild type (Fig. 7.2). 
 
 
 
Figure 7.2: Growth of YFH1 mutants. 10-fold serial dilutions of cell suspension of 
wild type, yfh1 and yfh1 transformed with plasmids harbouring the indicated YFH1 
mutant genes under the control of the tetO-regulatable wild type or mutant yfh1 were 
plated on minimal synthetic medium –ura DO containing (+) or lacking (-) doxycycline 
(dox). Plates were incubated at 30ºC for 2 days. 
WT haploid
∆yfh1
YFH1
∆yfh1
86/90/93/101/103A
‐ dox + dox
122‐4
86/90/93A
101/103A
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 In addition, as we previously reported [3, 14], Yfh1-122-4 cells grew 
poorly when the variant was expressed at reduced levels (plus 
doxycycline), while cells expressing low levels of Yfh1-86/90/93A grew 
as well as wild type cells. Yfh1-101/103A cells growth was only slightly 
affected but, when these mutations were combined with those of Yfh1-
86/90/93A, altering five of the charged residues in the acidic ridge, 
growth was severely compromised. Consistent with this growth 
impairment phenotype, mitochondria isolated fromYfh1-101/103A had 
lower levels of activity of the Fe-S enzyme, aconitase even when the 
mutant protein was expressed at normal levels (Fig. 7.3). This effect 
was more extreme in Yfh1- 86/90/93/101/103A mitochondria, which had 
only 40% the aconitase activity of wild type mitochondria. Consistent 
with the effects on growth, Yfh1-122-4 mitochondria had only 20% the 
aconitase activity as wild type mitochondria.  
 
Figure 7.3: Aconitase activity. Measured for mutant mitochondria represented 
as a percentage of wild type aconitase activity. 
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7.4.2. Iron Binding 
Since iron binding is an essential functional feature of frataxin, we 
asked if iron-binding properties of the Yfh1 variants were affected. In 
order to exclude iron-induced frataxin oligomerisation effects, we have 
investigated iron-binding at low stoichiometry (up to 2 Fe(II)/Yfh1), i.e. 
under conditions in which oligomerisation does not take place. We have 
used Trp-fluorescence to monitor iron binding to Yfh1 variants, as Trp 
emission is a specific reporter for iron-binding to frataxin. Our 
measurements indicated that mutations altering the iron binding region, 
D86A, E93A, D101A and E103A, had no effect on the iron binding 
capacity at low stoichiometry, the variants showed decreased binding 
affinity (Table 7.1). Conversely, iron must be able to bind to frataxin 
through other residues, as even the quintuple mutant Yfh1-
86/90/93/101/103A retained the ability to bind ~2 Fe(II)/Yfh1. We 
hypothesise that iron is binding to secondary sites with a lower affinity, 
as evidenced by the higher affinity constants (~20 M). In fact, a 
previous NMR study[8] has 
shown that under identical 
conditions at low iron 
stoichiometry, iron binding 
to Yfh1 affected multiple 
sites: mainly interactions 
with carboxylate and 
nitrogen from acidic 
residues within the 1/1 
ridge (His83, Asp86, Glu93, 
Table 7.1: Iron binding affinity determined 
by Trp fluorescence for Yfh1 and its 
functional mutants. 
 
Protein 
Kd 
(M)a 
Wild Type 10.4 ± 2.1 
N122K 11.0 ± 3.8 
N122A 14.0 ± 1.0 
K123T 18.8 ± 2.4 
Q124A 13.2 ± 3.8 
N122A/K123T/Q124A 27.1 ± 1.0 
101/103A 20.9 ± 0.6 
86/90/93A 21.3 ± 1.0 
86/90/93/101/103A 22.8 ± 0.9 
a(n=2)  
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His95, Asp101, Glu103), but other residues (Ala94, Leu104, Ser105 
and Asn140) were also found to change their resonance positions upon 
binding of up to 2 irons per frataxin [8].  
The lower binding affinity that we have determined in the Yfh1 
variants (nevertheless still in the micromolar range comparable to that of 
human frataxins) could possibly indicate the recruitment of secondary 
positions, rather than unspecific binding. However, iron-binding remains 
functional, as shown by the fact that yeast expressing these variants still 
have some aconitase activity (Fig. 7.3), an activity that depends on 
frataxin-mediated iron transfer [24]. In addition, a previous study 
confirms our observations: single point mutations to alanine on residues 
86, 90, 93, 101 and 103 reduce Yfh1 affinity to iron but do not abolish 
iron binding [11]. Single point mutations in the Asn122-Gln124 segment 
seem to have an intermediate effect in respect to the binding affinity 
(~14-18 M). Presumably, alterations in the protein-protein interaction 
region of Yfh1 result in long-range effects on the iron-binding acid ridge 
leading to decrease of the iron binding affinity.  
7.4.3. Isu Binding  
Since low stoichiometry iron binding was not impaired in the mutants, 
we next evaluated whether the interaction between Yfh1 and Isu was 
compromised. This interaction is mediated by iron, as only holo-Yfh1 
interacts with Isu [7]. Yfh1-86/90/93A was found to bind to Isu with a 
wild type like affinity (Kd ~5M), while no interaction with Yfh1-122-4 
was detected, which is consistent with previously published results [3] 
and [14], respectively. The fact that the alteration of residues 122, 123 
and 124 individually (N122K, N122A, K123T or Q124A) severely affects 
the Isu interaction supports the hypothesis that all three residues are 
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important for this interaction. No interaction between Isu and Yfh1-
101/103A (or Yfh1-96/90/93/101/103A) was detected in our in vitro 
assay. This reduced interaction is somewhat surprising considering that 
Yfh1-101/103A could significantly rescue the growth defect of yfh1∆ 
cells, even when expressed at low levels (Fig. 7.2). Mutating these two 
residues have only been found to cause a growth defect when the 
alterations are to lysines and the medium is supplemented with high 
levels of iron [4]. In vivo, other cellular factors may promote the 
interaction between Yfh1-101/103A and Isu, explaining the difference 
between the in vivo and in vitro results. Indeed frataxin was found to 
interact with Isd11 of the Nfs1/Isu complex and multiple mitochondrial 
chaperones [25]. It appears that significantly reduced affinity may be 
tolerated in vivo. 
7.4.4. Activity-Stability Trade-off 
In order to evaluate if functional impairments may result from 
decreased protein stability, the effect of the alterations on Yfh1 folding 
thermodynamics was analysed by comparing the thermal stability of 
mutant variants to that of wild type. According to the analysis of the far-
UV CD spectra at 20ºC, before and after thermal denaturation, thermal 
unfolding was reversible for all protein variants studied and no 
aggregation was observed after thermal unfolding. The results showed 
that charge-to-neutral alterations in the acidic ridge result in an 
impressive stabilisation of the protein fold: an increase of up to ~24ºC 
was noted for the Yfh1-86/90/93/101/103A variant while alterations in 
the sheet surface had almost no effect on protein thermal stability 
(Fig. 7.4, Table 7.2).  
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Figure 7.4: Thermal denaturation curves at pH 7.0 following Trp emission. Impact of 
mutations on Yfh1 thermal stability. (■)  Wild Type , (a) single point mutations of -
sheet surface residues (122-123). (□) N122A, (∆) K123T, (○)Q124A, (b) Mutations on 
putative iron binding sites: (▲) D86A E90A E93A, (◊) 86/90/93/101/103 A. Lines 
represent fits to the two-state model [18]; for parameters see Table 7.2. 
 
The protein stability decreased in the order: Yfh1-86/90/93/101/103 A 
> Yfh1-86/90/93 A > Yfh1-101/103 A > Yfh1-N122K > Yfh1-K123T > 
Wild Type > Yfh1-N122A/K123T/Q124A > Yfh1-Q124A > Yfh1-N122A. 
The exception for the effect on the sheet surface are the mutations in 
residue Asn-122: changing to an alanine (Tm = -4.5 ºC) or to a lysine 
(Tm = +4.3 ºC) had opposite effects, probably due to the impact that 
would be expected by these alterations on the hairpin between 
strands 3 and 4. This hairpin involves two hydrogen bonds 
(Asn122-Trp131 and Val120-A133); while the insertion of an Ala at 
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position 122 likely disrupts the hydrogen bond with Trp131, the 
positively charged Lys might strengthen it, thus stabilising the protein. 
The 101/103A alterations stabilise the protein in spite of compromising 
2 of the 3 hydrogen bonds involved in the hairpin connecting 
strands1 and 2. This suggests that minimising repulsive interactions 
overcomes the stabilisation obtained by the two hydrogen bonds.  
 
Table 7.2: Thermodynamic parameters for thermal denaturation of yeast frataxin 
variants. Effect of functional mutations on the protein thermal stability. 
 
Protein H 
(kcal.mol-1) 
Ga
(cal.mol-1) 
Tm 
(ºC) 
Tm 
(ºC) 
G)b
(cal.mol-1) 
Wild Type 28.2 ± 0.3 1421.3 40.4 ± 0.1 - - 
N122K 34.8 ± 0.5 1857.6 44.7 ± 0.1 + 4.3 ± 0.2 546.5 
N122A 30.1 ± 0.4 981.4 35.9 ± 0.1 - 4.5 ± 0.2 -588.3 
K123T 28.7 ± 0.4 1481.3 41.0 ± 0.1 + 0.6 ± 0.2 77.2 
Q124A 34.3 ± 0.3 1282.5 39.0 ± 0.1 - 1.4 ± 0.2 181.2 
N122A/K123T/Q124A 21.7 ± 0.3 1401.4 40.2 ± 0.1 - 0.2 ± 0.2 25.8 
101/103A 55.1 ± 0.8 2629.4 52.0 ± 0.1 + 11.6 ± 0.2 1441.3 
86/90/93A 51.3 ± 0.9 2759.6 53.2 ± 0.1 + 12.8 ± 0.2 1584.6 
86/90/93/101/103A 77.1 ± 1.5 3988.5 64.2 ± 0.1 + 23.8 ± 0.2 2850.2 
a G at 25ºC, considering an estimate for Cp of 12 cal/mol/K. 
b G) =[(Tm)] x Sm = [(Tm)] x (Hm/Tm), where Sm and Hm are values for the wild type. 
 
 
Since protein conformational plasticity affects both protein function 
and degradation rates, we next analysed whether the functional 
mutations were also affecting frataxin flexibility, by performing limited 
proteolysis experiments using trypsin. Our underlying rationale was that 
mutations resulting in an increased structural flexibility would increase 
trypsin access to cleavage sites and consequently increase the 
degradation rate. The results show two distinct patterns, depending on 
the region in which the alteration is located (Fig. 7.5). Alterations on the 
acidic ridge had a pronounced effect on frataxin dynamics, making the 
protein more rigid and substantially less susceptible to proteolysis. In 
fact, the Yfh1-86/89/93/101/103A variant remains essentially intact 
Yfh1 Functional Regions  
191 
 
under conditions in which wild type frataxin is essentially completely 
digested (80% versus 10% integrity after 100 min digestion). On the 
other hand, alterations on the -sheet surface (Yfh1-
N122K/K123T/Q124A) behave almost identically to the wild type, 
suggesting that modifications in this region have either a very small or 
no effect on the protein conformational plasticity.  
Overall, alterations in the acidic ridge that prevent iron binding at the 
primary sites increased substantially the protein stability, presumably 
due to decreased flexibility. It is possible that decreases in the structural 
flexibility may prevent conformational changes necessary to allow the 
interaction with protein partners. This increase in both thermal stability 
and resistance to proteolytic degradation suggests that the iron binding 
region is particularly susceptible to an activity-stability trade off. 
 
 
Figure 7.5: Time course of trypsin limited proteolysis. Comparison between wild type 
and functional mutants (A) SDS-PAGE analysis of the time course trypsin limited 
proteolysis experiments. (B) Evaluation/quantification of frataxin degradation during 
incubation with trypsin. Gels (A) densitometric analysis allowed the quantification 
frataxin for the different incubation times with trypsin. (■)  Wild Type, (□) N122A 
K123T Q124A, (▲) D86A E90A E93A, (◊) 86/90/93/101/103 A.  
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7.5. Discussion 
Here we present a detailed characterisation of eight yeast frataxin 
functional variants, that either alter the acidic ridge between -helix 1 
and -sheet 1 or the conserved -sheet surface between strands 3 and 
4. Changing the conserved -sheet residues Asn122-Lys-123-Gln124 
had almost no effect on Yfh1 stability and plasticity, indicating that 
changes in this region did not disrupt overall conformation but are 
relevant for the Yfh1-Isu interaction. Alteration of up to five residues in 
the acidic ridge region, four of which had been identified as iron binding 
sites [8], significantly increase frataxin stability. This illustrates a rather 
interesting trade off between activity and stability in this region. In 
addition, our study suggests that residues Asp101 and Glu103 are 
involved in the iron-mediated interaction between Isu and Yfh1 but their 
alteration does not abrogate the interaction, as evidenced by the rescue 
of the yfh1 phenotype.  
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8.1. Summary 
 
Frataxin has been shown to be stabilised by different metal ions, in 
addition to iron. In this section we explore the potential binding 
properties of this mitochondrial protein. We have evaluated the potential 
binding of other common metals present within the mitochondria, namely 
manganese, zinc and copper and others like magnesium, sodium, 
calcium and nickel. Most of the metals were tested due to their effect on 
the protein stability [1] but nickel was included due to its ability to rescue, 
at least partially, FRDA-mutants cellular deficiencies [2]. Studies 
performed by Trp fluorescence emission revealed that, apart from iron, 
frataxin only binds copper and also that this feature (Cu(II) binding) was 
further confirmed by EPR. Frataxin was able to bind both copper 
oxidation states and the stoichiometries observed were nearly identical 
(the protein was shown to bind 3 Cu(I) or alternatively 4 Cu(II)). 
However, the protein affinity towards Cu(I) was higher. In contrast to 
what was observed during iron binding, DLS measurements have shown 
that copper is not able to induce Yfh1 oligomerisation. Thus, if Yfh1 has 
an antioxidant effect regarding copper toxicity, this is not associated to 
the protein oligomerisation capacity as in iron detoxification. Copper 
titrations of the functional Yfh1 mutants, described in the previous 
chapter, suggest that the copper binding region may also be located on 
the acidic ridge. Furthermore, Yfh1 was tested for a potential role as a 
copper-chaperone. In spite of exhibiting a dissociation constant in the 
micromolar range, Yfh1 was shown to be able to act as a copper-
chaperone promoting apo-SOD1 metallation.  
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8.2.  Copper in the mitochondria 
 
Iron, zinc, copper and manganese are found in the in the 
mitochondria (Table 8.1 for metal mitochondrial concentration in yeast 
cells) [3]. The mitochondrial steady stated concentration of copper is 
nearly one order of magnitude above the predicted to be required for the 
activation of the mitochondrial Cu-dependent cytochrome c oxidase 
(CcO), the most abundant cupro-protein within the mitochondria [3].  The 
excess of copper is located within the mitochondrial matrix on a non 
proteinaceous pool of copper; in yeast, this corresponds to 85% of the 
total mitochondrial copper, while in the mouse liver extracts it 
corresponds to 70% [3-4]. This pool constitutes the copper source for 
the maturation (metallation) of the two described mitochondrial copper-
dependent enzymes: CcO and superoxide dismutase (Cu,ZnSOD or 
SOD1) [5-7]. In the matrix, copper (Cu(I)) forms a low molecular complex 
(CuL) with an unidentified non-proteinaceous ligand whose structure 
remains known. The targeted expression of two heterologous Cu(I) 
binding proteins, human SOD1 and yeast Cr5 metallothionein, depletes 
the complex as copper is directed to the maturation of those proteins [8]. 
Thus, CuL complex seems to work as a Cu(I) storage but, once needed, 
copper is transfered to the appropriated copper-chaperones to further 
take part on the metallation reactions within the mitochondrial inner 
membrane.  The copper-free 
ligand is also present in the 
cytosol, but how this ligand is 
transferred to mitochondrial 
matrix is still not clear. Once 
free copper binds to the 
ligand, it forms an anionic 
Table 8.1: Metal concentrations within the 
mitochondria. 
Metal 
Mitochondrial 
concentration 
(nmol/mg of protein) 
Iron 2.3 ± 0.1 
Copper 1.3 ± 0.2 
Zinc 0.7 ± 0a 
Manganese 0.13 ± 0a 
aS.D.≤ 0.5 
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complex and it is postulated that this copper-ligand complex is further 
targeted to the matrix. 
 Within the inner mitochondrial space (IMS), several proteins (Cox17, 
Cox19, Sco1 and Cox11) transiently bind copper and contribute to the 
metallation/activation of CcO. SOD1, the other mitochondrial copper-
binding protein, is also localised within the IMS. Although most SOD1 is 
cytosolic, 1-5% of total cellular SOD1 is within the IMS where its 
metallation takes place. The metallochaperone Ccs1 activates SOD1 by 
inserting Cu(I) into the apo-protein and by catalysing the formation of an 
essential disulfide bond. Moreover, this metallochaperone is also 
responsible for the accumulation of SOD1 within the mitochondrion.  
There might be another copper chaperone involved in SOD1 
maturation. It was observed that human, mouse and C. elegans SOD1 
activity is retained in Ccs cells [3, 9-13], meaning that these organisms 
should have a SOD1 activation pathway that is Ccs-independent. The 
existence of an alternative copper chaperone promoting Ccs-
independent SOD1 metallation may be suggested, however, Ccs-
independent metallation has some constrains, as it strictly depends on 
reduced glutathione or on low redox potentials of the cells and is 
sensitive to certain structural perturbations in SOD1 structure [8,11]. 
Like iron, copper also catalyses the generation of ROS, thus its 
intracellular transport requires strict regulation and copper chaperones 
(Table 8.2), such as Ccs and Cox17 among others, which sequester and 
deliver copper imported via Ctr1 or/and DMT1. This last protein is a key 
protein in intestinal iron uptake, however its broad substrate range 
includes copper making it a potential alternative for the cellular copper 
import [14].  
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Table 8.2: Examples of Copper-binding and copper homeostasis proteins. Their known 
functions and binding parameters. 
Protein Function N* Kd (M)  
Technique, 
Ref. 
Amyloid 
precursor 
(APP) ‡ 
Protein involved in neuronal 
development and potentially Cu 
metabolism; cleavage leads to 
generation of  peptide that 
aggregates in senile plaque 
associated with Alzheimer's 
disease 
2 10 x 10-3 SPR,[15] 
Atox1† 
Metallochaporine that delivers 
Cu to ATP7A and ATP7B Cu(I) 
transporters 
0.5 3.5×10-4 ITC, [16] 
CCS† 
Metallochaperone that delivers 
Cu to Cu,Zn SOD 
2† < ~ 10-14 
 
[17], [18] 
Cox17† 
Metallochaperone that transfers 
Cu to Sco1 and Cox11 ft cyt 
oxidase C loading in the 
mitochondria 
4 13 x 10-9 
UV absorption 
and Trp fluor, 
[19] 
CopZ† 
Archaeoglobus fulgidus [2Fe-2S] 
and Zn2+-containing Cu 
chaperone  
0.5 10−11-10−12 
BCS 
competition 
assay,  [20] 
SOD1† 
Antioxidant enzyme, catalyses 
the disproportionation of 
superoxide to hydrogen peroxide 
and dioxygen 
1 6 x 10-9 [17] 
PrP‡ 
Protein whose function is 
unclear but binds Cu via the N-
terminal octapeptide repeats 
Up 
to 6 
13-66 x 10-3 
Trp Fluor and 
CD, [21] 
S100A13‡ 
Is involved in the nonclassical 
export of signal peptide less 
proteins such as fibroblast 
growth factor (FGF-1) and 
interleukin 1α 
2 12 and 55 ITC, [22] 
* Binding sites per monomer 
† Cu(I) 
‡ Cu(II) 
 
The coordination chemistry of Cu(I) and Cu(II) is often distinct, with 
Cu(I) preferring sulphur donors such as cysteine and methionine, 
whereas Cu(II) prefers nitrogen donors such as histidine or oxygen 
donors such as glutamate or aspartate [23]. The metal-binding motif, 
MXCXXC, is common not only among copper chaperones (ATPases 
ATP7A and ATP7B) but also in chaperone-like proteins, such as 
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cadmium and mercury binding proteins [23]. Cox17 presents a different 
motif, CXXC [24], as well as the high affinity copper importer Ctr1, MX3M 
[23]. Other copper binding proteins show abnormal copper binding 
motifs such as RNAse A that binds copper through two histidines and a 
glutamic acid [25]. Histidine (His) has a very efficient nitrogen donor in 
its side chain imidazole. This residue provides 2 nitrogen donors and 6-
memberate chelate rings for coordination. Its coordination properties will 
however depend enormously on the residue position on the polypeptide 
chain. 
Here, we extend the characterisation of frataxin metal binding 
properties, to examine its ability to bind copper in both oxidation states 
and its possible implications at the cellular level. 
 
8.3. Materials and Methods 
Protein purification 
The mature form of Yfh1 (amino acids 52-174), in both wild type and 
mutant variants, with an N-terminal His tag and a thrombin cleaving site 
in between was cloned into pET-3a vector (Novagen, Madison, WI, 
USA) [26-27]. Protein expression was induced over 3h at 37ºC in 
BL21(DE3) E. coli by adding IPTG (isopropyl-b-galactopyranoside) at a 
final concentration of 0.5mM. Cells were harvested and lysed on a 
French press. Cell lysate was subjected to His-binding resin 
(Amersham) chromatography and the protein was eluted with 500mM 
Imidazole in the binding buffer (50mM Tris-HCl Ph8.0, 200mM NaCl, 
10mM Imidazole). The His tag was cleaved using biotinylated thrombin 
and thrombin was removed by streptavidin agarose (Amersham). When 
necessary (purity less than 90%) the protein was further purified 
applying the sample on a Superdex  75. At the end, the buffer was 
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changed to 10mM HEPES, 50mM NaCl pH 7.0 using Centricons 
(Millipore). Protein concentration was determined using the extinction 
coefficient 280nm = 15470 M-1.cm-1. 
 
Fluorescence binding assay 
Binding was followed by fluorescence spectroscopy, essentially as 
described previously for iron binding [28]. Briefly, tryptophan 
fluorescence was measured in 1 mL quartz cuvettes with continuous 
stirring. The excitation and monitoring wavelengths were 290 and 340 
nm, respectively. For the measurements, a 15 M solution of apo 
frataxin was titrated with stock solution of different metals. The 
quenching of tryptophan fluorescence induced by the binding was used 
to calculate the fraction of binding sites occupied. The stoichiometry, p, 
and apparent dissociation constant, Kd, were then obtained as previously 
described by Winzor and Sawyer [29]. 
 
DLS measurements 
DLS measurements were performed at a protein concentration of 0.5 
mg/ml at pH 7.0. Protein samples were passed through a 0.22 μm filter 
before DLS measurements. All experiments were performed at a 90° 
scattering angle on a Malvern Instruments Zetasizer Nano-ZS. 
Measurements were carried out at 25°C using a built-in temperature 
controller. The experimentally measured hydrodynamic radius (Rh) of 
the protein was determined by the Zetasizer software 6.01 software 
(Malvern instruments Lda). The radius is represented as a function of 
volume and not intensity, to avoid errors resultant from the increased 
intensity associated to larger particles.   
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SOD1 reconstitution[30] 
The reconstitution of SOD1 was performed under anaerobic 
atmosphere in a VAC Atmospheres glove box. The copper source as 
either Cu(I) -glutathione complex (10M) or Cu-bound Yfh1(10M)  was 
combined with ZnSO4 (10M) and reduced GSH (1mM) in one 
eppendorf; the apo-SOD1 (2M) and BCS chelate competitor (200M) in 
another. Both solutions were prepared anaerobically in deoxygenated 
and Chelex-treated, 50 mM potassium phosphate buffer, pH 7.8, and the 
total copper concentration was normalised for all reaction samples. The 
two solutions were then combined and incubated in a heating block at 34 
°C for 2 h. Reconstitution was also performed with copper II. An aliquot 
of each reaction mixture was extracted from the anaerobic chamber and 
diluted into an aerobic 50 mM potassium phosphate buffer, pH 7.8, for 
assay of SOD activity by standard cytochrome c assay [31]. 
Because SOD1 can incorporate copper ions from solution, control assay 
were performed and consisted in adding equal amounts of copper (but 
not bond to Yfh1); the copper insertion evaluation was performed in 
respect to these controls. The activity of the apo-SOD1, without any 
metal additions, was also measured as a control.  
8.4. Results 
8.4.1. Yfh1 Copper Binding Properties 
Fluorescence spectroscopy was used to monitor binding of different 
metals to frataxin (Yfh1). We have seen that among calcium, copper, 
sodium, magnesium, nickel, manganese and zinc, only copper binding 
can be detected by Trp fluorescence quenching (data not shown). Cu(II) 
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binding analysis revealed a stoichiometry of 4.2 ± 0.1 and a Kd = 26.0 ± 
4.3 M (n=4) (Fig. 8.1A). Further, the binding of Cu(I) was also 
evaluated but, since Cu(I) is not soluble under our assay conditions, we 
have complexed it with GSH [30].  When comparing the binding of Cu(I) 
and Cu(II) to Yfh1, we observed that, although the protein has a lower 
stoichiometry for Cu(I) (3CuI:1Yfh, n=4), its affinity is higher (steeper 
slope observed for copper I titration, Fig. 8.1 A) [29].  
 
 
 
Furthermore, we have studied Cu(II) binding to Yfh1 by electron 
paramagnetic resonance (EPR). We have performed steady state 
measurements (Fig.8.2A) and we have titrated both the protein and the 
buffer solution with increasing amounts of copper (Fig.8.2B). This study 
allowed us to confirm that copper is binding directly to the protein using 
different binding sites. Yfh1 has 3 histidine, 2 methionines and 1 
cysteine, which constitute Yfh1 potential copper binding sites. In 
addition, frataxin glutamates and aspartates may also be involved in 
Cu(II) coordination. The fact that all Glu and Asp residues cluster around 
  
Figure 8.1: Copper binding and its stabilising effect. Left. Binding curve for copper I 
and copper II. Right. Yfh1 thermal denaturation curves in the presence and 
absence of copper II. 
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the iron binding region, suggests that iron and copper binding regions 
are likely to overlap. 
Next, we evaluated whether copper binding stabilised Yfh1. As shown 
by the analysis of the thermal denaturation curves in the presence and in 
the absence of copper, this metal induces a stabilisation of up to ~10ºC 
(Fig. 8.1B). The same stoichiometry of iron:Yfh1 (8Fe(II):Yfh1) shows a 
more modest effect in terms of protein stabilisation, leading to a Tm 
~4ºC [1].  
  
Figure 8.2: Cu(II) binding evaluated through EPR. A: EPR spectra of (■) FXN 50M + 
200M Cu(II), (○) FXN after desalting to remove Cu(II), (∆) concentrated (○), (◊) 50M 
FXN in HEPES buffer and (□) 200M in HEPES buffer. B: EPR spectra as a function of 
Copper concentration ((■) no copper, (○) 54M (1eq.), (∆) 97M (2eq.), (◊) 165 M 
(3.6eq.) and (□) 265M (6eq.). Top: FXN (50mM) titration and bottom HEPES titration 
(control). 
 
Furthermore, we have explored the protein metal-induced 
oligomerisation properties. Previously it has been demonstrated that 
Yfh1 undergoes iron induced oligomerisation and this feature seems to 
be related to the protein’s antioxidant function. Copper, as well as iron, 
may produce reactive oxygen species through the Fenton reaction. 
Thus, if this protein also oligomerises in the presence of excess copper, 
2700 2800 2900 3000 3100 3200
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2700 2800 2900 3000 3100 3200
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50M FXN titration
A B 
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preventing its oxidation and the consequent formation of reactive oxygen 
species, these would represent a direct role of Yfh1 on copper 
metabolism. Dynamic light scattering (DLS) measurements for the Yfh1 
monomer are in agreement with Yfh1 overall molecular dimensions 
determined by NMR, 47Å x 29Å x 23Å (corresponding to radius of 2.4nm 
x 1.5nm x 1.2nm). Thus, we have further used this technique to follow 
Yfh1 oligomerisation.  
 
Substantially increasing the 
copper concentration (up to 40 
times the concentration of protein) 
does not induce copper-induced 
Yfh1 oligomerisation. This 
increase in copper concentration 
results in a modest variation of the 
particles radius ~0.8nm (Fig. 8.3). 
The same Fe(II) to protein ratio 
induces Yfh1 oligomerisation and 
the particles radius increase from 
~2 nm to ~45 nm (diameter of ~900Å) (in agreement with previously 
published data [32]), which corresponds to a 20-fold increase compared 
with the radius measured in the presence of copper.  
8.4.2. Putative Copper Binding Sites 
Considering the yfh1 mutants described on the previous chapter, we 
have evaluated if any of those showed reduced copper stoichiometries 
relative to the wild type protein (Table 8.3). Since three of the variants 
contain mutations of extremely conserved residues associated to iron  
Figure 8.3: Dynamic light scattering 
(DLS) measurements, in the presence of 
excess of copper or iron. 
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binding, if these residues are 
also involved in copper 
binding their mutation may 
partially compromise Yfh1 
copper binding properties. 
Analysis of the binding 
curves shows that residues 
D86, E90 and E93 constitute 
putative copper binding 
sites. These residues 
mutation leads to a reduction 
in the binding stoichiometry 
of 4 to 1 copper ion per 
monomer, along with the 
concomitant increase in the 
Kd. Mutations on the 
conserved -sheet that have 
a reduced impact on the 
protein copper binding 
properties (Table 8.3).  
Since copper binding sites 
seem to overlap with iron 
binding, at least partially, we 
hypothesised that the 
presence of copper may 
modulate frataxin iron 
chaperone function, displacing iron from the surface of Yfh1. To test this 
hypothesis we titrated iron bound holo-Yfh1 with Isu1 in the presence of 
increasing amounts of copper (Fig. 8.4). The addition of copper to holo-
Fe(II)-Yfh1 solution appears to partially displace iron, since copper 
Table 8.3: Copper binding parameters 
obtained according to the methods described 
in [29] .  
 
Protein Cu(II)
p Kd (M) 
Wild Type 4.2 26.0 
N122A 2.8 44.3 
K123T 3.2 34.7 
Q124A 3.0 30.6 
N122A/K123T/Q124A 3.3 54.0 
101/103A 3.5 38.5 
86/90/93A 1.3 46.2 
86/90/93/101/103 A 1.3 59.9 
 
 
 
  
 
 
Figure 8.4: Binding of Isu1 to Yfh1. Possible 
displacement of iron by the presence of 
copper. The iron stoichiometry was retained 
for all titration (2FeII per Yfh1) but increased 
amounts of copper (CuII) where added to the 
titrated solution. 
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addition results in reduce binding of holo-Yfh1 to Isu. However, excess 
of copper fails to abolish the Yfh1-Isu interaction, which suggests that 
copper is unable to cause a complete displacement of iron from Yfh1 
surface.  
8.4.3. Frataxin Can Also Be a Copper Chaperone 
Frataxin binds iron and acts as an iron chaperone, thus we have 
further looked into a potential role of frataxin as a copper chaperone. We 
have followed SOD1 reconstitution without a copper-chaperone by 
adding free copper directly to the SOD1 solution, and by using copper-
loaded Yfh1 as a putative copper chaperone. Frataxin was shown to be 
able to facilitate copper insertion onto apo-SOD1 as the presence of 
copper-loaded Yfh1 approximately doubles the reconstitution efficiency 
obtained by the addition of free copper to the reconstitution mixture (Fig. 
8.5); hCcs 
chaperone activity 
is however 
higher. In the 
presence of hCcs, 
the copper-
chaperone 
responsible for 
the SOD1, 
metallation 
efficiency is twice 
the quantified for 
the copper-loaded 
Yfh1 [30].  As a 
control, the 
 
Figure 8.5: SOD1 activity after anaerobic reconstitution 
with free copper (grey bars) and or alternatively with 
copper bound to yeast frataxin (white bars). The SOD1 
concentration was the same in all the assay (n=3). 
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activity of Apo-SOD1 prior to the reconstitution experiment was 
evaluated and was shown to be identical to the observed for the control 
reconstitutions.   
8.5. Discussion 
Our results suggest that frataxin may also play a role in copper 
homeostasis. The protein binds copper with an affinity identical to the 
observed for iron and it may also act as a copper-chaperone as 
evidenced by the SOD1 reconstitution experiment. By binding copper, 
frataxin prevents copper Fenton reactions (and in fact the protein has a 
higher affinity towards Cu(I)) and, in addition, its reduced copper binding 
affinity allows it to "direct" the copper within the mitochondrial matrix to 
the appropriate metallochaperones and indirectly promote copper 
metallation. Thus, we hypothesised that frataxin may be contributing to 
the homeostasis of the non-proteinaceous mitochondrial copper pool. In 
order to test this hypothesis, and to test whether Yfh1 binds copper in 
vivo and if it  may in fact be involved in metallation reactions, in vivo 
experiments must be performed. Using the yeast model system, we can 
obtain yeast cells with different controlled Yfh1 expression levels. yfh1 
cells must be transformed with a plasmid coding for Yfh1 with a tight 
control expression and Yfh1 copper binding must be evaluated in vivo. 
As previously described, the matrix Cu(I) can be mobilised by the 
expression of copper containing enzymes [8], thus, if increased Yfh1 
expression leads to a depletion of matrix Cu(I), this will strongly indicate 
that Yfh1 binds Cu(I) in vivo. 
Frataxin does not contain a typical copper binding motif which could 
explain its reduced binding affinity. Other proteins such as S100 are also 
known to bind copper with affinities lower than the observed for the 
identified copper chaperones (some with affinities identical to the 
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observed for frataxin). Their ability to bind copper is associated to a wide 
range of biological functions which also include a protective mechanism 
against copper toxicity [33].  
Frataxin binding sites must be further explored and the use of 
chemical compounds such as DEPC, that chemically modifies histidines, 
[34]  or methanethiosulfonates [35], that modifies cysteines, may be 
useful for the identification of the residues involved in copper binding.  
Current results cannot yet clarify what is the biological meaning of the 
frataxin’s ability to bind copper, thus further studies must be performed 
in order to clarify this intriguing yet interesting new feature of frataxin 
cellular function. 
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9.1. Frataxin and FRDA 
9.1.1. FRDA in Heterozygous Patients 
Genetic diseases resulting from missense mutations can involve 
many different and distinct pathological mechanisms. A single amino 
acid chain can trigger a disease by causing loss of function, 
accumulation of toxic species, such as aggregates or amyloid fibers, or 
through dominant negative effects inhibiting the normal function of the  
protein [1]. Single nucleotide polymorphisms are rather common in the 
human genome: about 10 million [2] have been identified, which 
corresponds to over 1% of nucleotides, but only an estimate of 67,000-
200,000 of these polymorphisms are nonsynonymous. This type of 
polymorphism is a missense variation of a single base in a coding 
region that results in an amino acid change in the corresponding 
protein.  Missense mutations have been associated to several diseases 
such as cystic fibrosis, phenylketonuria, amylotrophic lateral sclerosis 
(ALS) or Parkinson's disease.  
In FRDA, the link between frataxin point mutations, described in 
compound heterozygous patients, and the disease physiopathology 
remain unclear. Hypothetical scenarios for the impact of mutations 
include an effect on the folding efficiency, maturation, protein stability 
and proteolytic susceptibility or function. In addition to these direct 
effects on the expressed protein, missense mutations may also alter the 
splicing of pre-mRNA, resulting in aberrant spliced mRNA that could be 
rapidly digested and leading to decreased levels of synthesised protein 
[3]. Here we have studied different FRDA-related point mutations found 
in compound heterozygous patients. These mutations can be grouped 
according to FRDA symptoms: whereas the I154F and W155R 
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mutations lead to severe FRDA phenotype, the mutations G130V and 
the D122Y account for milder clinical symptoms [3]. Reports on these 
mutations and also the recently developed cellular models based on 
frataxin missense mutations (G130V and I154F) indicate that the 
studied mutations do not interfere with mRNA splicing [3-5]. In addition, 
the mild phenotypes are suggestive of the cellular presence of frataxin 
with partially reduced function [3]. Focusing on the impact the different 
clinical point mutations have on the protein conformation, flexibility and 
function and framing our results with recent data on in vivo systems we 
have aimed at contributing to a better molecular and structural 
understanding of FRDA mechanism. 
From a structural point of view, our results demonstrate that none of 
the mutations change significantly the protein fold at room temperature. 
Furthermore, frataxin flexibility is not significantly altered by the insertion 
of the mutations. Nevertheless, the four mutant variants present a 
reduced thermodynamic stability, which, in vivo, is likely to cause an 
increase of the molecular motions and enhance the protein 
susceptibility to aggregate and/or to be degraded by the cellular 
proteases. At 37ºC, the mutant frataxin’s have an increased 
susceptibility towards proteolytic degradation as shown by the limited 
proteolysis experiments. This suggests that increasing the temperature 
from 25ºC to physiological conditions increases the molecular motions 
enough to allow proteolysis. In addition to a higher tendency towards 
degradation, the mutants have also reflected a higher tendency towards 
aggregation and a lower folding efficiency, which may suggest that the 
mutations affect the protein folding kinetics. Accordingly, it has been 
found that there is an inverse correlation between the level of protein 
expression and the aggregation rate [6], so that proteins are only 
marginally soluble to function and aggregation can result from small 
changes such as chemical modifications (e.g. as a consequence of 
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oxidative stress) or genetic mutations (e.g. as in the case of FRDA 
heterozygous patients). 
Isaya and co-workers have demonstrated that human frataxin 
expression can rescue Yfh1-deficient cells (yfh1) phenotype and have 
further used this hybrid system to explore the biogenesis and functional 
impairment of two clinical variants: FXN-G130V and FXN-W173G. In 
contrast to the phenotype associated to the G130V mutation, W173G 
mutation results in a severe phenotype similar to the one observed for 
homozygous and heterozygous patients expressing the mutants FXN-
W155R or FXN-I154F. While the expression of FXN-G130V mutant 
complemented yfh1 cells, FXN-W173G expression lead to typical 
yfh1 phenotype.  However, both mutants showed decreased stability, 
resulting in decreased levels of mature frataxin.  The protein maturation 
process is also reduced by the W173G mutation, decreasing even 
further the levels of mature FXN-W173G protein [7]. In addition, the 
expression of mutants FXN-G130V, FXN-I154F, FXN-W155R, FXN-
W173G and FXN-L156P in HEK293T cells suggests that, with exception 
of mutations I154F and W155R, the other three mutations, including 
G130V, are likely to affect frataxin expression, maturation or 
degradation, since these are poorly expressed in the mature form [8]. 
These in vivo observations are in agreement with our data on the 
decreased stability and increased flexibility, described for the clinical 
mutants in vitro, and sustain the hypothesis that FRDA pathology in 
compound heterozygous may be associated to either a decreased 
folding ability or/and increased degradation. 
Further, we have evaluated the mutants’ function in terms of their 
iron binding ability. Iron titrations have shown that all the clinical 
mutants under study have their iron binding abilities partially impaired. 
While mutants FXN-D122Y and FXN-G130V have a lower binding 
stoichiometry, FXN-I154F and FXN-W155R mutants precipitate upon 
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exciding a threshold of 2FeIII/monomer. This observed reduction in iron-
binding capacity could also be related to increased molecular motions. 
In vivo, cellular models based on frataxin missense mutations show a 
pattern of iron deposits that is compatible with the iron binding 
deficiencies we have detected in vitro. While only 10% of fibroblasts 
expressing the FXN-G130V mutant show small iron deposits, these are 
present in over 50% of fibroblasts expressing the FXN-I154F mutant [5]. 
Direct measurement of mitochondrial iron content showed a 2-fold 
increased in the FXN-I154F expressing cells in respect to wild type 
expressing cells (from 5 to 10 mmol/mg of protein) [5]. In addition, 
expression of the mutants FXN-G130V and FXN-W173G in Yfh1-
defficient cells also leads to an identical observation [7]. Mitochondrial 
iron level in yfh1 [FXN-G130V] cells is identical to the observed for 
yfh1 [FXN-wt] cells, however, expressing the mutant associated to a 
severe phenotype leads to a 4-fold increase of the mitochondrial iron 
levels [7]. In addition, the biochemical pattern concerning the activity of 
FeS clusters containing enzymes is identical for these two model 
systems, as in both systems mutations associated to severe 
phenotypes lead to more significant impairments of the FeS clusters 
containing enzymes activities [5, 7]. 
The functional impairment cannot be fully explained by the partial 
impairment of frataxin iron binding properties, suggesting that adverse 
physiological conditions occurring in vivo, such as oxidative stress [9-
12] and iron accumulation, can potentiate mutants' defects, leading to 
further perturbation of frataxin structure and dynamics; these could also 
lead to frataxin inactivation or misfolding, further reducing the cellular 
concentration of functional frataxin.  
Altogether, the clinical effects in heterozygous FRDA patients are 
likely to result from a combination of effects, as observed in other 
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human diseases. For example, in amyotrophic lateral sclerosis the 
mutations identified in SOD1 are very different in character and it has 
been suggested that the pathology emerges as a result of different 
reasons, or a combination of reasons, from apo-protein destabilisation 
to local unfolding [13]. Also, missense mutations leading to lysosomal 
storage diseases are associated to different pathological mechanisms 
like active-site impairment, pH-dependent protein instability, protein 
degradation, improper protein trafficking or disruption of protein-protein 
interaction crucial for cellular function. In Gaucher's disease, the most 
prevalent lysosomal disorder, the phenotypic diversity is very large and 
cannot be solely explained by the effect of mutations on enzyme 
activity, suggesting that increased degradation may also be associated. 
 In the case of FRDA, the results obtained in the present study 
suggest that factors such as a reduced efficiency of protein folding 
(resulting in an increase of the aggregation rates), an accelerated 
degradation in vivo (leading to decreased frataxin levels) and 
misfolding and conformational destabilisation contribute to a decrease 
in the levels of functional frataxin. In this scenario, FRDA in 
heterozygous patients carrying frataxin single point mutations could be 
considered a type of protein misfolding disorder leading to a "loss of 
function" phenotype [14]. In addition, the existence of frataxin clinical 
mutants whose mutations cause severe functional impairment and 
whose phenotype does not result from increased conformational 
instability cannot be excluded. Our studies on the yeast model system 
have allowed for the identification of one of those mutations: Yfh1-
N122K (in human frataxin, FXN-N146K). This mutation involves a well 
conserved residue on the protein exposed -sheet surface and severely 
compromises the interaction between frataxin and its protein partner Isu 
without compromising the protein stability or its plasticity. However, the 
FXN-N146K mutation is associated to a severe phenotype and 
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biochemical analysis of the (yfh1) cells expressing Yfh1-N122K 
(corresponding to human FXN-N146K) show iron accumulation and 
severe aconitase activity deficiency [15-16]. 
 
9.1.2. Modulators of FRDA variants 
Defects in protein folding constitute the basis for many human 
diseases which can be associated to trafficking impairment (1-
antitrypsin deficiency and cystic fibrosis), misfolding (cancer and ALS) 
or increased aggregation propensity (familial amyloidosis, Scrapie or 
Alzheimer's) [17-20]. Although some misfolding diseases are directly 
associated to mutations, these are not an absolute requirement for 
misfolding to occur [21]. Protein stabilisers, small molecules now 
described as chemical chaperones, have been shown to be able to 
correct numerous folding defects [21-24]. Thus, we have analysed 
whether the presence of chemical chaperones could revert the FXN-
D122Y and FXN-I154F mutants’  decreased folding efficiency and 
stability. In spite of the basic mechanism responsible for the osmolyte 
effect [21, 25-27] some are very effective in inducing structure while 
others are more likely to solubilise native proteins. Studies on the 
physical and chemical origins of the osmolyte action have revealed that 
their overall effect results from a combination of favourable and 
unfavourable interactions with backbone and side chains which explains 
the apparent discrepancy in their mode of action [25-26, 28-30].  Three 
complementary approaches were followed and the effect of four small 
molecular weight compounds (glycerol, trimethylamine-N-oxide (TMAO), 
trehalose and 4-phenylbutirate (4PBA)) during early folding events and 
on the native state was here explored. 
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 The small compounds presence during early folding events can 
have a strong positive effect on the FXN-I154F folding efficiency, their 
impact on FXN-D122Y folding efficiency is however modest. An 
opposite effect is observed when looking at the folded protein. The 
chemical chaperones were efficient in reverting the decreased stability 
observed for FXN-D122Y but their impact on FXN-I154F stability was 
marginal. The effect of the small compounds on the fold 
quality/conformation was also mutant dependent. The fold quality was 
assessed through GroEL partitioning experiments; GroEL has a high 
affinity to non-native exposed hydrophobic regions, thus partitioning will 
depend on the protein conformation. Control experiments have shown 
that, under the conditions used, FXN wild type does not partition onto 
GroEL. In contrast, both mutant variants show an identical partition onto 
GroEL which is indicative of their fold defects. FXN-D122Y conformation 
was more easily corrected by the presence of the tested small 
compounds. Trehalose completely abrogates FXN-D122Y partitioning 
onto GroEL whereas 4PBA and TMAO partially impair it. On the other 
hand, FXN-I154F partitioning is only decreased by the presence of 
TMAO, all the other compounds either have no effect or even lead to an 
increase partitioning, meaning that their presence causes an exposure 
of hydrophobic regions that are recognised by GroEL.  
The fact that small molecules have different effects depending on the 
mutation considered can be rationalised in terms of the impact each 
mutation has on the protein plasticity and conformation [31-33]. It also 
suggests that the pathological process resulting from each mutation is 
likely to be different.  The data here presented suggests that chemical 
chaperones may rescue FXN-D122Y phenotype since their presence 
increases the protein's stability and fold quality and, most likely, also 
decreases the protein’s propensity towards degradation. Thus, therapy 
with ‘protector’ molecules may increase the amount of functional FXN-
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D122Y, rescuing the mild phenotype observed. On the other hand, the 
mutant FXN-I154F is not significantly stabilised by the presence of 
chemical chaperones nor does their presence reverts the partitioning 
onto GroEL. They do however increase the mutant's folding efficiency, 
which may result in an increased amount of soluble protein and 
consequently may lead to a reduction of the phenotype severity.  These 
in vitro experiments allowed us to evaluate the potential use of chemical 
chaperones supplementation in FRDA and, according to the results, 
some of the clinical mutant's conformational deficiencies may be 
partially rescued by the presence of chemical chaperones. The optimal 
conditions to improve both mutants’ stability and folding efficiency have 
been selected and in vivo studies must now be performed. The recently 
cellular models expressing frataxin containing FRDA-related missense 
mutations would be ideal for these studies [5]. 
In addition to the direct study of the impact of chemical chaperones 
on two clinical mutants, this study has also allowed to establish a 
valuable method to study the effect of chemical chaperones on proteins. 
The GroEL sink assay, differential scanning fluorometry and the effect 
on folding efficiency give complementary information on the impact of 
chemical chaperones and have proven to be valuable approaches for 
the initial screen of potential rescuers of proteins associated to 
misfolding diseases.  
9.1.3. Oxidative Stress Related Modification and FRDA 
The exact role of oxidative stress in FRDA and the understanding of 
how frataxin promotes an antioxidant function have not so far been fully 
understood. However, increased ROS production is undoubtedly 
associated to FRDA development. Oxidative stress markers are used to 
monitor disease progression [34-36]; overexpressing frataxin leads to 
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decreased amounts of carbonylated proteins and cells increase their 
ability to sustain exogenous oxidative stress. Furthermore, the most 
promising FRDA treatment involves the administration of Idebenone 
[37-38]. This compound can interact with the mitochondrial respiratory 
chain as an electron carrier, supporting mitochondrial function and ATP 
production and it also acts as an antioxidant.  However, other 
experimental evidences dismiss a role of oxidative stress in FRDA 
pathogenesis:  overexpression of antioxidant enzymes in fly and mouse 
models fails to rescue the FRDA phenotype if frataxin gene is deleted 
[12, 39]. Further, in yeast, mouse and cellular mouse models, the 
absence of frataxin in aerobic conditions is associated to aconitase 
degradation and accumulation of oxidatively modified proteins in both 
the cytosol and mitochondria, which in yeast has been shown to lead to 
Pim1 expression and proteasome inhibition [9]. Murine fibroblasts 
expressing frataxin clinical mutants (FXN-G130V and FXN-I154F) show 
an increased sensitivity towards exogenous oxidative stress but, while 
the levels of catalase are reduced to at least half the values observed 
for the wild type, the SOD expression remains unaltered [5]. In 
agreement, when using the FRDA Drosophila model it was shown that 
the FRDA phenotype could be rescued by catalase overexpression but 
overexpressing SOD's had no effect [40]. However, the effect of 
overexpressing SOD’s should have been performed with concomitant 
overexpression of catalase since overexpression of SOD’s may result in 
an accumulation of H2O2 and the FRDA Drosophila model shows a 
great sensitivity towards H2O. Recently, Tamarit and co-workers have 
shown that yfh1 cells show reduced SOD1 and SOD2 activities but, if 
the medium is supplemented with copper or manganese, these 
activities are restored and cellular oxidative damage prevented [41]. 
Thus, either directly or indirectly, frataxin seems to be important for 
maintaining the oxidative balance.  
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A question that remained to be answered was what happens to 
frataxin itself, which is present at reduced levels in all FRDA patients, if 
this balance is disturbed. A priori, frataxin is a potential target for 
oxidative stress modifications, not only due to its location in the 
mitochondria, where oxygen and nitric oxide are available in a reducing 
environment, but also as a result of its iron-binding properties, which 
may prompt the formation of ROS via Fenton chemistry reactions. 
Oxidative damage on proteins is extremely relevant in vivo since this 
modulates the protein function (both positively and negatively), its 
fragmentation, oligomerisation and turnover [42]. Residues at the 
protein surface are primary targets as these are more susceptible to 
oxidation reactions. The latter can alter the protein hydrophilicity and, 
consequently, its conformation and function [43-44]. Thus, it is not 
surprising that these modifications are involved both in ageing and 
diseases such as Alzheimer’s and Parkinson’s disease and amyotrophic 
lateral sclerosis, where an increase in protein carbonyls and 3-
nitrotyrosin is observed [42, 45]. Here, we have explored the 
consequences of subjecting the human orthologue to conditions 
mimicking increased oxidative stress. The human frataxin core is 
susceptible to oxidative stress related modifications; four nitration sites 
(Tyr143, Tyr175, Tyr205 and Trp155) and one carbonylation site 
(Trp155) were identified by MS analysis. Interestingly the only residue 
identified as carbonylated (W155) was also found to be susceptible to 
nitration. There are two factors that may account for this residue's 
increased susceptibility towards modifications: its nature and its 
localisation/orientation.  Tryptophans are highly susceptible to oxidative 
stress related modifications, however, there are two other relatively 
solvent accessible tryptophans, Trp168 and Trp173, which were 
analysed, and were not modified, suggesting that a bias for Trp is not 
occurring. Trp155 is strictly conserved across frataxin orthologues and 
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its location at the protein surface with the aromatic ring turned to the 
outside facilitates the access of reactive species to this residue. Thus, 
the second factor location/orientation seems to significantly contribute to 
Trp155 increased susceptibility towards oxidative stress related 
modifications. 
The oxidative related modifications did not alter the wild type frataxin 
ability to bind iron nor its ability to avoid Fenton chemistry. However, 
they do result in destabilising conformational changes ranging from 0.3 
to 1.0 kcal.mol-1, and induce an ‘open’ conformation. This decreased 
stability may not be relevant in the context of the wild type protein, 
however, in compound heterozygous patients, this small reduction in 
stability, associated to the mutants’ intrinsic decreased stability, may 
trigger the development of FRDA. Preliminary data on thermal stability 
of mutant frataxin suggests that treatment with metals plus hydrogen 
peroxide or with peroxynitrite may induce different variations on the 
thermal stability of mutant proteins. While peroxynitrite seems to induce 
a considerable stabilisation of the FXN-G130V, the opposite effect is 
observed for FXN-W155R mutant. However, the impact of oxidative 
related modifications on the FRDA-related mutants has to be further 
explored. First, the extent of the modifications has to be evaluated 
followed by its impact. 
At this point no pathological meaning can be attributed to oxidative 
modifications in frataxin but a possible role should not be completely 
excluded. Interestingly, one of the known clinical point mutations 
associated to a severe phenotype also involves the tryptophan highly 
susceptible to modifications, Trp 155; its mutation to an arginine is 
described in FRDA compound heterozygote patients [3]. The 
characterisation of the impact of this mutations at the protein level, has 
shown that modifying this residue does not disrupt frataxin fold but does 
increase the susceptibility towards proteolytic degradation and partially 
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compromised iron binding [33, 46]. So it might be relevant, in the FRDA 
context, that a residue whose mutations result in FRDA is also a hot 
spot for carbonylation and nitration modifications. Furthermore the 
characterisation of the effect of oxidative modifications on the frataxin 
interactome may rule out the hypothesis that modification on frataxin 
protein may trigger FRDA development or in the other hand it may 
exclude that possibility. 
9.2. Frataxin Function 
9.2.1. Characterisation of Functional Mutants 
The human and yeast frataxin orthologs have a high degree of amino 
acid (65%) and structural identity. In addition, the phenotype observed 
as a consequence of frataxin’s deficiency is very similar in human and 
yeast cells [47-48] and thus the yeast model system has been 
frequently used to study frataxin’s function, as well as the pathological 
events associated with FRDA. Here, yeast frataxin orthologue was used 
on the studies focused on frataxin functional properties. Yeast frataxin 
functional mutants allowed for the exploration of the conformational and 
functional relevance of the two putative functional regions in frataxin 
structure: the acidic ridge between -helix 1 and -strand 1 and 
residues in the conserved -sheet surface between strands 3 and 4.  
Mutations on the acidic ridge have shown that frataxin iron binding 
capacity is quite robust and that the acidic ridge is particular sensitive to 
an activity-stability trade off. Mutating up to five acidic residues, four of 
each identified as iron binding sites [49], significantly increases the 
protein’s stability without compromising its iron binding stoichiometry. 
However, these mutations diminish frataxin’s affinity to iron (~2-fold), 
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suggesting that the mutated residues (D86, E90, E93, D101 and E103) 
constitute primary iron binding sites. The existence of primary iron 
binding sites had already been suggested for the E. coli  orthologue 
[50]. The quintuple mutant shows a significant increase in terms of both 
protein stability (Tm~23ºC) and protein rigidity (lower propensity 
towards proteolytic digestions), thus the acidic ridge, in addition to its 
direct functional implications, also determines frataxin conformational 
properties. Evaluating the functional impairment caused by the 
replacement of negative charges in the acidic ridge must then be done 
cautiously, as charge-to-neutral mutations also alter the protein 
flexibility, which may impair the conformational fluctuations that are 
crucial for protein-protein interactions and interfere with complementary 
protein-protein interactions dependent on electrostatic interactions.  
In addition, the studies here presented suggest that the variant Yfh1 -
101/103A could be a valuable model to study frataxin cellular role and 
ultimately FRDA development. Under normal growth conditions, if only 
one of the residues, Asp 101 or Glu103, is mutated, no phenotype is 
observed [51-52]. However, the double mutant, D101/E103A, even 
when Yfh1 expression levels are normal, results in a reduction of 
aconitase activity (<80% of the wild type). No in vitro interaction is 
detected between this mutant and Isu. Nevertheless, growth impairment 
is only observed when these two residues are changed to lysines and 
the medium supplemented with iron [51]. The decreased interaction 
between variant Yfh1-101/103 A and Isu cannot be explained by the 
reduced conformational plasticity observed for this mutant as Yfh1-
86/90/93A shows an identical reduction in flexibility and its interaction 
with Isu is still detected in vitro. Hence, residues Asp101 and Glu103 
should be involved in the interaction with Isu but its alteration is not 
enough to completely abolish the interaction in vivo. Mutation of the 
corresponding residues in the human orthologue have not been 
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identified in FRDA patients but this double mutant seems to confer 
partial functional impairment and thus more detailed in vivo functional 
studies; using this variant may shed some light onto the controversial 
FRDA pathway.  
The characterisation of the mutants involving the conserved -sheet 
residues 122-123, excludes any structural relevance that might be 
attributed to them as their alteration has only a modest impact on Yfh1 
stability and plasticity. As previously reported, the mutation Yfh1-N122K 
has been identified in an heterozygous patient (corresponds to FXN-
N146K); our study suggests that the phenotype observed results from a 
direct functional impairment, the mutation comprises Yfh1 interaction 
with Isu.  The rescue by chemical chaperones or small molecules 
protectors should not be efficient for these strictly functional mutants.  
9.2.2. Copper Binding: A New Functional Feature of 
Frataxin? 
Frataxin has been shown to be stabilised by different cations and 
metals [53]. In addition, CyaY weakly interacts with calcium and 
manganese with a Kd in the mM range, while zinc promotes its 
aggregation at higher ion/protein ratios [54]. Furthermore, in vivo 
studies have shown that nickel supplementation can improve frataxin-
Isd11 interaction and partially rescue the interaction between FRDA-
related mutants and Isd11 [8]. Thus, we have explored whether yeast 
frataxin could bind other metal ions. Apart from iron, only copper was 
able to bind frataxin. The addition of calcium, manganese or zinc, that 
were shown to interact with CyaY, had no effect on the protein 
fluorescence spectra. Either Yfh1 does not interact with these ions or 
the interaction is too weak to be detected and if so its biological 
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meaning is also questionable. Nickel had no effect on the protein 
spectra nor on its thermal stability. 
The interaction of frataxin with copper has not yet been reported, but 
iron and copper homeostasis are tightly linked in Eukaryotes (as shown 
by studies on the yeast and human systems) [55]. Iron uptake depends 
on cytosolic copper availability since it depends on the activity of Fet3p. 
This enzyme catalyses the oxidation of Fe(II) to Fe(III) and Fet3p-Fe(III) 
is the substrate for the permeation facilitated by Ftrp1, resulting in iron 
uptake [56-57]. However, Fet3p activity depends on the post-
translational insertion of 4 copper ions [58-59]; thus, the disruption of 
any of the genes involved in copper homeostasis leads to a deficiency 
in Fet3p activity and in other high affinity iron transporters [60-61].  The 
first evidence of a direct connection between iron and copper 
homeostasis was only recently disclosed. Yfh1 deletion activates the 
iron regulon AFT1, which in turn promotes Ftr1 and Fet3p expression 
and iron acquisition [62-63]. These alterations lead to cytosolic copper 
depletion that ultimately compromise SOD1 activity, promoting the 
inactivation of FeS clusters containing enzymes and triggering the 
formation of chelatable iron [41].  Supplementation of yfh1 cells with 
small concentrations of Cu(II) (5M) enables the recovery of SOD1 
activity and prevents protein oxidation by superoxide [41], however, if 
the cells are exposed to higher Cu(II) concentrations, this will lead to 
cell growth arrest (0.5mM) [64].  
The toxicity exerted by copper supplementation (0.5mM) has been 
associated to the copper ability to generate oxygen radicals via Fenton 
reaction [64] but, since frataxin can also bind copper, this explanation 
may have to be reviewed. Frataxin can bind Cu(I) and Cu(II), but its 
affinity for Cu(I) is higher. Frataxin antioxidant capacity may then also 
involve its ability to bind copper, preventing the formation of reactive 
species and, at same time, contribute to the mitochondrial copper 
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homeostasis. Nonetheless, the presence of excess of copper does not 
induce oligomerisation, thus frataxin ability to prevent copper oxidation 
via Fenton chemistry is limited to its stoichiometry: 3/4 copper ions per 
frataxin. Considering this hypothesis, the toxicity exerted by copper 
supplementation may result from mitochondrial copper homeostasis 
imbalance caused by frataxin deletion.  
Copper binding sites overlap at least partially with frataxin iron 
binding sites, however, excess of copper does not abolish frataxin 
interaction with Isu. Thus, in spite of a new putative function involving 
copper, frataxin role in FeS clusters biogenesis as a iron donor should 
still constitute its prime cellular function.  
 
Figure 9.1: Schematic representation of mitochondrial copper trafficking 
pathways including the putative role of frataxin in copper metabolism. Copper in 
the matrix may also be bound to frataxin in addition to forming the anionic 
complex previously described. Adapted from [65]. 
 
The results here presented also suggest that frataxin may act as a 
copper chaperone. Frataxin is able to bind copper and further deliver it 
to apo-SOD1 promoting SOD's reconstitution. In vivo, it has been 
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shown that the copper levels in the mitochondria are significantly higher 
than expected, considering the mitochondrial copper needs for the 
activation of mitochondrial copper-dependent proteins [66]. Further, it 
was demonstrated that the excess of copper is, as frataxin, localised in 
the mitochondrial matrix. This copper within the matrix corresponds to 
70-85% of the total mitochondrial copper and it has been associated to 
a non proteinaceous pool [66-67]. While many mitochondrial proteins 
have been associated to the metallation of cytochrome C oxidase [65, 
67-70], only one metallochaperone, Ccs1, has been identified as 
responsible for the metallation of SOD1 [71].  SOD1 activity is retained 
in Ccs cells, although with some constrains, which suggests that an 
alternative copper chaperone may exist.  
In view of the mitochondrial copper localisation, as well as its 
quantity, our results may suggest that frataxin could contribute to the 
copper homeostasis in the mitochondrial matrix. Frataxin may have a 
dual role on mitochondrial copper regulation: it may prevent Fenton 
chemistry and, at the same time, promote the trafficking of copper from 
the non-proteinaceous pool to the metallochaperones known to be 
directly involved in copper insertion/metallation. However, further 
experiments on the role of frataxin in copper homeostasis in vivo must 
be performed.  
 
Throughout the work developed we have aimed at contributing to a 
better understanding of FRDA pathology as well as to a better 
molecular understanding of frataxin conformational and functional 
properties. Since the frataxin gene was first described in 1996, the 
studies on frataxin and on the pathological pathway leading to FRDA 
have been extremely intense but still many uncertainties and challenges 
remain.    
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Most proteins need to fold to a specific three-
dimensional structure in order to be functional. Usually
this process is extremely efficient but not perfect: stress
conditions such as changes in the cellular environment and
genetic mutations are known to compromise its efficiency.
The cells’ protein quality control system, comprising
chaperones and proteases, deals with the burden of
misfolded proteins. Its capacity, however, is limited and
protein misfolding and aggregation are now recognised as
the cause of a large and diverse group of diseases called
protein conformational/misfolding diseases.
This dissertation focuses on the study of frataxin, a small
mitochondrial protein whose deficiency is associated with
the neurodegenerative disease Friedreich's ataxia (FRDA).
Aiming at a better understanding of the frataxin’s
conformational and functional properties, two lines of
research were followed: first, the effect of FRDA-related
mutations in human frataxin (FXN) were studied and the
role of oxidative stress related modification addressed;
second, yeast frataxin (Yfh1) orthologue was used to
explore the conformational and functional properties of
the protein.
